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Glioblastoma is the most common primary brain tumor which has a median survival of only 14.6 
months. The central nervous system localization, heterogeneity of the cells and resistance to 
treatment constitute a significant challenge to establishing an efficient and durable therapy. 
Glioblastoma lesions contain a dense network of defective blood vessels which are permeable to 
high molecular weight constructs such as nanocarriers. Furthermore, glioblastoma lesions are 
known to depend upon several tyrosine kinases in order to facilitate their development, 
progression, invasion and treatment resistance. 
As a consequence, we assessed the cytotoxicity of multiple tyrosine kinase inhibitors (TKIs), 
singularly or in combination, against a panel of glioblastoma cell lines in vitro. The most promising 
combination of crizotinib, an inhibitor of Met and ROS1, and dasatinib, an inhibitor of SRC and 
focal adhesion kinase (FAK), were pursued as the lead compounds. In addition, these TKIs were 
encapsulated into polystyrene co-maleic acid micelles to improve their pharmacokinetic profiles 
in vivo by selective accumulation in tissues with fenestrated vasculature. The micelles were 
characterized based on their loading, charge, size, solubility and release rate. Both formulations 
were assessed for their ability to alter protein expression profiles, induce cell death and reduce 
proliferation. The ability of the treatments to prevent migration, invasion and angiogenesis in a 
panel of glioblastoma cell lines was also assessed. 
The micelles had favorable physicochemical characteristics, with a size sufficient to promote a 
prolonged plasma half-life, a near neutral charge to prevent opsonization and a steady release rate. 
The expression and phosphorylation of the target kinases Met, ROS1, SRC, and FAK were 
consistently reduced by the combination treatment. The combination treatment also reduced the 
expression of EGFR despite neither TKI targeting this receptor. The inhibition of these targets and 
subsequent suppression of downstream AKT activity induced apoptotic cell death in glioblastoma 
cells. The cell death following removal of the drug after a 72 h treatment period, defined as 
washout, was assessed to determine the ability of the cells to escape from treatment-induced cell 
death. Following washout, the apoptosis was maintained for 72 h following the removal of the 
drugs in the free but not the micellar formulations. The induction of cell death correlated with the 
induction of polyploidy in the free but not micellar formulations. This polyploidy was not causative 
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of cell death but was associated with genetic instability. Both free and micellar formulations 
showed effective prevention of invasion, migration and angiogenesis in vitro.  
This study demonstrated the efficacy of the combination of crizotinib and dasatinib in a panel of 
glioblastoma cell lines. This combination strongly induced apoptotic cell death. Furthermore, the 
combination also effectively combated several treatment resistance pathways such as invasion and 
vascular mimicry, potentially augmenting the efficacy of the current therapies. The micellar 
formulations show comparable efficacy to the free formulations but also provide the potential for 
the improvement of in vivo pharmacokinetic parameters. In conclusion, the combination of 
crizotinib and dasatinib shows significant promise in vitro and warrants further investigation in 
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1.  Introduction 
1.1   Glioblastoma 
1.1.1   Incidence  
Glioblastoma is the most commonly diagnosed primary brain tumor in adults. This tumor type is 
highly heterogeneous, comprised of four subtypes each, with different lineage signatures (Verhaak 
et al., 2010). The incidence of glioblastoma is higher in males (1.6:1), Caucasians and the elderly 
(Table 1:1) (Dobes et al., 2011; Dolecek et al., 2012; Ostrom et al., 2014). In New Zealand, the 
age-standardized rate does not vary significantly between Māori and non-Māori populations 
(Alexander et al., 2010).  
Table 1:1: Glioblastoma incidence in the population of the United States of America.   
Age (years) Rate/100,000 95% confidence intervals 
0-19 0.15 0.14–0.17 
20-34 0.41 0.39–0.43 
35-44 1.23 1.18–1.28 
45-54 3.59 3.51–3.67 
55-64 8.03 7.90–8.16 
65-74 13.09 12.87–13.31 
75-84 15.03 14.74–15.34 
85+ 8.95 8.60–9.32 
Ethnicity Rate/100,000 95% confidence intervals 
Caucasian 3.45 3.42–3.48 
Black 1.70 1.64–1.77 
Asian 1.43 1.22–1.66 
Hispanic 2.43 2.35–2.52 
Data adapted from Dolecek et al. (2012). 
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Several factors have been associated with an increased risk of developing glioblastoma including 
epilepsy (Schlehofer et al., 1999), cytomegalovirus infection (Ranganathan et al., 2012), excessive 
alcohol consumption (Baglietto et al., 2011), previous radiotherapy (Fisher et al., 2007) and low 
lifetime estrogen exposure for women (Schlehofer et al., 1999). Acute infectious diseases (such as 
colds and flu) (Schlehofer et al., 1999), allergic conditions (such as asthma and eczema) 
(Schlehofer et al., 1999; Schoemaker et al., 2006) and a high lifetime estrogen exposure (early 
menarche, never breast feeding, use of hormone replacement therapy) (Huang et al., 2004) have 
been associated with a lower incidence of glioblastoma. These trends indicate that the immune and 
endocrine systems play a prominent role in the development and progression of glioblastoma, 
though this role is poorly understood. 
1.1.2  Treatment 
Despite advancements in diagnostic technologies, surgical techniques, treatment regimens, and 
radiotherapy application, the prognosis of patients with glioblastoma has remained poor relative 
to other primary brain tumors (Figure 1:1) and gains in survival have been slow (Kawano et al., 
2015). The current standard of care involves, wherever possible, surgical resection, radiotherapy, 
and chemotherapy. The relative survival advantage of each treatment can be seen in Table 1:2. 
Corticosteroids are also an essential component of the treatment strategy, reducing the edema 
which is a sequela of the blood-brain barrier (BBB) disruption by glioblastoma (Dietrich et al., 
2011). 
 




Complete surgical resection of glioblastoma, defined as the absence of post-operative magnetic 
resonance imaging (MRI) contrast enhancement (as seen in Figure 1:2), confers longer overall 
survival (OS) but is often not feasible due to the need to preserve surrounding brain structures. 
When tumors arise in areas of the brain such as the thalamus, brainstem, basal ganglia, and corpus 
callosum, they are considered unresectable, not just due to their depth but also because damage to 
these structures can result in paralysis and loss of sensory or motor information. As such, complete 
resection is only possible in approximately 13 – 25% of patients (Barker et al., 1996; Curran et al., 
1993; Keles et al., 1999; Nitta & Sato, 1995; Simpson et al., 1993).  










No 7.8 6.4-10.6 
Yes 9.4 7.5-13.6 
Partial Yes 
No 11.7 9.7-13.1 
Yes 13.5 11.9-16.4 
Complete Yes 
No 12.1 11.2-13.0 
Yes 14.6 13.2-16.8 
Data adapted from Stupp et al. (2009). 
Surgeons in the 1920s and 1930s attempted to cure glioblastoma by performing a 
hemispherectomy, complete removal of the affected brain hemisphere. This strategy was 
discontinued because approximately 40% of patients died during the procedure and, of the 
surviving patients, 30-60% died of recurrent disease in the contralateral hemisphere (Bell & 
Karnosh, 1949; Dandy, 1928). Subsequently, surgical strategies focused on removal of the lesion 
and portions of the purportedly healthy brain that surrounds the tumor lesion in order to reduce the 
number of residual tumor cells. This is particularly important as the brain adjacent to the tumor 
accounts for approximately 49% of the tumor cell burden (Levin et al., 2015). Despite resection 
of portions of the surrounding brain, tumors reoccur within 2.0 cm of the resection margin in 
50-95% of cases (Burger et al., 1983; De Bonis et al., 2013; Gaspar et al., 1992; Konishi et al., 




Figure 1:2: The invasive profile of glioblastoma prevents surgical resection from being 
curative.  A) The central tumor lesion is identified in green. Yellow identifies the cells that are 
invading the surrounding brain parenchyma. Adapted with permission from Burden-Gulley et al. 
(2011). B) An example of occipital lobe glioblastoma recurrence following complete surgical 
resection, radiation and temozolomide chemotherapy. The lesion developing post-operation is 
close to the resection margin and resulted in the death of the patient 17 months following the 
surgery. Adapted with permission from Nakada et al. (2007).  
Radiotherapy is commonly employed for the treatment of glioblastoma even if surgery or 
chemotherapy is not utilized (Mrugala, 2013). The use of radiotherapy, however, is limited by the 
healthy tissue surrounding the tumor as neurons are particularly sensitive to the effects of radiation. 
Neurons are damaged by as little as 10 Gray of radiation (Raber et al., 2004) while over the course 
of standard treatment, patients may receive as much as 60 Gray in 2 Gray fractionated doses to 
reduce toxicity (Stupp et al., 2009).  
The efficacy of chemotherapy is also limited as many chemotherapeutic agents do not reach 
effective concentrations in the brain. Although the BBB is disrupted in the region of well-
developed tumors, as will be discussed further, the penetration of chemotherapeutics into the 
surrounding brain is not sufficient to affect invading cells. This is because the BBB prevents the 
passive diffusion of molecules into the brain that are hydrophilic and/or have a molecular weight 
exceeding 500 Da and actively effluxes agents from the central nervous system (CNS) (Blyth et 
al., 2009). As such, many chemotherapeutic agents do not reach pharmacologically relevant 
concentrations within the CNS. Temozolomide is a lipophilic, 194 Da, BBB permeable alkylating 
agent. Temozolomide induces cell death by damaging DNA via the addition of a methyl group to 
purine DNA bases creating adducts such as 06-methyl-guanine (06-MeG). These adducts mispair 
with thymidine rather than cytosine when the DNA is copied. The thymidine of the daughter strand 
can be excised by the DNA mismatch repair protein but the 06-MeG is retained in the template 
strand. This causes cycles of thymidine being incorporated and excised which predisposes the 
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DNA to strand breaks, cell cycle arrest and subsequent cell death (Zhang et al., 2012). 
Temozolomide treatment confers an average survival advantage of 2.5 months when combined 
with radiotherapy and complete surgical resection (Table 1:2). However, the benefit of 
temozolomide is dependent upon the methylation status of the promoter of the suicide repair 
enzyme O6-methylguanine–DNA methyltransferase (MGMT) which can remove the methyl group 
(Hegi et al., 2005). Methylation of the promoter prevents the transcription and translation of 
MGMT and subsequently patients with a methylated promotor that receive temozolomide plus 
radiotherapy have a median survival of 21.7 months, 6.4 months longer than with radiation alone 
(Hegi et al., 2005). Conversely, patients without a methylated MGMT promoter have a median 
survival of 12.7 months, only 0.9 months longer than with radiation alone (Hegi et al., 2005).   
In 2009, the vascular endothelial growth factor (VEGF)-A directed antibody bevacizumab was 
granted fast track approval for the treatment of glioblastoma. The approval was granted on the 
basis that glioblastoma patients treated with bevacizumab showed a smaller contrast enhancing 
lesion when compared to historical controls according to the MacDonald radiographic criteria 
(Cohen et al., 2009). This criterion was problematic as antiangiogenic agents can normalize the 
distorted, fenestrated tumor vasculature (as will be discussed further in Section 1.4.) which can 
reduce the contrast enhancement independently of the size of the lesion (Wen et al., 2010). In order 
to confirm the benefit of bevacizumab in glioblastoma treatment, two Phase III trials were 
conducted, the Radiation Therapy Oncology Group (RTOG) 0825 and the Avastin in Glioblastoma 
(AVAglio) trials. The RTOG trial included 978 patients and was sponsored by the National Cancer 
Institute (Gilbert et al., 2014). The AVAglio trial included 921 patients and was sponsored by 
F. Hoffmann–La Roche, the drug company with the patent for bevacizumab (Chinot et al., 2014). 
Neither study showed an increase in OS. However, the RTOG trial showed decreased quality of 
life while the AVAglio trial showed maintenance of life quality (Chinot et al., 2014). Indeed, the 
majority of the publications showing favorable clinical outcomes following bevacizumab 
treatment disclosed conflict(s) of interest, a common occurrence in industry-funded trials in the 
medical field (Bhandari et al., 2004; Djulbegovic et al., 2000; Friedberg et al., 1999; Lexchin et 
al., 2003; Ridker & Torres, 2006). 
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1.1.3   Subtypes of glioblastoma 
Studies investigating the subtype and origin of glioblastoma have established that the diagnosis of 
glioblastoma is an umbrella term applied to four distinct tumor subtypes. These subtypes display 
diverse amplification, deletion, and mutation of proteins involved in oncogenesis and pathological 
processes. These subtypes are termed the mesenchymal, proneural, classical and neural subtypes 
which were identified using genomic analysis and show great promise for the refinement of 
glioblastoma treatment (Verhaak et al., 2010).  
The proneural subtype (31% of core samples) expresses markers of oligodendrocytes and is most 
commonly associated with secondary glioblastoma. The proneural subtype shows no significant 
survival advantage of intensive therapy (concurrent radiotherapy and chemotherapy) relative to 
less intensive therapy (non-concurrent radiotherapy and chemotherapy). This subtype is associated 
with the amplification of the platelet-derived growth factor receptor (PDGFR), point mutations in 
isocitrate dehydrogenase-1 (IDH1) and p53 mutation (Verhaak et al., 2010) (Figure 1:3). PDGFR 
amplification stimulates pro-growth and survival pathways while IDH1 mutation will increase the 
production of 2-hydroxyglutarate which prevents the breakdown of hypoxia inducible factor-1α 
(HIF-1α) resulting in persistent transcription of hypoxia-related genes (Dimitrov et al., 2015). 
PDGFR amplification and IDH1 mutation are mutually exclusive. 
The neural subtype (16% of core samples) is characterized by the expression of neural markers 
such as gamma-aminobutyric acid A receptor α1 and SYT1 which encodes synaptotagmin-1, a 
Ca2+ sensor that assists with the trigger of neurotransmitter release (Verhaak et al., 2010). The 
neural subtype shares a high degree of transcriptional similarity to normal brain despite the 
unequivocal distinction in morphology. This subtype, therefore, displays a differentiated 
phenotype with genetic signatures consistent with neurons, astrocytes, and oligodendrocytes 
(Verhaak et al., 2010). This subtype shows no significant benefit of intensive therapy. 
The classical subtype of glioblastoma (21% of core samples) expresses astrocytic markers. This 
subtype shows the greatest benefit of intensive therapy and is defined by epidermal growth factor 
receptor (EGFR) abnormalities and cyclin-dependent kinase inhibitor (CDKN) deletion. The 
EGFR abnormalities include high-level amplification of the EGFR receptor tyrosine kinase (RTK) 
and the expression of EGFRvIII; a truncated EGFR variant characterized by the deletion of amino 
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acids 6-273 of the extracellular domain (Figure 1:3). The deletion of the extracellular domain of 
EGFR confers ligand-independent, constitutive activity (Wikstrand et al., 1998). Furthermore, the 
classical subtype has deleted the locus for the CDKN-2A and CDKN-2B in 95% of samples, 
promoting more rapid cell cycle progression (Figure 1:3). 
The mesenchymal subtype is the most common subtype (32% of core samples) and also shows a 
significant survival advantage in response to intensive treatment. This subtype is characterized by 
astroglial markers and the low expression of neurofibromin-1 (NF1), a negative regulator of the 
cell growth promoting rat sarcoma pathway (Verhaak et al., 2010). The mesenchymal subtype also 
shows the most frequent amplification of the Met locus. This RTK is also amplified in over 50% 
of the other glioblastoma subtypes but not in the healthy brain samples, indicating that Met serves 
as a relatively specific target across a wide range of glioblastoma subtypes (Figure 1:3) (Verhaak 
et al., 2010).  
Due to the relatively recent establishment of these subtypes and the slow validation of targets in 
clinical trials, these subtypes do not yet influence treatment. Furthermore, these subtypes do not 
encompass the breadth of heterogeneity in the tumor types. As can be seen in Figure 1:3, though 
the amplification, mutation or deletion of a given gene may be associated with a particular subtype, 
it is often not exclusive to that subtype. For example, EGFR amplification may be observed in 
95% of the classical samples, but it is also present in 67% and 29% of neural and mesenchymal 
samples, respectively. Therefore, targeting subtype associated proteins such as EGFR may be more 
frequently effective in the classical subtype but should not be uniformly rejected for neural and 
mesenchymal subtypes.  
There are several critiques of these classifications. The subtypes were identified from core samples 
only and subsequent research has shown that a patient may harbor more than one subtype in 
different regions of the tumor (Snuderl et al., 2011). These subtypes were also classified based 
upon genetic analysis, not protein expression profiles. Though gene copy number may be 
increased, this may not translate to higher protein expression due to a lack of transcription, 
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35% 13% 5% 9% 
IDH1 
mutation 
30% 5% 0% 0% 
P53 mutation 
54% 21% 0% 32% 
Mesenchymal 
NF1 deletion 
6% 17% 5% 38% 
Met 
amplification 
54% 92% 84% 95% 
Figure 1:3: The frequency of mutation, deletion, and amplification of several subtype 
associated genes in glioblastoma.  Red denotes the proportion of positive samples while gray 
denotes the proportion of negative samples. Numbers in the upper left corner of the segments 
denote the exact percentage of positive samples. Data sourced from Verhaak et al. (2010). 
Alternatively, abnormalities detected by genetic screening are not able to give information 
regarding the subsequent effect of that abnormality on the expression of other proteins. A pertinent 
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example is p53, commonly mutated in the proneural subtype which affects the expression of 
several genes that may not be mutated, amplified or deleted. For instance, p53 suppresses the 
expression of the focal adhesion kinase (FAK). Therefore inactivating mutations of p53 increases 
expression of FAK despite the gene for FAK not being altered (Golubovskaya et al., 2004). 
1.2  Tyrosine kinases 
Tyrosine kinases are a subgroup of protein kinases that transfer the γ phosphate of adenosine 
triphosphate (ATP) to the hydroxyl group of a tyrosine. Tyrosine kinases may be further divided 
into the subgroups of RTKs and non-receptor tyrosine kinases (nRTKs).  
RTKs are characterized by an extracellular domain that binds the ligand, a transmembrane domain 
and an intracellular catalytic domain with an ATP binding pocket. RTKs on the plasma membrane 
can be activated by extracellular ligands and intracellular associated kinases to stimulate 
downstream signaling pathways. In addition, they also localize in and signal from intracellular 
membranous structures such as vesicles, mitochondria or the nucleus (Krause & Van Etten, 2005). 
Most RTKs, when in the inactive form, are monomeric and the ATP binding site is 
unphosphorylated. Upon activation, the receptors oligomerize promoting trans-auto-
phosphorylation of the kinase activation loop. This induces a conformational change that stabilizes 
the active state of the kinase (Hubbard & Miller, 2007; Krause & Van Etten, 2005).  
The nRTKs do not have an extracellular or transmembrane domain although some nRTKs do have 
a short segment for anchoring to the plasma membrane. These tyrosine kinases are often found in 
the cytosol, nucleus or on the internal surface of the plasma membrane. The activation of nRTKs 
is tightly regulated through auto-inhibition or inhibition by other cellular proteins. Activation of 
nRTKs is mediated via oligomerization and auto-phosphorylation by transmembrane receptors or 
via transphosphorylation by other kinases including RTKs and other nRTKs (Krause & Van Etten, 
2005).   
As previously discussed, glioblastoma is frequently associated with overexpression of RTKs such 
as EGFR and Met (Figure 1:3). This overexpression confers higher sensitivity to low levels of 
ligand and increases the likelihood of ligand-independent activation by receptor homo- or 
hetero-dimerization (Casaletto & McClatchey, 2012; Danilkovitch-Miagkova & Zbar, 2002). 
Mutations are also observed such as with EGFRvIII in the classical subtype (Figure 1:3). These 
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mutations are responsible for the malignant progression of some tumor cell types. Therefore, 
targeting these proteins could constitute an effective therapeutic option and is currently being 
pursued in several clinical trials in glioblastoma, as will be discussed further. However, aberrant 
tyrosine kinase expression and/or activity does not necessarily mean that inhibiting that kinase will 
result in clinical efficacy. For example, EGFR inhibitors have been ineffective in glioblastoma, 
despite the frequency of EGFR amplification in tumor samples. This has been attributed to a 
number of different mechanisms employed by the cells to escape the treatment including switching 
the maintenance of downstream signaling to another RTK such as Met and PDGFR (Stommel et 
al., 2007) or inactivation of tumor suppressor proteins (Feng et al., 2012). 
The failure of treatments targeted to tyrosine kinases or their ligands, including small molecule 
tyrosine kinase inhibitors (TKIs) and antibodies, is a consequence of a diverse number of factors 
including the intra- and inter-patient heterogeneity of this tumor type, redundancy in signaling 
pathways, development of resistance through mutation or truncation, alteration of efflux pump 
expression or activity and/or the tendency to switch dependence to a different tyrosine kinase or 
alternative signaling pathway. For this reason, a combination strategy to prevent or delay the 
development of one or more resistance mechanisms was pursued. 
1.2.1   Dasatinib and associated proteins 
1.2.1.1 SRC family kinases 
The SRC family kinases (SFKs) are a nine member family including sarcoma (SRC), Yamaguchi 
sarcoma virus homologue (YES), FYN, Gardner-Rasheed feline sarcoma viral oncogene homolog 
(FGR), lymphocyte-specific protein tyrosine kinase (LCK), haematopoietic cell kinase (HCK), 
B lymphocyte kinase (BLK), LYN and YES-related kinase (YRK) (Parsons & Parsons, 2004).  
These proteins show a highly conserved structure with a lipid-modified N-terminal region, 
regulatory SRC homology domain-3 (SH3), SH2 and linker domains, a tyrosine kinase domain 
and a C-terminal tail (Figure 1:4) (Boggon & Eck, 2004). The distribution of each SFK member 
is variable with FYN, SRC, YES and YRK showing ubiquitous expression while BLK is located 
exclusively in B cells, FGR is found in B cells and myeloid cells, HCK is found in myeloid cells, 
LCK is found in T cells, natural killer cells and in the brain while LYN is located in B cells, 
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myeloid cells and the brain (Parsons & Parsons, 2004). Importantly, FYN, SRC, LYN, YES, HCK 
and BLK are all overexpressed in glioblastoma relative to healthy brain tissue (Lu et al., 2009).  
The kinases targeted by dasatinib are known to be involved in the function of immune cells. For 
example, dasatinib, through the inhibition of LCK dependent T-cell receptor function, inhibits 
T-cell proliferation and cytokine production in vitro and in vivo (Schade et al., 2008). Furthermore, 
dasatinib treatment is able to reduce the in vitro cytotoxicity of natural killer cells by 90% at just 
25 nM (Blake et al., 2008). Inhibition of Lyn by dasatinib inhibits the B cell receptor signaling 
cascade (Bendall et al., 2011), resulting in reduced circulating B cells in patients being treated 
with dasatinib and subsequent immunosuppression (Sillaber et al., 2009).  
SRC, which localizes in the cytoplasm, nucleus, and mitochondria, is of particular interest. SRC 
mediates signaling from proteins that facilitate cell to cell connections such as integrin receptors 
(Playford & Schaller, 2004) but also mediates the downstream signaling of PDGFR β, Met, EGFR 
and EGFRvIII (Blake et al., 2000; Herynk et al., 2007; Lu et al., 2009; Maa et al., 1995; Twamley-
Stein et al., 1993). Through these varied partners, SRC regulates downstream proliferative, 
survival, angiogenic and invasive signaling in healthy and diseased tissue (Figure 1:4).  
The diverse and redundant activation and signaling mechanisms of SRC makes abnormalities in 
SRC prone to cause disease. SRC was the first oncogene discovered when Peyton Rous established 
that a virus that had incorporated SRC into its genome, resulting in constitutive activity, induced 
tumor development in chickens (Rous, 1911). Similarly, mice engineered to overexpress SRC by 
linkage to the glial fibrillary acidic protein promoter spontaneously developed glioblastoma-like 
lesions (Weissenberger et al., 1997) and SRC is activated in 61 - 100% of glioblastoma biopsy 
samples (Du et al., 2009; Taylor et al., 2015). Furthermore, the role of SRC in the integration of 
multiple signaling pathways makes the kinase prone to be involved in resistance to upstream 
signaling inhibition. This role in resistance has been firmly established in the case of EGFR 
inhibitors in breast cancer, non-small cell lung cancer (NSCLC) and head and neck squamous cell 
carcinoma (HNSCC) wherein SRC facilitates the signaling switch to Met (Dulak et al., 2011; 
Mueller et al., 2008; Xu et al., 2011). Therefore, while serving as a mechanism for inhibiting the 
downstream signaling of multiple RTKs, SRC inhibition also holds the potential to prevent the 




Figure 1:4: Activation and signaling pathways of SRC.  SRC has an SH2, SH3, and a kinase 
domain. When SRC is inactive, Y257 is phosphorylated and Y416 is unphosphorylated. When a 
SRC binding partner, such as an RTK, is activated the SH2 and SH3 domains release the domains 
of SRC and bind to the binding partner, Y527 is de-phosphorylated and Y416 is phosphorylated. 
This activates the SRC kinase domain and allows the protein to signal downstream to mediate 
angiogenesis, growth and protein synthesis, proliferation and migration of glioblastoma cells. 
Figure adapted from Boggon and Eck (2004); Frame (2002). 
1.2.1.2 Focal adhesion kinase 
FAK is an nRTK that is inhibited by dasatinib. FAK is composed of a focal adhesion kinase 
targeting (FAT) domain which binds to paxillin and a four-point-one, ezrin, radixin, moesin 
(FERM) domain which mediates auto-inhibition of the kinase (Figure 1:5). Following binding of 
the FERM domain to its binding partners, such as the RTKs Met, EGFR, and PDGFR, the 
auto-inhibition ceases and FAK will be activated following a multistep process (outlined in Figure 
1:5) prior to signaling downstream.  
FAK is associated with focal adhesion sites through interaction with the focal adhesion scaffold 
protein paxillin which is essential for the coordination and integration of adhesion and growth 
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factor signals (Turner, 2000) (Figure 1:5). FAK is particularly important for several physiological 
processes including embryological development (Furuta et al., 1995; Shen et al., 2005) and wound 
healing (Gates et al., 1994; Li et al., 2002) by promoting cell invasion and migration. FAK also 
regulates downstream signaling from focal adhesion sites to allow cellular communication. 
Invasive cells suppress their proliferation which makes them relatively insensitive to DNA 
damaging agents such as radiotherapy and chemotherapy (Lal et al., 2005). Thereby FAK 
expression contributes to treatment resistance of glioblastoma.  
 
Figure 1:5: Activation and signaling pathways of FAK.  The FERM domain of FAK assists 
with auto-inhibition, binding to the kinase portion of FAK. This blocks the active site, preventing 
SRC recruitment and thereby averting auto-phosphorylation. Auto-inhibition is abolished when 
FERM attaches to a binding partner (such as the proteins MET or EGFR or lipids such as PIP2) 
which allows auto-phosphorylation of Y397, partially activating FAK. Phosphorylation of Y397 
recruits and activates SRC via the phosphorylation of Y416 in the kinase domain of SRC. SRC 
then fully activates FAK via phosphorylation of Y576 and Y577 and downstream signaling 
commences. Signaling through ERK alters cellular proliferation, signaling through AKT promotes 
cell survival and signaling through Rac, WASP and PAK promotes cytoskeletal rearrangement 
and cell motility. The numbered text indicates the order of events. Figure adapted from data in 
Mitra and Schlaepfer (2006). 
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The expression of FAK and the closely related pro-invasive protein proline-rich tyrosine kinase 2, 
which is also inhibited by dasatinib, increases with the histological grade of astrocytoma 
(Gutenberg et al., 2004). The pharmacological inhibition of FAK auto-phosphorylation decreased 
viability and clonogenicity, induced apoptosis and synergized with temozolomide in glioblastoma 
cells (Golubovskaya et al., 2013). Furthermore, FAK activation has been associated with higher 
invasion and migration of glioblastoma cells (Jones et al., 2001; Kolli-Bouhafs et al., 2012; 
Lipinski et al., 2005; Loftus et al., 2012; Natarajan et al., 2006; Obara et al., 2002; van der Horst 
et al., 2005; Zagzag et al., 2000). However, it must be noted that some reports have contradicted 
this literature, suggesting that FAK decreases the invasion of glioblastoma cells (Lipinski et al., 
2003; Lipinski et al., 2005).  
1.2.1.3 Dasatinib 
The SRC inhibitor dasatinib, formerly known as BMS-354825, is a second generation 
BCR-ABL/SRC inhibitor developed by Bristol-Myers Squibb, currently approved for the 
treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute 
lymphoblastic leukemia.  Dasatinib is a competitive inhibitor of the ATP-binding site of several 
tyrosine kinases including SRC family kinases, FAK, PDGFR, and Kit (Table 1:3).  
Dasatinib uptake into cells appears to be mediated by passive diffusion through the plasma 
membrane as there is no difference in uptake of dasatinib at 37oC or 4oC and inhibitors of the 
transporters responsible for the uptake of structurally related TKIs have no effect (Hiwase et al., 
2008). However, dasatinib shows limited penetration into the CNS with a brain to plasma ratio of 
0.12:1 in mice (Chen et al., 2009). This is a consequence of P-glycoprotein (P-gp) and breast 
cancer resistance protein (BCRP). Treating mice with elacridar, an inhibitor of P-gp and BCRP, 
increased CNS concentrations 5- to 10-fold while P-gp (-/-) and BCRP (-/-) mice showed an 8- to 
13-fold increase in CNS concentration (Chen et al., 2009; Lagas et al., 2009). Clinical trials 
utilizing dasatinib and the alternative SRC inhibitor bosutinib in glioblastoma patients have been 
initiated with several studies declaring results (Table 1:4 - Table 1:5).  
Orally administered dasatinib is rapidly absorbed showing a Tmax of 30 min and a half-life of 3.6 h 
(Christopher et al., 2008). Dasatinib is primarily excreted in the feces, 19% as dasatinib and 66% 
as dasatinib metabolites (Christopher et al., 2008). The excretion of unchanged dasatinib is 
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potentially a consequence of incomplete oral absorption, hydrolysis of conjugated dasatinib and/or 
conversion of the M5 metabolite back to dasatinib via reduction by gastrointestinal bacteria 
(Christopher et al., 2008). Of the five major metabolites of dasatinib, three show relevant activity 
against the SRC-dependent cell line mSRC-A4 with the metabolites M4, M5 and M20 showing 
79.0%, 10.8%, and 5.4% of the activity of dasatinib, respectively (Christopher et al., 2008). The 
M4, M5 and M20 metabolites account for 1.3%, 39.8% and 4.1% of plasma radioactivity, 
respectively at 2 h. Dasatinib is primarily metabolized by CYP3A4, which is responsible for the 
generation of M4 and M20 metabolites, while M5 is generated by flavin-containing 
monooxygenase (Wang et al., 2008).  
Table 1:3: IC50 of dasatinib against its targets in cell-free assays.  
Target Localization IC50 Reference 
PDGFR β Endothelial cells and fibroblasts 28.0 nM (Lombardo et al., 2004) 
Kit Ubiquitous 5.0 nM (Lombardo et al., 2004) 
FAK Ubiquitous 0.2 nM (Bantscheff et al., 2007) 
SFKs 
BLK B cells   
FGR B and myeloid cells   
FYN Ubiquitous 0.2 nM (Das et al., 2006) 
HCK Myeloid cells   
LCK The brain, T and natural killer cells. 0.4 nM (Das et al., 2006) 
LYN The brain, B and myeloid cells 3.0 nM (Bantscheff et al., 2007) 
SRC Ubiquitous 0.5 nM (Das et al., 2006) 
YES Ubiquitous 0.5 nM (Das et al., 2006) 
YRK Ubiquitous   
 
1.2.2  Crizotinib and associated kinases 
1.2.2.1 Met 
Met is an RTK that is activated by hepatocyte growth factor (HGF), which is secreted by 
mesenchymal cells (Forte et al., 2006). The Met protein is synthesized as a pro-form of 180 kDa 
which is cleaved by furin to a 140 kDa protein. This mature protein has an extracellular ligand 
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binding domain, a transmembrane domain, and an intracellular catalytic domain which activate 
downstream signaling pathways (Figure 1:6) (Trusolino & Comoglio, 2002).  
Met, via regulation of cell motility, plays a crucial role in placentogenesis, embryogenesis and 
wound repair (Corso et al., 2005; Ueno et al., 2013). Met is expressed in astrocytes, human 
glioblastoma cell lines and 100% of glioblastoma samples (Koochekpour et al., 1997; Lamszus et 
al., 1998; Moriyama et al., 1995; Verhaak et al., 2010). Met is amplified in over 50% of 
glioblastoma samples regardless of the subtype (Figure 1:3) (Verhaak et al., 2010). Following 
HGF binding to Met, the receptor is rapidly endocytosed via clathrin-coated vesicles and trafficked 
to the perinuclear endosomes where it continues to mediate downstream signaling (Joffre et al., 
2011; Kermorgant & Parker, 2008; Kermorgant et al., 2004; Kermorgant et al., 2003; Menard et 
al., 2014).  
Moreover, the activation of Met does not necessarily require exposure to HGF. Met can 
heterodimerize with and be activated by a substantial number of other receptors including EGFR, 
human epidermal growth factor receptor (HER)-2, HER-3, RET, G-protein coupled receptors, the 
hyaluronan receptor CD44, intercellular adhesion molecule 1, semaphorin receptors, recepteur 
d'origine nantais (RON) and PDGFR (Fischer et al., 2004; Organ & Tsao, 2011; Reinehr & 
Häussinger, 2012; Tanizaki et al., 2011). Met can also be activated by other RTKs without making 
contact with them. For example, glial cell line–derived neurotrophic factor activates Met by using 
SRC as an intermediary (Popsueva et al., 2003). This breadth of activation mechanisms, even in 
the absence of its ligand, underscores the versatility and potential importance of Met in 
glioblastoma where many of these receptors are known to be overexpressed or display aberrant 
activity. Moreover, the HGF independent activation of Met highlights the potential for the 




Table 1:4: Current clinical trials of SRC inhibitors for the treatment of glioblastoma. 
Trial number Name Phase Dose Status Tumor type Combinations Results 
NCT01331291 









Progression – 100% 
Toxicity – 77.8% 
(Taylor et al., 2015) 
NCT00895960 













Dasatinib and Bevacizumab in 
treating patients with recurrent 
or progressive high-grade 











Dasatinib in treating patients 
with recurrent glioblastoma or 
gliosarcoma 




Progression – 100% 
No relationship between 
response and expression 
of dasatinib targets 
(Lassman et al., 2015)  
NCT00948389 
Study of Lomustine plus 
Dasatinib in recurrent 
glioblastoma 
I 
100 mg  
1-2 times 
daily 
Terminated  Glioblastoma Lomustine 
Progression – 84% 
Toxicity – 11% 
Both – 3% 
(Franceschi et al., 2012) 
NCT00734864 
Dasatinib/Protracted 











Trial number Name Phase Dose Status Tumor type Combinations Results 
NCT00869401 
Dasatinib or placebo, radiation 
therapy, and Temozolomide in 
treating patients with newly 
diagnosed glioblastoma 










(Laack et al., 2012) 
NCT00609999 





Completed Glioblastoma Erlotinib  
6 month PFS -  2% 
(Reardon et al., 2008) 
NCT01644773 
Study of the combination of 
Crizotinib and Dasatinib in 
pediatric research participants 
with diffuse pontine glioma and 
high-grade glioma 
















22% grade III A.E.s 
(Taylor et al., 2015) 
A.E.s: adverse events, PFS: progression free survival. 
 
Table 1:5: Current clinical trials investigating SRC inhibitors for multiple cancer types including glioblastoma. 
Trial number Name Phase Dose Status Tumor type Combinations Results 
NCT01744652 
Dasatinib and Crizotinib in 
advanced cancer 
I 
50 - 140 
mg daily 
Recruiting Advanced Cancer Crizotinib 
36 - 41% grade III 
A.E.s 
(Kato et al., 2015) 




Figure 1:6: Activation and signaling pathways of Met.   Met forms a homodimer in response to 
HGF stimulation, phosphorylating Y1234 and Y1235 within the catalytic site (Longati et al., 
1994). Subsequent phosphorylation of Y1349 and Y1356 allows these tyrosines to serve as 
docking sites in order to mediate downstream signaling. Simplified and abridged signaling 
pathways of the Met receptor following activation with HGF are shown. Through Met activation, 
migration, proliferation, growth and protein synthesis is stimulated while apoptosis is inhibited 
(Xiao et al., 2001). SRC associates with the plasma membrane and receives signaling from a 
variety of plasma membrane-associated receptors including Met (Herynk et al., 2007). 
Astrocytes and glioblastoma cells respond differently to the stimulation of Met. Both cell types 
phosphorylate the Met receptor in response to HGF, but only glioblastoma cells became motile, 
increasing their invasive potential and proliferation in response (Koochekpour et al., 1997). HGF 
can increase migration of glioblastoma cells by up to 140-fold (Lamszus et al., 1998). Furthermore, 
HGF expression in glioblastoma is 3.5-fold higher than in non-tumorous tissue obtained from 
epilepsy patients (Koochekpour et al., 1997). In the clinic, high Met expression was associated 
with shorter survival (11.7 vs. 14.3 months), multifocal lesions (50.0% vs. 20.5%), decreased time 
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to recurrence (6.1 vs. 11.5 months), increased tumor grade and radioresistance (Kong et al., 2009; 
Liu et al., 2011; Nabeshima et al., 1997). Part of the difficulty in treating glioblastoma is the ability 
of glioblastoma stem-like cells (GSCs) to replenish the tumor population following surgery, 
chemotherapy and radiotherapy (Jun et al., 2014; Rath et al., 2013). Met expression in GSCs is 
high and the inhibition of Met in GSCs decreases clonogenicity and invasive potential (Joo et al., 
2012).   
1.2.2.2 ROS1 
ROS1 is a poorly understood RTK that was first identified in the avian sarcoma virus UR2 in 1982 
where it was fused to the gag gene to form a chimeric protein with constitutive tyrosine kinase 
activity (Feldman et al., 1982; Shibuya et al., 1982). ROS1 is 259 kDa and has the largest 
extracellular domain of any RTK, which is composed largely of fibronectin type III (FTIII) 
domains (Figure 1:7) (Bloom & Calabro, 2009).  
ROS1 does not have an identified ligand but is highly conserved among the Animalia kingdom, 
showing significant homology with the sevenless protein of Drosophila melanogaster (up to 74% 
in the intracellular kinase domain and up to 43% in the extracellular domain) (Chen et al., 1991).  
The sevenless protein of Drosophila, with an extracellular domain distinguished by multiple FTIII 
domains as is seen in ROS1, is activated by the bride of sevenless (BOSS). BOSS is a 
transmembrane protein with a large extracellular domain, seven transmembrane domains, and a 
C-terminal cytoplasmic domain. Upon binding to sevenless, the BOSS protein is transferred from 
the BOSS expressing cell to the sevenless expressing cell and internalized (Cagan et al., 1992). 
This is an unusual mechanism of ligand binding and activation and so, should the mechanism for 
ROS1 activation be similar, it is unsurprising that the ROS1 ligand has not yet been established. 
There are no homologous proteins to BOSS outside of the Insecta class.  
The lack of an identified ligand and the diverse expression patterns between species has hampered 
the understanding of the role of ROS1 in mammals. For example, ROS1 knockout mice show 
normal anatomy and physiology with the exception of males being infertile as a consequence of 
improperly formed spermatozoa flagella (Yeung et al., 1999). It is unknown whether this result is 
relevant to human males. In the human male reproductive tract ROS1 is found throughout the 
epididymis and is absent in the proximal caput while, in mice, ROS1 is only found in the caput. 
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The highest expression of ROS1 in adult humans is found in the lungs (Acquaviva et al., 2009) 
and subsequently, ROS1 is commonly associated with lung cancers (Takeuchi et al., 2012a). 
 
Figure 1:7: Activation and signaling pathways of ROS1. ROS1 displays an extremely large 
extracellular domain comprised of FTIII domains and a small, highly conserved intracellular 
kinase domain (Bloom & Calabro, 2009). The ligand is unknown. Signaling through ERK may 
increase proliferation while signaling through AKT increases survival and mediates ROS1-
induced transformation. Signaling through the RhoA pathway modulates skeletal re-organization 
to facilitate invasion and migration (Ou et al., 2012).  
The oncogenic potential of ROS1 was reported in 1984 when a truncated, ligand-independent 
ROS1 was shown to transform NIH3T3 cells to form tumors (Fasano et al., 1984) indicating a 
potential role of ROS1 in cancer development. In glioblastoma, there is conflicting information 
about the rate of fusion and overexpression of ROS1. For example, ROS1 fusions which confer 
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ligand independence, have been implicated in the genesis and growth of glioblastoma in in vitro 
studies (Birchmeier et al., 1987; Charest et al., 2003; Charest et al., 2006; Sharma et al., 1989) 
and previous research has suggested that ROS1 and ROS1 fusion products are expressed in some 
primary glioblastoma samples (Mapstone et al., 1991; Watkins et al., 1994) although there is 
conflicting information about the frequency and importance of this expression and fusion (Lim et 
al., 2015). Nevertheless, the research into the importance of ROS1 in the genesis and pathology of 
glioblastoma is significantly hampered by the lack of an identified ligand. 
1.2.2.3 Crizotinib 
Crizotinib, previously known as PF02341066 and marketed as Xalkori by Pfizer, is an inhibitor of 
the tyrosine kinases Met, anaplastic lymphoma kinase (ALK) and ROS1 (Table 1:9). Crizotinib 
competitively binds the ATP binding pocket of these tyrosine kinase receptors, preventing 
ATP-dependent activation of the kinase and subsequent downstream signaling.  
Crizotinib shows a Tmax of 4-6 h and a total bioavailability of 43% following oral administration 
(Pfizer, 2011). The primary excretion route is through feces where 53% of the dose is excreted 
unchanged (Johnson et al., 2015). Crizotinib enters cells through passive diffusion and is both a 
substrate and an inhibitor of CYP3A4/5 and P-gp (Pfizer, 2011; Zhou et al., 2012). The inhibition 
of CYP3A4/5 alters the metabolism of both crizotinib and other CYP3A4/5 substrate drugs, 
resulting in a terminal half-life, i.e. the half-life following the establishment of the plasma steady 
state, of 42 h (Pfizer, 2011). The commonly reported side effects of crizotinib in the clinic include 
nausea and vomiting. However, grade 3-4 neutropenia has been reported in 5.2 -13.0% of patients 
(Shaw et al., 2013; Solomon et al., 2014; Timm & Kolesar, 2013). The mechanism is unestablished 
as both immune mediated and Met receptor mediated mechanisms have been proposed (Osugi et 
al., 2016; Toyota et al., 2014).  
The inhibition of P-gp by crizotinib, although not as potent as specific P-gp inhibitors such as 
elacridar, can increase the sensitivity of cells to P-gp substrates such as doxorubicin (Zhou et al., 
2012). The assessment of crizotinib in preclinical in vivo glioblastoma models is limited; however 
crizotinib was shown to deplete GSCs in vivo (Rath et al., 2013). GSCs are particularly problematic 
in glioblastoma as, although comprising a small proportion of the overall tumor population, these 
cells are chemoresistant, radioresistant and have a high tumorigenic potential (Altaner, 2008). 
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Table 1:6: Current clinical trials of small molecule Met inhibitors for the treatment of glioblastoma. 
Trial number Name Phase Dose Status Tumor type Combo Results 
NCT01644773 
The combination of Crizotinib and 
Dasatinib in pediatric research 
participants with diffuse pontine 











Safety and efficacy of INC280 and 
Buparlisib in patients with recurrent 
glioblastoma 






Buparlisib  - 
NCT00960492 
Safety study of Cabozantinib in 
combination with temozolomide and 
radiation therapy in the initial treatment 
of adults with glioblastoma 
I 






Thrombocytopenia – 31% 
Leukopenia – 27% 
(Schiff et al., 2016) 
NCT00704288 





Complete Glioblastoma - - 
NCT01068782 
Study of multiple doses and regimens 
of Cabozantinib in subjects with grade 





Complete Glioblastoma - 
≥50% reduction - 38% 
24-49% reduction - 35%  
(de Groot et al., 2009) 
NCT01433991 
E7050 in combination with E7080 in 
subjects with advanced solid tumors 
and in subjects with recurrent 
glioblastoma or unresectable Stage III 
or Stage IV melanoma after prior 
systemic therapy 














Table 1:7: Current clinical trials of antibodies targeting Met or HGF for the treatment of glioblastoma. 
Trial number Name Phase Dose Status Tumor type Other drugs Results 
NCT01189513 
SCH-900105 in recurrent 
glioblastoma 
I 
10 mg/kg on 
days 1, 8 and 





Glioblastoma - - 
NCT00427440 











Stable disease - 10-15%  
Grade III-IV A.E.s - 5-10% 
(Wen et al., 2010) 
NCT01113398 
AMG 102 and Avastin for 













A study of onartuzumab in 
combination with bevacizumab 
compared to bevacizumab alone 
or onartuzumab monotherapy in 


















Table 1:8: Current clinical trials of Met inhibitors for multiple cancer types including glioblastoma. 
Trial number Name Phase Dose Status Tumor type Other drugs Results 
NCT01441388 
A study of Crizotinib plus VEGF 
inhibitor combinations in patients 
with advanced solid tumors. 















Study of INC280 in patients with 
c-MET dependent advanced solid 
tumors 








Study assessing efficacy and 
safety of crizotinib in patients 
harboring an alteration on ALK, 
MET or ROS1 
II 










Crizotinib in treating young 
patients with relapsed or 
refractory solid tumors or 
anaplastic large cell lymphoma 
I and II Not specified Completed 





MTD 280 mg/m2 
Neutropenia – 32% 
Leukopenia – 24% 
(Mossé et al., 2013) 
NCT01324479 
Study of INC280 in patients with 
c-MET dependent advanced solid 
tumors 





Sorafenib or Crizotinib and 
Vemurafenib in advanced cancer 
1 
250 mg once 
daily 
Recruiting Advanced Cancer Vemurafenib - 
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Trial number Name Phase Dose Status Tumor type Other drugs Results 
NCT01548144 
Pazopanib or Pemetrexed and 
Crizotinib in advanced cancer 
I 
250 mg once 
or twice daily 




MTD; maximum tolerated dose, CNS; central nervous system, NSCLC; non-small cell lung cancer.
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Table 1:9: IC50 of crizotinib against its targets in cell-free assays 
Targets IC50 Reference 
ALK 24.0 nM (Crescenzo & Inghirami, 2015) 
Met 12.0 nM (Crescenzo & Inghirami, 2015) 
ROS1 11.0 nM (Crescenzo & Inghirami, 2015) 
 
Currently, clinical trials are investigating the potential of small molecule inhibitors of Met 
including crizotinib (Table 1:7, Table 1:9) and antibodies targeting Met or HGF (Table 1:8) 
however the data is not published for the majority of these studies. Crizotinib has previously been 
used in a case study for the treatment of a Met overexpressing glioblastoma lesion in a 62 year-old 
woman. Crizotinib treatment resulted in a 40% decrease in the contrast enhancing lesion following 
two treatment cycles and stable disease after four treatment cycles. The disease remained stable 
for six months post crizotinib initiation. This case demonstrates the potential efficacy of Met 
inhibitors in the clinic (Chi et al., 2012). 
1.2.3  Interaction of crizotinib and dasatinib targets 
Met and SRC are known to interact extensively in order to mediate various cellular processes. For 
instance, invasion, which plays an important role in the poor survival of glioblastoma patients, is 
known to be mediated by both SRC and Met. However, crosstalk between these tyrosine kinases 
is crucial for the invasive phenotype (Herynk et al., 2007; Sridhar & Miranti, 2006). For example, 
SRC and Met interactions are essential to mediate resistance to SRC inhibition in HNSCC 
(Weissenberger et al., 1997). In addition, Met and SRC cooperate in order to compensate for lost 
EGFR signaling following treatment of breast cancer cells with EGFR inhibitors (Mueller et al., 
2008). This data indicates that the simultaneous inhibition of Met, SRC, and EGFR may be critical 
for reducing the incidence of resistance to TKI treatment in glioblastoma. 
1.2.4  Crizotinib and dasatinib in clinical trials for glioblastoma 
There are currently a number of clinical trials utilizing dasatinib and crizotinib or agents that target 
the same kinases for the treatment of glioblastoma. A currently recruiting Phase I clinical trial is 
assessing the combination of crizotinib and dasatinib in children with diffuse intrinsic pontine 
glioma and glioblastoma. This study is primarily geared towards assessing the pharmacokinetics 
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and pharmacodynamics of the drug combination. This is an essential study as both crizotinib and 
dasatinib are substrates of CYP3A4 while crizotinib is also a time dependent inhibitor of CYP3A4 
(Wang et al., 2008; Zhou et al., 2012). This may alter the plasma concentration of both drugs as 
they will both be competing for the binding sites of a reduced number of active enzymes. 
Furthermore, crizotinib inhibits the function of P-gp (Zhou et al., 2012), the efflux pump 
responsible for the efflux of both crizotinib and dasatinib from the cell and the CNS (Chen et al., 
2009; Chuan Tang et al., 2014). This may facilitate the accumulation of these drugs within 
glioblastoma cells in the CNS, resulting in higher efficacy in patients. 
1.3  The functional properties of cancer 
Some of the functional capabilities of cancer are outlined in Figure 1:8. These properties are found 
in most cancers including glioblastoma where they pose significant barriers to the currently 
employed glioblastoma treatment strategies. Therefore, in order to be effective, treatment 
strategies must be able to combat all of these hallmarks. 
1.3.1  Resistance to apoptosis 
Apoptotic cell death is characterized by a relatively rapid reduction of cytoplasmic and nuclear 
volume, nuclear fragmentation and plasma membrane blebbing. This mode of cell death often 
involves the programmed engulfment of apoptotic bodies by surrounding phagocytic cells, 
clearing the cellular debris and preventing an inflammatory response (Galluzzi et al., 2007). Some 
attempts have been made to distinguish between so-called intrinsic and extrinsic cell death 
mechanisms. These distinctions have become somewhat gratuitous due to the extensive cross-talk 
between the pathways (Krammer, 2000; Scaffidi et al., 1998; Zamzami et al., 2000).  
Glioblastoma cells, like many cancer types, are highly resistant to apoptosis which contributes to 
the low efficacy of chemotherapy and radiotherapy (Eisele & Weller, 2013). The apoptosis 
resistance is a consequence of several factors including p53 mutation (Figure 1:3) or increased 
Bcl2L12 activity (Stegh et al., 2010). Therefore, glioblastoma cells are more susceptible to 
necrotic cell death than apoptotic cell death. This is a major concern for clinicians as the necrosis 
can promote inflammation and damage to the surrounding cerebral tissues, ultimately exacerbating 
cerebral edema, the leading cause of morbidity in glioblastoma patients (Burger et al., 1979; Saad 
& Wang, 2014; Sheline et al., 1980). Furthermore, necrotic cell death can also promote the growth 
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of tumors and their vasculature via the induction of inflammation which in turn induces 
mechanisms for tissue repair including angiogenesis, stromagenesis and endothelial cell 
proliferation (Edwards et al., 2003; Leek et al., 1999; Vakkila & Lotze, 2004). This may partially 
account for treatment-induced necrosis being a poor prognostic indicator in glioblastoma and a 
variety of other tumor types (Burger & Green, 1987; Curran et al., 1993; Koukourakis et al., 2003; 
Poleri et al., 2003; Tomes et al., 2003).  
 
Figure 1:8: The functional properties of tumors.  The figure is modified from personal images 
and images sourced with permission from Castro (2016); Czakó et al. (2009); Hanahan and 
Weinberg (2000); Stanford (2016). 
1.3.2  Unlimited replicative potential 
Healthy cells have what is termed the Hayflick limit, a limit to the number of times that cells may 
divide. This is determined principally by the telomeres that cap the chromosomes, protecting the 
chromosome from deterioration. Telomeres are maintained by telomerase, a reverse transcriptase 
enzyme that uses RNA as a template in order to insert a TTAGGG sequence onto the 3’ end of the 
chromosome. This enzyme is highly active in embryonic and adult stem cells, but is inactive in the 
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majority of somatic cells. In glioblastoma, telomerase activity is detected in 30 – 80% of 
glioblastoma samples (Chen et al., 2006; Hakin-Smith et al., 2003; Kheirollahi et al., 2013). 
Furthermore, up to 25% of glioblastoma samples show alternative lengthening of telomeres which 
is independent of telomerase activity and commonly associated with the proneural subtype (Chen 
et al., 2006; Hakin-Smith et al., 2003; Heaphy et al., 2011). In a subgroup of tumors, no telomere 
maintenance mechanism is able to be determined, although this may be a consequence of assay 
interference by tumor-associated macrophages (Hung et al., 2016). 
The ability to maintain telomere length makes cancer cells, in principal, immortal (Shay & Wright, 
2000). The combination of an unlimited replicative potential, self-sufficiency in growth signals 
and resistance to tumor suppressors means that tumor cells consistently replicate. This, while 
posing a challenge to achieving a cure, does provide an (inexact) target to discriminate between 
healthy cells and cancer cells as cancer cells are more likely to be dividing at a higher rate and 
therefore be sensitive to agents that damage the DNA or the replicative machinery. Therefore, 
chemotherapies specifically target this increased replicative rate. Unfortunately, some normal cell 
populations also rapidly replicate, such as cells of the hair follicles and gastrointestinal tract, 
resulting in potentially debilitating side effects. Moreover, glioblastoma cells are able to escape 
cell death induced by the DNA damaging agent temozolomide via the activity of the MGMT 
enzyme which removes the methylation from the DNA bases (Hegi et al., 2005). 
Though glioblastoma cells are able to replicate due to their modulation of the Hayflick limit, 
pro-proliferative signaling is necessary to initiate the replication. Therefore, inhibition of cellular 
receptors and signaling proteins that promote the replication, such as FAK, EGFR, and Met, can 
alter the proliferative rate of glioblastoma cells. 
1.3.3  Invasion and metastasis 
The invasive profile of glioblastoma cells contributes most significantly to the failure of treatment. 
For example, the invasion of glioblastoma cells into the surrounding healthy brain is the reason for 
surgical failure. This invasion is so aggressive that even hemispherectomy fails to cure 
glioblastoma (Bell & Karnosh, 1949). Furthermore, the proliferation of invading cells is 
suppressed and therefore chemotherapeutics that target replicating cells are relatively ineffective 
against invading cells (Giese et al., 2003). Despite this invasive profile, glioblastoma rarely 
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metastasizes outside of the CNS. This has been suggested to be a consequence of glioblastoma 
cells being particularly dependent on the microenvironment of the brain or glioblastoma patients 
dying before the cells establish detectable extra-CNS lesions (Beauchesne, 2011). 
 
Figure 1:9: Relationship between hypoxia and invasion in glioblastoma. A) Hypoxia in 
glioblastoma promotes the invasion of cells away from the hypoxic region towards the normoxic 
region. This results in a hypercellular border around the necrotic zone, termed a pseudopalisade. 
B) The signaling interplay between invasion and angiogenesis. Met and HIF-1α suppress 
proliferation and promote invasion which reduces sensitivity to chemotherapy and radiotherapy. 
Met increases the expression (E) of VEGFR, which promotes angiogenesis. VEGFR serves as a 
negative feedback mechanism, decreasing the activity (A) of Met. The increased VEGFR activity 
promotes angiogenesis, hypoxia reduces and the proliferative rate of the cells increases while 
invasion decreases. Pseudopalisade image adapted from Brat et al. (2004). 
A characteristic of glioblastoma is the presentation of structures called pseudopalisades. These 
structures are used to distinguish glioblastoma from lower grade gliomas (Figure 1:9). 
Pseudopalisades are areas of necrosis caused by insufficient blood supply that are surrounded by 
a hypercellular zone. The hypercellularity is not a consequence of a higher proliferation rate but 
rather hypoxia-induced invasion. Insufficient blood supply promotes HIF-1α expression, inducing 
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the expression of Met which stimulates invasion, resulting in a hypercellular ring around the 
necrotic region (Brat et al., 2004; Pennacchietti et al., 2003; Rahimi et al., 1998; Sridhar & Miranti, 
2006) (Figure 1:9). Subsequently, high Met expression promotes high expression of the vascular 
endothelial growth factor receptor (VEGFR) (Wojta et al., 1999) and VEGF (Takeuchi et al., 
2012b). The high expression of VEGFR then regulates Met expression in a negative feedback loop. 
Following binding of VEGF to VEGFR, VEGFR forms a heterodimer with Met, recruiting protein 
tyrosine phosphatase-1B to dephosphorylate the Met receptor, reducing tumor cell invasion (Lu et 
al., 2012). Therefore, the binding of VEGF by bevacizumab prevents the dephosphorylation of the 
Met receptor by VEGFR and cells remain invasive (Lu et al., 2012). 
SRC plays an important role in the in vivo invasive potential of glioblastoma. The role of SRC in 
the invasion of glioblastoma cells is primarily via its action as an effector of RTKs, including 
EGFR, and nRTKs, including FAK. The interplay between FAK and SRC is well documented in 
healthy cells and cancer cells. In both cell types, the interaction between SRC and FAK promotes 
the formation of lamellipodium, the specialized cell projections on the leading edge of the cell. 
This complex also promotes the secretion of proteins that will degrade the extracellular matrix 
(ECM) including matrix metalloproteinase (MMP)-2, MMP-9 and urokinase plasminogen 
activator (Mitra & Schlaepfer, 2006).  
1.3.4 Genomic instability 
Genomic instability has become in area of intense interest in cancer treatment. This is due to the 
multifaceted roles of the genomic instability in generating the mutations that contribute to the 
development and progression of the disease. In order to acquire the mutant genes that confer a 
survival advantage, cells must either increase susceptibility to DNA damaging agents, impede the 
function of the proteins that maintain genomic stability and/or inactivate the mechanisms that 
regulate the pro-senescent or pro-apoptotic response to mutations (Hanahan & Weinberg, 2011; 
Negrini et al., 2010). 
The mutation of caretaker genes in glioblastoma increases significantly in response to treatment. 
For example, analysis of samples of untreated glioblastoma showed 1.4 silent somatic mutations 
per sample while in the treated sample subset this background mutation was raised to 5.8. The rate 
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of mutation was highest in patients previously treated with temozolomide and lomustine (TCGRN, 
2008). 
The inactivation of DNA damage sensors such as p53, which is inactivated in 21-54% of the 
proneural, neural and mesenchymal subtypes (Figure 1:3) is a classic example (Verhaak et al., 
2010). This mutation results in cells that do not die in response to DNA damage such as that 
achieved by radiation or temozolomide treatment. Subsequently mutations are preserved and 
accumulate resulting in progression to malignancy. The rate of mutation of p53 increases 20.5% 
following treatment in glioblastoma. Therefore, the genetic instability induced by sensitivity to 
DNA damaging agents therefore increases the likelihood that a cell will acquire a mutation that 
will promote further genomic instability.  
1.3.5  Sustained angiogenesis 
Glioblastoma tumors are highly vascularized (Keunen et al., 2011; Ricci-Vitiani et al., 2010). The 
generation of a large blood supply contributes significantly to the ability of individual cancer cells 
to proliferate, contributing to the overall tumor burden.  
Met, induced by hypoxia, signals through the MAPK pathway to inhibit the expression of 
thrombospondin-1 which prevents angiogenesis via reduction of endothelial cell proliferation and 
survival (Giehl et al., 2008; Jiang et al., 1997; Zhang et al., 2003). Met simultaneously increases 
the expression of VEGFR and VEGF, which increase their expression sufficiently to reduce Met 
signaling, thereby increasing endothelial cell proliferation and angiogenesis (Takeuchi et al., 
2012b; Wojta et al., 1999).  However, the construction of blood vessels in tumors is imprecise, 
resulting in distorted vessels with fenestrations that allow plasma, proteins, and large molecular 
weight constructs to leak into the tissue as will be discussed further in Section 1.4. 
1.3.6 Immune evasion 
The immune evasion displayed by tumors is an interesting and consistent theme (Hanahan & 
Weinberg, 2011). Investigations using immunodeficient mice have established that both the innate 
and adaptive immune systems play a role in the suppression of tumor development and growth 
(Kim et al., 2007; Teng et al., 2008). Glioblastoma, which is less prevalent in subjects prone to 
allergies (Schlehofer et al., 1999; Schoemaker et al., 2006), is noted for systemic 
immunosuppression (Dix et al., 1999) and a significant bias toward T helper 2 cells, which have 
34 
  
immunosuppressive actions (Kumar et al., 2006; Li et al., 2005; Shimato et al., 2012). Indeed, 
glioblastoma cells themselves secrete the anti-inflammatory cytokines IL-10 and TGF-β (Dix et 
al., 1999; Huettner et al., 1997). 
Furthermore, tumors not only evade destruction by the immune system but also utilize immune 
cells to support their own growth and invasion. Tumors are able to recruit tumor promoting 
macrophages, mast cells, neutrophils and T and B lymphocytes (Coffelt et al., 2010; DeNardo et 
al., 2010; Egeblad et al., 2010; Johansson et al., 2008; Murdoch et al., 2008). These cell types can 
release growth promoting factors such as EGF, VEGF, pro-inflammatory cytokines and 
chemokines and enzymes that degrade the extracellular matrix.  
1.3.7 Deregulated cellular energetics 
Cancer cells must balance the energetic demands of increased cell proliferation with the fluctuation 
in nutrient supply. Subsequently the cells often display significantly differences in energy 
metabolism and nutrient balance. Glioblastoma, for example, has mutated IDH1, a critical 
component of the citric acid cycle (Weller et al., 2011), in 30% of proneural subtype samples 
(Verhaak et al., 2010). The mutation results in the acquisition of the ability to convert 
α-ketoglutarate to 2-hydroxyglutarate (Dang et al., 2009), resulting in the elevation of 
2-hydroxyglutarate, up to 100-fold of wild type samples (Dang et al., 2009). The mutation of this 
enzyme is commonly associated with slower growth rate and therefore a longer survival time 
(Bralten et al., 2011). 
1.4    Nanomedicine 
Nanomedicine is the medical application of nanotechnology whereby drugs may be encapsulated, 
conjugated or associated with nano-sized constructs specifically for medical use. Nanomedicine is 
used extensively for a wide variety of applications such as implants, infection control, contrast 
enhancers and drug delivery vehicles (Bai et al., 2015; Jaramillo-Ruiz et al., 2016; Lee et al., 2016; 
Nagao et al., 2016). This diversity reflects the versatility and functionality of nanoconstructs which 
can be modulated to provide several advantages over the free formulations of the same drugs. For 
example, nano-encapsulated drugs can confer water solubility to otherwise hydrophobic 




1.4.1 The enhanced permeability to and retention of macromolecules in tumor tissue 
Nanoconstructs are also pursued in order to exploit the enhanced permeability and retention (EPR) 
of macromolecules in tumor tissue, first described by Matsumura and Maeda in 1986 (Matsumura 
& Maeda, 1986). The enhanced permeability of tumor tissue to macromolecules relative to the 
surrounding healthy tissue is a consequence of the defective vasculature of the tumor. The vascular 
fenestrations occurs as a consequence of several factors. Primarily, the rapid angiogenesis that is 
driven by an imbalance in pro- and anti-angiogenic factors such as VEGF and SEMA3E, 
respectively (Adams & Alitalo, 2007; Bao et al., 2006). Endogenous factors may be produced by 
the tumor cells or associated stromal, endothelial, or immune cells (Table 1:10).  
The increased retention of the EPR effect is caused by faulty lymph vessels, which fail to drain the 
extracellular fluid and associated macromolecules from the interstitial space. This failure is due to 
a combination of high levels of anti-lymphangiogenic agents such as TGF-β (Table 1:10) and the 
mechanical stress of the tumor causing the unreinforced vessels to collapse. This results in 
accumulation of macromolecules such as conjugates, liposomes, and micelles in tumor tissues that 
is not seen in the surrounding healthy tissues that have appropriate vascular construction and 
functional lymphatics (Taurin et al., 2012).  
The EPR effect in brain tumors is influenced by factors that are not as important for peripheral 
diseases. The vasculature of the CNS is more complex than in many other organs, containing the 
normal endothelial cells, pericyte cells and basement membrane but also including the astrocytic 
foot processes (Figure 1:10). This intricate, multilayered barrier regulates ionic composition, 
controls the penetration of systemic neurotransmitters and macromolecules, protects against 
neurotoxins and infection and supplies the brain with adequate nutrition from the blood (Abbott et 
al., 2010). 
The structure of the healthy BBB and the blood-tumor barrier (BTB) is given in Figure 1:10. The 
endothelial cells of the healthy BBB are connected by adherent junctions, composed of cadherins 
and catenins (Persidsky et al., 2006) and are essential for the formation of tight junctions, 
composed of occludins and claudins. In glioblastoma, there is selective loss of claudin-1, claudin-3 
and claudin-5 which are critical for the formation of tight junctions and a loss of plakoglobin that 
is essential for endothelial junction maturation (Liebner et al., 2000; Wolburg et al., 2003) 
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resulting in the endothelial cell coverage of the BBB being incomplete, forming fenestrations 
between the endothelial cells (Dinda et al., 1993). 
Table 1:10: Endogenous agents involved in the EPR effect in tumor tissues.  
Agent Produced by Action References 
Bradykinin Tumor cells 
Increases vascular 
permeability 
(Matsumura et al., 1988) 





(Doi et al., 1996) 





Degradation of the 
ECM 
(Coussens et al., 2002) 
(Fang et al., 2011) 
Prostaglandin All nucleated cells 
Preventing thrombus 
Vasodilation 
(Maeda et al., 2000) 














(Zheng et al., 2014) 
(Yu et al., 2014) 
  
The pericytes of the healthy BBB cover approximately 20 – 30% of the microvascular surface 
(Persidsky et al., 2006) providing structural support (Ramsauer et al., 2002) and regulating 
capillary blood flow (Bandopadhyay et al., 2001). Furthermore, pericytes also regulate the 
permeability of the BBB to water and transcytosis of high and low molecular weight constructs 
(Armulik et al., 2010). In glioblastoma, there is evidence that GSCs are able to differentiate into 
pericytes which promote vessel stability and vascular sprouting, therefore facilitating tumor 




Figure 1:10: Structure of the blood vessels in the healthy BBB and the BTB.  Endothelial cells 
of the BBB line the blood vessel and are connected by tight junctions. Pericytes and astrocytic foot 
processes surround this endothelial layer forming an effective barrier against large or hydrophilic 
molecules. In the BTB, the continuity of the endothelial cell layer is compromised, pericytes detach 
from the endothelial cells and the basement membrane, the basement membrane changes 
composition to promote angiogenesis, and the astrocyte coverage is reduced. These changes 
collectively result in fenestrated, leaky vessels allowing the extravasation of large molecular 
weight molecules from the vasculature into the CNS. It is through these fenestrations that 
nanoconstructs (blue spheres) are able to extravasate into tumor tissue where it normally would 
not cross the BBB. Figure based upon data sourced from Levin et al. (2015). 
The extracellular matrix of the BBB serves as an anchor for the endothelial cells via integrin 
receptors which in turn influence the expression of endothelial tight junctions and therefore the 
continuity of the barrier (Savettieri et al., 2000; Tilling et al., 1998). In glioblastoma, the basement 
membrane loses agrin, a molecule that maintains the barrier function, and gains tenascin, which 
promotes angiogenesis (Levin et al., 2015; Rascher et al., 2002).  
Finally, the BBB is surrounded by astrocytic foot plates which play a vital role in the induction 
and maintenance of BBB properties in the endothelial cells (Hayashi et al., 1997; Janzer & Raff, 
1987). Indeed, corticosteroids mimic a number of effects of astrocytes on the integrity of the BBB 
and consequently are used for the treatment of glioblastoma associated edema (Antonetti et al., 
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2002; Romero et al., 2003). In glioblastoma, the tumors are deficient in normal astrocytes, 
resulting in improper coverage of and signaling to the microvasculature and subsequent breakdown 
in the integrity of the BBB (Janzer & Raff, 1987). 
The extensive angiogenesis and flawed constriction and maintenance of blood vessels allow the 
extravasation of high molecular weight molecules from the plasma into the CNS (Kaur et al., 2004; 
Wang et al., 2005) causing edema, the predominant cause of morbidity in glioblastoma patients 
(Reichman et al., 1986). However, this can be a therapeutic advantage for delivery of 
macromolecular drugs or nanomedicine. The EPR effect in glioblastoma has been demonstrated 
by selective leakage of the conjugate of Evans blue dye (EBD) and plasma albumin (totaling 
69 kDa) into brain tissue affected by glioblastoma relative to healthy brain (Ambruosi et al., 2006; 
Reichman et al., 1986) (Figure 1:11). 
  
Figure 1:11: Extravasation of macromolecules into glioblastoma tissue but not healthy brain 
following IV administration. A) Image of selective extravasation of EBD into glioblastoma 
lesions in Sprague-Dawley rats (Reichman et al., 1986). B) Fluorescence of EBD following 
intravenous administration in contralateral brain tissue and 101/8 glioblastoma lesions in Wistar 
rats relative to days after implantation (Ambruosi et al., 2006). 
These studies, while validating the potential of macromolecules to selectively accumulate in these 
tumors, also highlight the variability of the effect. For example, the degree of permeability changes 
based on the relative tumor burden whereby the accumulation of macromolecules is high in the 
tumor core but is reduced in areas of the lesion closest to the normal brain (Figure 1:11 A) 
(Reichman et al., 1986). The accumulation of macromolecules also alters with the development of 
the tumor, rising as the lesion grows and falling once the tumor becomes large enough to develop 
a necrotic core (Figure 1:11 B) (Ambruosi et al., 2006). Therefore, the use of nanomedicine in 
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glioblastoma must include consideration of this spatial and temporal variability in accumulation. 
Despite this variability, studies investigating the use of nanomedicine in glioblastoma treatments 
have been initiated (Table 1:11), although these are all early Phase trials.  





Number Phase Status Results 
Liposomes 




(Beier et al., 2009) 
Rhenium NCT01906385 I and II Recruiting - 
CPT-11 NCT00734682 I Completed No results published 
Cytarabine NCT01044966 I and II Terminated - 
Microspheres 
5-FU N/A Pilot Completed 
Well tolerated 
(Menei et al., 1999) 
5-FU N/A Pilot Completed 
OS – 40 weeks 
(Menei et al., 2004) 
Polymers 
Paclitaxel NCT01402063 II Completed 
38.8% grade III 
A.E.s 
Paclitaxel NCT00763750 II Completed 24% grade III A.E.s 
N/A: not applicable, A.E.s: adverse events, 5-FU: Fluorouracil, CPT-11: Camptothecin-11, OS:  
overall survival. 
1.4.2 SMA micelles for selective TKI delivery 
Poly(styrene-co-maleic acid) (SMA) was chosen to encapsulate the TKIs. SMA is a polymer of 
alternating styrene and maleic acid groups, giving the polymer both hydrophilic and hydrophobic 
components. This polymer can be utilized to conjugate and encapsulate drugs. The early 
investigation into this polymer created SMANCS, a conjugate of SMA to the highly unstable 
neocarzinostatin, a macromolecular antibiotic/anticancer compound synthesized by Streptomyces 
carzinostaticus (Heyd et al., 2000; Maeda et al., 1985). This conjugation prolonged the half-life 
of neocarzinostatin by 10-fold, improved anti-cancer efficacy and reduced toxicity (Maeda et al., 
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1985). In 1994, this construct was approved in Japan for the treatment of hepatocellular carcinoma 
using intra-arterial administration (Maeda, 2012). The novel pharmaceutical showed exemplary 
efficacy against advanced hepatocellular carcinoma with a low incidence of adverse effects. For 
instance, the treatment increased aspartate aminotransferase and alanine aminotransferase plasma 
levels in only 16 and 10% of patients, respectively (Konno, 1992).  
 
Figure 1:12: Synthesis of crizotinib encapsulating SMA micelles. The SMA solution is adjusted 
to pH 5.0 and the drug to be encapsulated and the EDAC is added to the solution. The EDAC binds 
to the maleic acid groups of the SMA, releasing an OH- group and increasing the pH. The pH is 
maintained at 5.0 by addition of HCl until all available groups on the SMA have reacted with 
EDAC. This enables maximal contact between the hydrophobic styrene groups and the 
hydrophobic TKI. The pH is then raised to 11.0 using NaOH and maintained at this pH. This 
removes the EDAC from the maleic acid groups, resulting in the coalescence of the hydrophobic 
components to form a structure with a hydrophobic core and a hydrophilic shell (Greish et al., 
2004). 
SMA can also be used to encapsulate drugs using the protocol outlined in Figure 1:12. This 
procedure produces a micellar construct where the drugs are encapsulated inside, but not bound 
to, the SMA polymer using the catalyst Ethyl dimethyl aminopropyl carbodiimide (EDAC). This 
formulation is stable, large molecular weight construct with a critical micelle concentration of 
3.5-5.0 ng/mL (unpublished data).  
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The range of agents that can be successfully encapsulated into this construct is diverse, including 
doxorubicin, pirarubicin, epirubicin, cannabinoids, raloxifene, zinc protoporphyrin and curcumin 
derivatives (Greish et al., 2005; Greish et al., 2004; Iyer et al., 2007; Linsell et al., 2015; Parayath 
et al., 2015; Taurin et al., 2013; Taurin et al., 2014). The size of the micellar formulation prevents 
the free diffusion of encapsulated drugs across tissue barriers while facilitating accumulation of 
the drugs at the tumor site. For example, SMA doxorubicin micelles showed 13-fold higher 
accumulation of doxorubicin in tumor tissue relative to free doxorubicin following intravenous 
(IV) administration (Greish et al., 2004). This greater accumulation of drug at the tumor site 
potentiates the anticancer efficacy of the encapsulated agent. The selective tissue permeability of 
the macromolecular construct also increases the maximum tolerated dose of chemotherapeutics, 
increasing the safety of pirarubicin by 10-fold relative to the free drug (Greish et al., 2005). 
The use of SMA to encapsulate the TKIs will confer water solubility to the otherwise hydrophobic 
molecules and allows an increased plasma half-life as the constructs are too large to be excreted 
through the urinary route (Taurin et al., 2012). The use of SMA is particularly advantageous as 
this polymer generates a construct with neutral or near-neutral charge, therefore preventing 
opsonization of the construct and subsequent recognition by the reticuloendothelial system and 
removal from the circulation (Nie, 2010). SMA constructs including SMANCS and SMA based 
micelles also adsorb serum albumin onto the surface of the micelle, further preventing 
opsonization of the macromolecule (Elsadek & Kratz, 2012; Fang et al., 2011; Greish et al., 2005; 
Greish et al., 2004; Maeda et al., 2001).  
The encapsulation into this micellar system may also be beneficial to prevent premature 
metabolism of the TKIs. As previously discussed, dasatinib and crizotinib are extensively 
metabolized by hepatic enzymes, resulting in a relatively low bioavailability. Following micellar 
encapsulation, the reactive sites of the drugs are no longer available to the metabolic enzymes, 
preventing drug breakdown. 
1.5    Summary 
The aim of this study was to develop a broadly selective treatment option for the highly 
heterogeneous glioblastoma. As has been previously observed in a range of cancers, single agent 
chemotherapies are rarely curative. This may be due to the heterogeneity of the cell populations 
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wherein treatment with a single agent is unable to effectively treat all of the cell types present and 
so the treatment selects for resistant cells. The use of multiple treatments also decreases the risk of 
resistance developing as multiple pathways are being targeted. As a consequence, a combination 
treatment was pursued. As dasatinib is a substrate of P-gp and BCRP and these proteins have been 
found to restrict the penetration of dasatinib in the CNS (Chen et al., 2009), co-treatment with 
crizotinib, an inhibitor of P-gp (Zhou et al., 2012), may result in increased efficacy of dasatinib. 
Furthermore, the TKIs were modified by a micellar formulation in an effort to facilitate a favorable 
biodistribution profile of the drug in vivo. 
1.6    Hypothesis and aims 
1.6.1   Hypotheses 
Hypothesis 1) A combination of TKIs with diverse targets will produce improved efficacy against 
glioblastoma cells by targeting multiple pathogenic pathways including survival, invasion and 
angiogenesis.  
Hypothesis 2) Use of a micellar delivery system will allow favorable alteration of the 
physicochemical characteristics of the drugs with similar in vitro efficacy and allow the potential 
for passive targeting of the TKIs to the tumor via the EPR effect in vivo. 
1.6.2   Aims 
Aim 1) Establish a combination of TKIs that is effective against a panel of glioblastoma cell lines. 
Aim 2) Encapsulate these TKIs into SMA micelles.  
Aim 3) Establish the effect of free and micellar TKIs on glioblastoma cell death and signaling. 
Aim 4) Establish the effect of free and micellar TKIs on cell morphology and tyrosine kinase 
localization. 
Aim 5) Establish the ability of TKI combination treatment to suppress migration, invasion and 




2   Materials and Methods 
2.1  Materials 
Crizotinib (C-7900), dasatinib (D-3307), gefitinib (ZD-1839), imatinib (I-5577), lapatinib 
(L-4899), nilotinib (N-8207), pazopanib (P-6706), PD-173074 (P-3333), sunitinib (S-8877), 
selumetinib (S-4490), sorafenib (S-8599), tofacitinib (T-1377) and tozasertib (T-2304) were 
purchased from LC Laboratories (Massachusetts, USA).  
Specific antibodies against AKT (p44/42) (#9272), EGFR (#4267), Met (#8198), P-AKT (S473) 
(#4058), P-Met (Y1234/Y1235) (#3077), P-SRC (Y416) (#6943), SRC (#2123), and α-tubulin 
(CTE3873P) were purchased from cell signaling technology (Massachusetts, USA).  
4',6-diamidino-2-phenylindole (DAPI) (32670), bicinchoninic acid (BCA) solution (B9643-1L), 
dialysis tubing (D9527), EDAC, Fetal bovine serum (FBS) (12203C), paraformaldehyde (158127), 
propidium iodide (PI) (P4170), SMA (Molecular weight 1,600) (442380), Sulforhodamine B 
(SRB) (S9012), trisaminomethane (TRIS) (T1503) and β-tubulin (T5293) were purchased from 
Sigma-Aldrich (Auckland, New Zealand).  
Consumables (flasks, 96 well plates etc.) for cell culture and Immobilon-P blotting membrane 
PVDF (SCTIPVH00010) were purchased from Lab Supply (Dunedin, New Zealand).  
CL-XPosure Film (PIE34091), Geltrex™ LDEV-Free Reduced Growth Factor Basement 
Membrane Matrix (A1413202), normal horse serum (VES2000), ProLong Gold Antifade Reagent 
(P36934), Roswell Park Memorial Institute medium (RPMI) 1640 medium (11875119), 
SuperSignal West Pico (PIE34078), and TrypLE Express (12604-021) were purchased from 
ThermoFisher (Auckland, New Zealand).  
Trichloroacetic acid (TCA) (SCARAC31320250) was purchased from Global Science (Auckland, 
New Zealand).  
Annexin V (11828681001) was purchased from Roche (Auckland, New Zealand).  
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5-FAM-phalloidin (92-0-12) was purchased from American Peptide Company Inc (Sunnyvale, 
California, USA). 
Ultima Gold (6013321) and [H3]thymidine was purchased from SciMed Ltd. (Christchurch, New 
Zealand).  
EGM-2 BulletKit (CC-3162) was purchased from Alphatech Systems (Auckland, New Zealand). 
2.2  Cell culture 
Cells were maintained in complete growth medium composed of RPMI supplemented with 5% 
FBS. Cells were maintained in a humidified atmosphere at 37oC, 95% O2, 5% CO2. Cells were 
passaged using TRYPLe when they reached 80% confluency and established glioblastoma cells 
were not used above 20 passages. U87, NZG1003 and NZG0906 cells were kindly provided by 
Dr Melanie McConnell (University of Victoria, Wellington, New Zealand) and U373 cells were 
kindly provided by Dr. Andrew Bahn (University of Otago, Dunedin, New Zealand).  
NZG1003 and NZG0906 cells were isolated from patients who met histologic criteria for diagnosis 
with glioblastoma and who did not have any other active malignancy and had not previously 
received chemotherapy for any non-glioblastoma malignancies. Tumor tissue was resected and 
mechanically dissociated. The single cell-suspension was cultured in RPMI supplemented with 
10% FBS, 100 U/mL penicillin and 100 μg/mL streptomycin. All patient donors gave written 
informed consent, and ethical approval for tissue collection was obtained from the Central 
Regional Ethics Committee of New Zealand (Hunn et al., 2012).  
2.3  Micelle Synthesis 
Micelles were synthesized as follows. SMA was hydrolysed by dissolving the powder in 1.0 M 
NaOH at 70oC to achieve a concentration of 10 mg/ml. Hydrolyzed SMA was adjusted to pH 5.0 
and N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDAC) in a 1:1 ratio by 
weight with SMA, was dissolved in distilled water. TKIs were dissolved in dimethyl sulfoxide 
(DMSO) at a concentration sufficient for a target loading of 25% w/v. EDAC and the TKI were 
added to the SMA solution simultaneously and the pH was maintained at 5.0 until the pH stabilized 
in order to catalyze the reaction between EDAC and SMA that occurs at low pH. When the pH 
had stabilized at 5.0, the pH was raised to pH 11.0 and maintained until stable. This increase in pH 
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removes the EDAC from the carboxyl groups of the SMA and allows the hydrophobic core to 
condense around the hydrophobic TKIs. The pH was then lowered to 7.4 and the solution was 
filtered by 95%, 4 times using a Millipore labscale TFF system with a Pellicon XL 10,000 Da 
cutoff membrane. This filtration strategy removes more than 99.99% of water soluble EDAC and 
ions. The solution was then frozen at -80oC before being lyophilised. 
2.4  Characterization 
Loading was determined by weighing the micelle in triplicate. The samples were then disrupted in 
DMSO at a concentration of 1.0 mg/mL and the absorbance of the drug was read and compared to 
a standard curve in order to determine the weight ratio between the micelle and the loaded drug. 
The size and charge of the micelles was determined using the Malvern Instruments zeta sizer using 
a 10 mg/mL solution of micelles using double distilled water as the diluent for size and 10 mM 
KCl as the diluent for charge. The release rate was determined via the dialysis method. Micelles 
were dissolved at a concentration of 1.0 mg/mL in phosphate buffered saline (PBS) at pH 7.4 and 
6.8. pH 7.4 corresponds to the pH of the blood while pH 6.8 corresponds to the extracellular pH 
of the tumor. 1.0 mL of the solutions was inserted into a 1,000 Da cutoff dialysis membrane. This 
was immersed in 10 mL of PBS. At the indicated times, the surrounding PBS was removed and 
replaced with fresh PBS in order to reduce the error in measurement caused by drug breakdown 
and increase the sink effect. The quantity of TKI in the PBS was quantified using absorbance at 
320 nm as detected by a spectrophotometer.  
2.5  Cell number using a monolayer model 
Cell number was assessed to examine the potency of the free and micellar encapsulated crizotinib 
and dasatinib, alone and in combination. Cells were seeded into 96-well plates (density; U87: 
5,000, LN-18: 4,000, U373: 4,000, A172: 4,000, NZG1003: 5,000, NZG0906 5,000 cells/well) 
and incubated for 24 h. The seeding density was chosen based upon the number of cells needed to 
achieve 80% confluence following 96 h incubation. Following this period, the cells received the 
indicated treatments for 72 h. The cytotoxicity was assessed using a SRB assay as previously 
described (Vichai & Kirtikara, 2006). Briefly, cells were fixed with 50 µL of TCA overnight at 
4oC. The plate was washed with distilled water and dried and the protein stained with 50 µL of 
SRB dissolved in 1% acetic acid. SRB binds to basic amino acids in acidic conditions. The SRB 
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was aspirated and the plate washed with 1% acetic acid to remove unbound SRB. The plate was 
dried and the SRB was solubilized in 100 µL of TRIS at pH 10.5 to reverse the charge of the basic 
amino acids and release the SRB into solution. The plate was mixed and the absorbance was read 
at 490 nm, deducting the background at 630 nm. Validation of the correlation between optical 
density and cell number for the glioblastoma cells is presented in supplementary Figure 5:1. 
2.6  Cell number using a 3D model  
Though the monolayer is informative as to the ability of the formulations to penetrate cell layers 
is not a factor in the monolayer cytotoxicity model. Subsequently, cytotoxicity in 3D tumor 
spheroids was assessed. Agarose (15 mg/mL) was solubilized in PBS by autoclaving. The resulting 
solution was mixed and distributed (50 µL/well) in 96 well plates. The agarose was left to set for 
1 h and cells (5,000 cells/well) were seeded into the wells in a volume of 200 µL. As the cells are 
unable to adhere to or invade through the agarose, the cells adhere to one another in a liquid overlay 
culture (Carlsson & Yuhas, 1984; Friedrich et al., 2007). This results in the growth of 3D structures 
termed spheroids (Carlsson & Yuhas, 1984). The cells were incubated for four days to form stable 
spheroids. Following the four day incubation, 100 µL of media was removed and replaced with 
100 µL of pre-treated media to give a final well concentration of 0.2 µM dasatinib and/or 4.0 µM 
crizotinib and treated for four days. Following the treatment period, the viability of the spheroids 
was assessed via an acid phosphatase assay as described previously (Friedrich et al., 2007). The 
spheroids were collected (6 replicates per experiment), the media aspirated, and the spheroid 
washed with 500 µL of 4oC PBS. The cells were then suspended in 100 µL PBS and the spheroid 
disrupted by sonication. Each sample was pipetted into a well of a clean 96 well plate. Immediately 
before use, p-nitrophenyl phosphate (2 mg/mL) was solubilized in Triton: Na+ Acetate 
(0.1%:0.1 M) and 100 µL of the resulting solution was added to each well of the 96 well plate. The 
plate was incubated for 90 min (37oC) in the dark before the reaction was halted by the addition 
of 10 µL of 1.0 M NaOH. The resulting absorbance was read at 405 nm deducting background 
630 nm within 10 min of NaOH addition. Validation of the correlation between optical density 
and cell number for the glioblastoma cells is presented in supplementary Figure 5:2. 
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2.7  Apoptosis/necrosis 
The mode of cell death induced by the treatments was determined by fluorescence-activated cell 
sorting (FACS). The mode of cell death can be deduced via labeling with PI and annexin V. In 
necrotic cell death, the plasma membrane develops holes, allowing PI, which is not able to cross 
the intact plasma membrane, to enter the cell and stain the DNA, thereby identifying cells that are 
likely to be necrotic (Rieger et al., 2011; Vermes et al., 1995). Annexin V is an antibody to 
phosphatidylserine, a lipid that will typically only be exposed on the plasma membrane when the 
cell is undergoing apoptosis and promotes clearance of the cell by macrophages (Fadok et al., 
1992). 
Cells were seeded into 6-well plates and incubated for 24 h. Cells were then treated with 0.2 µM 
dasatinib and/or 4.0 µM crizotinib for 48 and 72 h. For washout experiments, the media was 
aspirated following 72 h of treatment, the cells washed with warmed PBS, before adding 2.0 mL 
of fresh, untreated RPMI, 5% FBS in each well. Following the incubation period, plates were 
removed from the incubator and media from each well transferred into separate tubes. The cells 
were washed twice with warmed PBS before 300 µL of trypsin was added to each well and the 
plates were incubated at 37oC for four min. Following incubation 300 µL of warmed PBS was 
added to each well and the cell suspension was collected. The well was washed twice with PBS to 
ensure all cells were collected and centrifuged at 4oC, 1,000 g for five min. The supernatant was 
aspirated and the pellet was washed twice in 600 µL of 4oC PBS and centrifuged. Following this, 
the supernatant was aspirated and the cells resuspended in 100 µL of FACS binding buffer 
(HEPES; 10.0 mM (pH 7.4), NaCl; 140.0 mM, and CaCl2; 5.0 mM) supplemented with PI and 
annexin V conjugated to FITC. The cells were incubated for 15 min in the dark at room temperature 
before the cells were resuspended in 300 µL of FACS binding buffer.  
Cell staining was assessed using a BD FACSCalibur machine. A dot plot showing all cells using 
the parameters FSC-H vs. SSC-H was gated to ensure that doublet cells were excluded but included 
sub-cellular events. A second graph of FL1-H (annexin V fluorescence) vs. FL2-H (PI 
fluorescence) was used to visualize the cells which was gated to the FSC-H vs. SSC-H plot. A 
minimum of 10,000 cells through the gate was required for a sample to be included in the analysis. 
Annexin V binds to phosphatidylserine, which is exposed on the outside of cells in the early stages 
of apoptosis and is considered to represent a cell that is committed to cell death. PI is a dye that 
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binds to DNA but is unable to pass through intact cell membranes and therefore stains only cells 
with pores in the plasma membrane. Cells stained with both PI and annexin V were not included 
in the analysis as this group could represent late apoptosis or late necrosis which cannot be 
distinguished using this assay (Elstein & Zucker, 1994). Representative examples of the 
designation of different populations for each cell line examined can be found in supplementary 
Figure 5:3. 
2.8  Western Blotting 
In order to assess the expression and activity of proteins involved in the survival, proliferation and 
invasion of glioblastoma, western blotting was undertaken as a semi-quantitative experiment. Cells 
were seeded in Petri dishes (200,000 cells/dish) and incubated for 24 h before being treated for 
48 h with the indicated drug concentrations. Following the treatment period, the cells were lysed 
with lysing buffer (Tris-HCl; 50 mM (pH 8), NaCl; 150 mM, Triton X-100; 1%, SDS; 1%, NaF; 
1mM sodium orthovanadate; 200 μM, leupeptin; 1 μg/mL, aprotinin; 1 μg/mL, and PMSF; 1 mM) 
and the protein was normalized across the treatments using a BCA assay as previously described 
(Walker, 1994). Following normalization, the samples were run on acrylamide gels and transferred 
onto Immobilon-P blotting membrane PVDF. The membrane was blocked with 1% bovine serum 
albumin (BSA) for 1 h and blotted with the indicated antibodies. Horseradish peroxidase 
conjugated secondary antibodies were used and reacted with SuperSignal West Pico for 
development and chemiluminescence was developed on X-ray film. The experiments were 
repeated three times and the level of expression quantified using ImageJ Analysis Software. 
Relevant examples of densitometry have been inserted in the text. The densitometry provided is 
percentage or fold of control as specified. The densitometry is provided for the purposes of 
indicating the reliability of the expression patterns throughout the replicates and is not an accurate 
representation of relative chemiluminescence. This is because the linear range for band intensity 
is very narrow when using chemiluminescence and X-ray film (Taylor et al., 2013). The values 




2.9  Thymidine incorporation 
In order to assess the effect of treatment on DNA syntheses, thymidine incorporation was assessed. 
Cells were seeded in 24-well plates (20,000 cells/well) and incubated for 24 h before 
synchronization of the cells in starvation media (media supplemented with 0.1% BSA) for 24 h. 
Starvation media was then removed and warmed growth media was added before the cells were 
treated. 20 h before the treatment end point, 0.25 µCuries of [H3]thymidine was added to each 
well. At the end of the treatment period the media was removed and the cells were washed with 
4oC PBS before being fixed with 250 µL of 5% TCA for 30 min. After fixation, the TCA was 
removed and the cells washed again with PBS before 0.5 mL of 0.5 N NaOH/0.5% SDS was added 
to the well and the cells thoroughly mechanically disrupted. The suspension was added to 
scintillation vials and 3.0 mL of Ultima Gold added before radioactivity was measured using a 
PerkinElmer Tri-Carb 2910 TR scintillation counter. 
2.10  Cell cycle 
In order to determine the distribution throughout the cell cycle in response to treatment, FACS was 
used to assess cellular DNA content. Cells were seeded into 6-well plates and incubated for 24 h. 
Cells were then treated with the indicated concentrations of crizotinib and/or dasatinib for 48 and 
72 h. For washout experiments, cells were treated for 72 h before the media containing the drugs 
was removed. The cells were washed with warmed PBS before 2.0 mL of warmed, fresh growth 
media was placed in the wells, and the cells were further incubated for up to 72 h. Following the 
incubation period, cells were removed from the incubator and media collected into separate tubes. 
The cells were washed twice with warmed PBS before 200 µL of trypsin was added to each well 
and the plates were incubated at 37oC for four min. Following incubation 300 µL of warmed PBS 
was added to each well and the cell suspension was collected. The well was washed twice with 
PBS to ensure all cells were collected and centrifuged at 4oC, 1,000 g for four min. The supernatant 
was aspirated and the pellet was washed via resuspension in 600 µL of 4oC PBS and centrifugation. 
Following this, the cells were resuspended in 300 µL of 4oC PBS and 700 µL of 4oC PBS was 
added drop-wise to fix the cells. The cells were incubated overnight at 4oC and protected from 
light. Following fixation, cells were removed, centrifuged and washed once with 4oC PBS. The 
cells were then resuspended in 300 µL of PBS, incubated in a 37oC water bath in a staggered 
manner for exactly five min, 0.5 µL of 25.0 µg/mL RNAse A was added and the cells were 
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incubated for a further five min before the reaction was stopped by placing the cells on ice. PI was 
then added and the cells were incubated at 4oC in the dark for 1 h before the degree of staining was 
assessed using a BD FACScalibur machine with a 15 milliwatt, air-cooled argon-ion laser. Cells 
were gated using SSC-H (measure of side scatter, reflective of internal complexity), FSC-H 
(measure of forward scatter, reflective of particle size), FL2-A (pulse area) and FL2-W (pulse 
width). 
A dot-plot of FSC-H vs. SSC-H was used to gate out debris by discriminating between healthy 
cells and cellular debris. A dot-plot of FL2-A vs. FL2-W allows discrimination of a G0/1 doublet 
vs. a G2/M cell. This is because a G0/1 doublet and a G2/M cell will have the same FL2-A signal but 
the cellular doublet will have a higher FL2-W reading due to the increased width associated with 
two joined cells passing through the laser path. This plot was used to gate out aggregated cells i.e. 
cells with a pulse width indicating one or more cells passed through the laser path together.  
Finally, a histogram plot was gated to exclude cells that were determined in the previous two dot-
plots to be likely to be cellular debris or clumped cells. This histogram had the parameters counts 
vs. FL2-A. This plot gives the area of the pulse in order to yield plots such as those presented in 
Figure 2:1. A minimum of 10,000 cells passing through both gates was required for a sample to be 
analyzed.  
The separate designation for DNA content in the cells used in this thesis and defined in Figure 2:1 
is because the typical application of karyotype designation is not true for some glioblastoma cells. 
For example, the chromosome number of LN-18 cells varies from 70 – 80 with a modal number 
of 78 (Diserens et al., 1981), A172 cells have ~77 chromosomes per cell (Bigner et al., 1983) and 
U87 cells have a modal chromosome number of 44 (Yoshida et al., 2013). Conversely, U373 cells 
have the expected chromosome number for the 2n karyotype, 46 chromosomes. Therefore the 





Figure 2:1: Representative images of the gating techniques employed for cell cycle.  LN-18 
cells were treated for 48 hours before the cells were processed as described above. A) free control, 
B) free dasatinib, C) free crizotinib, D) free combination, E) key for the respective designation of 
cell cycle.  
2.11 Immunocytochemistry 
In order to assess cellular distribution of relevant kinases, immunocytochemistry was undertaken. 
Cells were seeded onto glass slides (U373: 16,000, LN-18: 20,000 cells/well) and incubated for 
24 h. Following this period, the cells were treated with dasatinib (0.2 µM) and/or crizotinib 
(4.0 µM) for 48 h. Then, the cells were washed with PBS and fixed in 4% paraformaldehyde 
overnight at 4oC. Following fixation, the cells were washed with TRIS-buffered saline (TBS) twice 
and permeabilized with TBS:0.2% TWEEN for 20 min. The cells were then washed with TBS and 
blocked in TBS supplemented with horse serum (1.5%) for 1 h at room temperature. Anti-SRC or 
anti-Met antibodies were added and the cells were incubated overnight at 4oC or with an 
anti-α-tubulin antibody for 1 h. The cells were washed in TBS and FITC or Texas Red labeled goat 
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anti-rabbit or anti-mouse secondary antibodies were incubated for 1 h at room temperature. Cells 
were washed in TBS before being incubated in 50 µL of DAPI (50 ng/mL) for 30 min in the dark. 
The cells were washed five times with TBS and mounted onto microscope slides using ProLong 
Gold antifade reagent.  
2.12  Cytoskeleton visualization 
Staining of the cytoskeleton components filamentous actin (F-actin) and α-tubulin was undertaken 
in an effort delineate the effect of treatment on cell morphology and cytoskeleton integrity. 
Phalloidin coupled to 5-Carboxyfluorescein binds to F-actin to visualize the cytoskeleton. Cells 
were seeded onto glass slides (U87; 24,000, LN-18; 20,000, U373; 16,000, and A172; 16,000 
cells/well) and incubated for 24 h. Following this period, the cells were treated with the indicated 
concentrations of drug (dasatinib; 0.2 µM and/or crizotinib; 4.0 µM) for a period of 48 h. 
Following the treatment period, the media was aspirated, the cells were washed with PBS, and 
fixed overnight using 4% paraformaldehyde at 4oC. Following fixation, the cells were washed with 
TBS twice and permeabilized with TBS:0.2% Triton X 100 for five min. The cells were then 
washed three times with TBS and incubated with 60 µL of 50 µg/mL 5-fam-phalloidin for 40 min 
or anti-α-tubulin antibody overnight. Following the incubation with anti-α-tubulin antibody, a 
secondary FITC labeled anti-mouse antibody was applied and incubated for 1 h at room 
temperature. Following this, cells labeled for F-actin or α-tubulin were washed three times with 
TBS before being incubated in 50 µL of 50 ng/mL DAPI in the dark for 30 min. Following the 
incubation, the cells were washed five times with TBS and mounted onto microscope slides using 
ProLong Gold antifade reagent. Pictures were taken on a Nikon microscope. 
2.13  Transfection 
In order to assess the dependence of cytotoxicity on the expression and activity of Met kinase, 
clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 plasmids directed 
towards the first exon of the Met gene using the sequence TCAGCTGTCGCCCCGCATC were 
obtained from Genscript USA Ltd. This plasmid is used to produce a frameshift mutation in the 
gene, rendering it non-functional. The plasmid was amplified using E. coli DH5 alpha. Cells to be 
transfected were seeded (20,000 cells/well) in 6-well plates in growth media and incubated for 
24 h. Cell media was aspirated and replaced with 1.0 mL of Opti-MEM Medium and cells were 
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transfected using the lipofectamine 3000 reagent protocol as per the manufacturer’s instructions. 
Briefly, lipofectamine 3000 (60 µL/mL) was suspended in Opti-MEM Medium while DNA 
(40 µg/mL) and P3000 (80 µg/mL) were diluted in Opti-MEM Medium. The lipofectamine and 
DNA:P3000 solutions were mixed and stood at room temperature for 20 min before 250 µL of 
solution was pipetted onto each well, mixed and returned to the incubator for 24 h. Following the 
incubation, the media was removed and fresh growth media was applied. When the cells reached 
80% confluence, the cells were trypsinized and seeded in 250 mL flasks and maintained with 
1.0 µM of gentamicin to select cells carrying the plasmid for two weeks, passaging as necessary. 
Knockdown of Met was confirmed by western blotting. All procedures were approved by 
University of Otago Institutional Biological Safety Committee GMO05.UO015 and Book of 
Knowledge approvals GMD101730, GMD101717. 
2.14  Tube formation and Tube-like formation 
In order to assess the potential of the combination against angiogenesis and vascular mimicry the 
in vitro tube formation and tube-like formation models was used. Geltrex was defrosted at 4oC and 
35 µL of Geltrex was placed in the base of each well of a 96-well plate and placed in a 37oC 
incubator to solidify for 45 min. Following this, cells human umbilical vein endothelial cells 
(HUVEC); 15,000 cells/well, U87; 15,000 cells/well, U373; 14,000 cells/well, and A172; 14,000 
cells/well were seeded in a total volume of 100 µL into the wells containing the solidified Geltrex 
and allowed to fix to the basement matrix for 2 h before being treated. Following 20 h of treatment, 
pictures of the resulting tube formation were taken at 20 X magnification. LN-18 cells do not 
produce tube-like structures and so were not used in this assay. 
2.15  Scratch assay 
In order to assess the ability of glioblastoma cells to migrate in the presence of non-cytotoxic 
concentrations of TKIs, a scratch assay was employed. Cells were seeded into 6-well plates 
(100,000 cells/well) and grown to 80% confluency. A scratch was formed using a 10 µL tip and 
the well was washed with 1.0 mL of warmed PBS to remove the dislodged cells before 1.5 mL of 
fresh, warmed growth media was placed on the cells. Pictures were taken at 20X magnification 
and the cells were treated with 0.2 µM of dasatinib and/or 0.75 µM of crizotinib for 24 h before a 
second set of pictures were taken at the same place. This concentration was used as in order to 
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distinguish the influence of the drugs on migration without interference from a cytotoxic effect. 
U87 cells were not assessed for the scratch assay as U87 cells do not form a monolayer suitable 
for the experiment. 
2.16  Invasion 
As invasion constitutes one of the most significant barriers to successful treatment, the ability of 
non-cytotoxic concentrations of TKIs to prevent invasion was assessed. Geltrex was diluted 1:1 
with RPMI (no FBS) and 100 µL of the resulting solution was pipetted into the membrane (taking 
care to ensure that there was no bubbles) of 6.5 mm transwell chambers (8.0 µm polycarbonate 
membrane) and placed into the incubator to set for 1 h. Following the setting period, cells 
(20,000 cells/well) were seeded in a total volume of 100 µL of starvation media and 500 µL of 
growth media was placed in the bottom well to create a chemoattractant gradient. The upper well 
was treated immediately post seeding (0.2 µM dasatinib and 0.75 µM crizotinib in order to not 
induce cell death) and incubated for 24 h. Following the 24 h period, the transwells were removed 
from the growth media and the cells and fixed and stained via sequential staining with the 
DiffQuick staining kit according to the manufacturer’s instructions. The Geltrex was carefully 
removed from the transwells and the transwells were left to dry. The polycarbonate membrane was 
cut from the mold, placed between glass slides and the cells were counted manually using a Nikon 
microscope. 
2.17  Statistics 
Cell cycle data was subjected to Logit transformation to compensate for the non-normal 
distribution of the data and analyzed using a 2-way analysis of variance (ANOVA) with a 
Bonferroni post hoc test.  
All other data was analyzed using a one-way ANOVA with a Bonferroni post hoc test. A 
Bonferroni post hoc test was used as this test is more conservative, reducing the type I error rate. 
Significance was set at p ≤ 0.05. 
All experiments were conducted in triplicate or sextuplicate as specified in the respective figure 
legends and independently repeated three times. All quantified data (micelle characterization, 
SRBs, acid phosphatase, apoptosis/necrosis, cell cycle, thymidine incorporation and the invasion 
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assay) is the mean ± SEM of all data points collected. All qualitative data (kinase localization, 
western blotting, cytoskeleton visualization, tube formation, scratch assays) is presented as 
representative images.  
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3   Results 
3.1  Screening 
Although tyrosine kinases are often mutated or overexpressed in glioblastoma, this does not 
necessarily guarantee that inhibition of these kinases will result in decreased proliferation or 
increased cell death. In order to assess which TKIs were able to reduce glioblastoma cell 
proliferation or viability, a screen of TKIs with a diverse target range was assessed in a panel of 
glioblastoma cells.  
The results of the TKI screening can be seen in Table 3:1. Pazopanib, imatinib, tofacitinib, 
lapatinib and gefitinib, all displayed IC50s at or above 10.0 µM in most of the cell lines examined. 
This indicates that the targets are either not strongly expressed on glioblastoma cells or are not 
important for survival or proliferation and so these drugs were not pursued further. Furthermore, 
the lack of efficacy of these drugs allowed the identification of VEGFR 1-3, PDGFR α, PDGFR 
β, Kit, and MEK as proteins that were not effective to inhibit in glioblastoma cells in vitro and so 
the expression and activity of these proteins was not assessed further. Although the EGFR 
inhibitors gefitinib and lapatinib showed low efficacy, the expression of EGFR was examined 
further in this work as previous research has established that the inhibition of EGFR alone is not 
effective due to Met compensating for the loss of EGFR activity and vice versa (Kawaguchi et al., 
2009; Mueller et al., 2012; Xu et al., 2011). 
The potency of the TKIs was influenced by both the targets and the cell lines. GL261, the mouse 
glioblastoma cell line considered for the in vivo model, was more sensitive to the TKIs than the 
human cell lines in almost all treatments. The remaining TKIs were assessed in combination 
against the established human cell lines (U87, LN-18, U373, and A172). Crizotinib, dasatinib, 
nilotinib, PD-173074, sunitinib, selumetinib, and sorafenib were assessed in all possible 
combinations to establish which combinations showed additive or synergistic activity and should 
be pursued further. An example of the combinations can be seen in supplementary Figure 5:4 
where all combinations with crizotinib in LN-18 cells are presented. All combinations were 
initially examined at 1.0 µM, except dasatinib which was assessed at 0.2 µM as there was a plateau 
57 
  
in cell number following this concentration and raising the concentration did not result in increased 
efficacy (data not shown).  
The results from this TKI screen allowed the identification of the combination of crizotinib and 
dasatinib as the most potent combination. The combination of sunitinib and crizotinib was also 
highly efficacious in vitro but this combination was not pursued further. This is because dasatinib 
was more potent as a single agent. Furthermore, at the initiation of the study, several Phase I 
clinical trials demonstrating the safety and tolerance of dasatinib in glioblastoma patients were 
available while the same safety information about sunitinib was not available. The combination of 
dasatinib and sunitinib was less potent than the combination of crizotinib and dasatinib (data not 
shown). These TKIs were pursued for further study. These TKIs were also encapsulated to form 
micellar dasatinib (SMA-D) and micellar crizotinib (SMA-Cr). The TKIs were encapsulated 
because dasatinib and crizotinib are highly hydrophobic compounds that have low water solubility 
and are extensively metabolized resulting in unfavorable pharmacokinetic properties. 
Encapsulation will allow IV administration of the drugs in a formulation that confers water 
solubility and prevents renal excretion, extending the plasma half-life, while also allowing passive 
accumulation at the tumor site via the EPR effect. 
 
Figure 3:1: Crizotinib in combination with other effective TKIs in LN-18 cells. The 
concentrations are 1.0 µM for crizotinib (C), nilotinib, PD173074, sunitinib, selumetinib and 
sorafenib and 0.2 µM for dasatinib (D). Bars denote mean ± SEM following 72 h treatment. 
Experiments were conducted in triplicate and independently repeated three times.  
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Table 3:1: IC50 of TKIs against glioblastoma cell lines, kinases and the increased expression and/or activity in glioblastoma.  
Drug 
IC50 
Targets IC50 in cell-free assays
 Increased expression 
or activity U87 LN-18 U373 A172 GL261 
Crizotinib 2.1 µM 1.57 µM 3.3 µM 3.0 µM 0.85 µM 
Met 
12.0 nM  
(Crescenzo & Inghirami, 2015) 
(Kong et al., 2009) 
ALK 
24.0 nM  
(Crescenzo & Inghirami, 2015) 
(Powers et al., 2002) 
ROS1 
11.0 nM  
(Crescenzo & Inghirami, 2015) 
(Maxwell et al., 1996) 
Dasatinib 0.31 µM 0.25 µM 0.5 µM 2.35 µM 0.18 µM 
SRCs 
0.5 nM  
(Gora-Tybor & Robak, 2008) 
(Lu et al., 2009) 
PDGFR β 
28.0 nM  
(Gora-Tybor & Robak, 2008) 
(Hermanson et al., 1992) 
KIT 
13.0 nM  
(Gora-Tybor & Robak, 2008) 
(Joensuu et al., 2005) 
Gefitinib >15 µM 12.2 µM >15 µM >15 µM 13.2 µM EGFR 
2.0 nM  
(Thomas & Grandis, 2004) 
(Ekstrand et al., 1991) 
Imatinib >15 µM >15 µM >15 µM >15 µM >15 µM 
ABL 1-2 
0.2 µM  
(Deininger et al., 2005) 
No 
PDGFR α 
0.4 µM  
(Deininger et al., 2005) 
(Hermanson et al., 1992) 
KIT 
0.4 µM  
(Deininger et al., 2005) 
(Joensuu et al., 2005) 
Lapatinib 12.5 µM 7.0 µM 12.6 µM 12.4 µM 7.1 µM 
EGFR 
10.2 nM  
(Rusnak et al., 2001) 
(Ekstrand et al., 1991) 
ERBB 2 
9.8 nM  
(Rusnak et al., 2001) 
(Hiesiger et al., 1993) 
Nilotinib 12.5 µM 14.9 µM >15 µM 10.2 µM 8.6 µM 
ABL 1-2 
30.0 nM  
(Weisberg et al., 2005) 
No 
PDGFR 
71.0 nM  
(Weisberg et al., 2005) 
(Hermanson et al., 1992) 
KIT 
27.0 nM  
(Weisberg et al., 2005) 





Targets IC50 in cell-free assays 
Increased expression 
or activity U87 LN-18 U373 A172 GL261 
NVP-AEW541 7.4 µM 4.9 µM 6.8 µM 5.9 µM 1.0 µM 
IGFR 1 
150.0 nM  
(Garcia-Echeverria et al., 2004) 
No 
SRC 
2.4 µM  
(Garcia-Echeverria et al., 2004) 
(Lu et al., 2009) 
Pazopanib >15 µM >15 µM >15 µM >15 µM >15 µM 
VEGFR 
1 
7.0 nM  
(Kumar et al., 2009) 




(Kumar et al., 2009) 




(Kumar et al., 2009) 
(Jenny et al., 2006) 
PDGFR α 
73.0 nM 
(Kumar et al., 2009) 




(Kumar et al., 2009) 
(Joensuu et al., 2005) 
PD-173074 11.6 µM 6.18 µM 13.8 µM 0.95 µM 7.8 µM FGFR 1 
26.0 nM  
(Dimitroff et al., 1999) 
(Morrison et al., 1994) 
Selumetinib 14.7 µM >15 µM 11.9 µM >15 µM 7.7 µM MEK 1 
14.0 nM  
(de Castro Carpeño & Belda-
Iniesta, 2013) 
No 
Sorafenib 7.3 µM 4.9 µM 8.0 µM 6.2 µM 5.4 µM 
VEGFR 
1 
9.0 nM  
(Kumar et al., 2009) 
(Plate et al., 1994) 
VEGFR 
3 
7.0 nM  
(Kumar et al., 2009) 
(Jenny et al., 2006) 
FGFR 1 
64.0 nM  
(Kumar et al., 2009) 
(Morrison et al., 1994) 
PDGFR α 
0.9 µM  
(Kumar et al., 2009) 







Targets IC50 in cell-free assays 
Increased expression 
or activity U87 LN-18 U373 A172 GL261 
Sunitinib 6.0 µM 5.5 µM >15 µM 12.0 µM 3.8 µM 
VEGFR 
1 
21.0 nM  
(Kumar et al., 2009) 
(Plate et al., 1994) 
VEGFR 
2 
34.0 nM  
(Kumar et al., 2009) 
(Plate et al., 1994) 
VEGFR 
3 
3.0 nM  
(Kumar et al., 2009) 
(Jenny et al., 2006) 
KIT 
40.0 nM  
(Kumar et al., 2009) 
(Joensuu et al., 2005) 
PDGFR β 
75.0 nM  
(Kumar et al., 2009) 
(Hermanson et al., 
1992) 
Tofacitinib >15 µM >15 µM >15 µM >15 µM >15 µM JAK 3 
1.0 nM  
(van Gurp et al., 2009) 
No 
Abbreviations are: ABL - Abelson Murine Leukemia; ALK – Anaplastic Lymphoma Kinase; EGFR – Epidermal Growth Factor 
Receptor; FGFR – Fibroblast growth factor receptor; IGFR – Insulin like Growth Factor Receptor; JAK – Janus Kinase; MEK – 





3.2  Characterization 
3.2.1  Physicochemical characteristics 
Though the encapsulation of the drugs into micelles increased water solubility, it also altered 
physicochemical parameters such as macromolecular size and charge. These parameters have 
important connotations for the plasma half-life of the constructs. In order to characterize these 
changes, water solubility, size and charge of the constructs was assessed.  
The characteristics of the micelles are shown in Table 3:2. The targeted micelle loading was 
targeted to 25% w/w for both drugs and the encapsulation of crizotinib (80.9%) was more 
efficient than the encapsulation of dasatinib (44.8%). The SMA encapsulated TKIs showed a 
TKI solubility of 27.2 and 53.7 mg/mL respectively. The size of the micelles was over 100 nm 
for both constructs. This size exceeds the 7.0 nm threshold for renal excretion and results in a 
prolonged plasma half-life. The charge of both micelles was negative (Table 3:2). 








Size ± SEM 
(nm) 
Charge ± SEM 
(mV) 
SMA-D 11.5% 44.8% 27.2 198 ± 64 -45.2 ± 7.47 
SMA-Cr 20.2% 80.9% 53.7 128 ± 55 -42.5 ± 7.63 
 
3.2.2  Release rate 
The encapsulation of TKIs results in the percentage of drug available to affect the cells being 
reduced as the TKI must first be released from the micelle. Therefore, the rate of release is 
important for confirming that the micelle is stable in solution and determining the rate at which 
free drug is liberated from the micelles.  
Subsequently, the rate of release of micellar encapsulated dasatinib and crizotinib from the 
micelles was assessed in PBS at pH 7.4 and 6.8 (Figure 3:2). pH 7.4 corresponds to the pH of 
the blood and pH 6.8 corresponds to the extracellular pH of glioblastoma tumors (Vaupel et 
al., 1989). The release rate was higher following incubation in pH 7.4 PBS than in pH 6.8 PBS 
(53.6% vs. 45.6% for crizotinib micelles and 39.7% vs. 35.7% for dasatinib micelles, 
respectively following 96 h incubation). This is consistent with observations of previous SMA 




Figure 3:2: Release rate of crizotinib and dasatinib from SMA micelles.  The release rate 
was assessed by dialyzing the micelle over a 96 h period using sink conditions. The micelles 
were dissolved in and dialyzed against in PBS at pH 7.4 and pH 6.8, 37oC, 70 RPM. Conditions 
are crizotinib pH 7.4 (●), crizotinib pH 6.8 (■), dasatinib pH 7.4 (▲), and dasatinib pH 6.8 
(▼). Data points represent the mean ± SEM. Experiments were conducted in quadruplicate.  
3.3  In vitro cytotoxicity  
3.3.1   Cell number 
Following the synthesis of the micellar encapsulated TKIs, optimization was conducted to 
determine the concentration of the free and micellar TKIs that would sufficiently reduce cell 
number in all of the cell lines. This involved applying concentrations ranging from 0.1 µM – 
1.0 µM for dasatinib and 0.5 µM – 5.0 µM for crizotinib in every possible combination. The 
combination with the lowest drug concentration which reduced cell number by at least 60% in 
all established glioblastoma cell lines for both free and micellar formulations was 0.2 µM of 
dasatinib and 4.0 µM of crizotinib (Figure 3:3).  
Free dasatinib (F-D) and free crizotinib (F-Cr) treatment reduced the number of cells by 35% 
to 52% and 45% to 75%, respectively, across all established and primary cell lines over a 72 h 
period. The free combination (F-Co) was more cytotoxic compared to the single treatments and 
decreased the number of cells by 71% to 90% across all cell lines (Figure 3:3). SMA-D and 
SMA-Cr showed lower potency relative to the free drug and reduced the number of cells by 
2% to 36% and 6% to 65%, respectively. Micellar combination (SMA-Co) reduced cell number 




Figure 3:3: Cell number following 72 h of free and micellar TKI treatment.  Cells were 
treated with 0.2 µM of dasatinib and/or 4.0 µM crizotinib in free (■) or micellar ( ) 
formulations and cell number was assessed using an SRB assay. A) U87, B) LN-18, C) U373, 
D) A172, E) NZG1003, and F) NZG0906 cells. Data is mean ± SEM, experiments were 
conducted in triplicate and repeated independently three times. * denotes p ≤ 0.05 as 
determined by a one-way ANOVA with a Bonferroni post hoc test.  
3.3.2  In vitro efficacy in 3D culture 
Although the ability of treatments to reduce cell number in monolayer culture is informative, 
it does not give information about the penetration of the drugs into 3D structures. In vivo, TKIs 
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would extravasate and diffuse through the dense perivascular cell layers into the tumor. 
Therefore, a 3D culture experiment was undertaken in order to determine the ability of the drug 
formulations to sufficiently penetrate cell layers to reduce viability. The cell lines U87 and 
NZG1003 were used for spheroids as these cell lines form stable spheroids that continue to 
grow throughout the treatment period. 
 
Figure 3:4: Cytotoxicity of TKIs using a 3D spheroid glioblastoma model. A) U87 
spheroids before (T0) and following four days of treatment (T4). B) Acid phosphatase activity 
of U87 spheroids following four days of treatment. C) NZG1003 spheroids before and 
following four days or treatment. D) Acid phosphatase activity of NZG1003 spheroids 
following four days of treatment. Data is mean ± SEM, experiments were conducted in 
sextuplicate and repeated independently three times. * denotes p ≤ 0.05 as determined by a 
one-way ANOVA with a Bonferroni post hoc test. Scale bars denote 200 µm.  
As can be seen in Figure 3:4, dasatinib treatment significantly reduced the diameter of U87 
spheroids following the free or micellar treatment. Crizotinib and combination treatments, free 
and micellar, reduced the spheroid viability by up to 75%. In NZG1003 spheroids, all of the 
treatment groups significantly decreased the viability of the spheroids although the micellar 
formulations were uniformly less effective than the free formulations. 
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3.3.3  Mode of cell death of glioblastoma cells following TKI treatment 
The mode of cell death induced by chemotherapies is vitally important in the treatment of 
glioblastoma as large amounts of necrosis induces inflammation which can exacerbate CNS 
edema. This results in an apoptotic mode of cell death being important for confirming the 
viability of a new treatment. Furthermore, BBB efflux and transient drug exposure, due to 
trough concentrations resulting from daily oral dosing or weekly IV administration, result in 
the penetration of drugs into the CNS varying significantly. Therefore, it is important to 
understand how the cells respond when the drug concentration falls in order to establish 
whether the cells can recover from the treatment rapidly in order to gain insight into the 
necessary frequency of dosing. In order to assess this, a washout experiment, where the cells 
were treated for 72 h before the treated media was removed and fresh growth media was 
applied, was assessed. 
 
Figure 3:5: Mode of cell death following TKI treatment and washout in U87 cells. Cells 
were treated and analyzed 48 and 72 h after treatment (-48 h and -72 h, respectively). Following 
this, the treatment was washed off and fresh media was applied. The cells were then analyzed 
24, 48 and 72 h after washout. A) Free formulations, B) micellar formulations. Bars denote 
necrotic; ■ (PI stained) and apoptotic;  (annexin V-stained). Data is mean ± SEM, experiments 
were conducted in triplicate and repeated independently three times. Statistical analysis utilized 
a one-way ANOVA with a Bonferroni post hoc test, p ≤ 0.05 relative to control for annexin V 
(*) and PI (ƚ). 
Glioblastoma cells treated with F-D or SMA-D showed no statistically significant increase in 
necrosis or apoptosis following treatment for 48 or 72 h or following drug washout when 
compared to control (Figure 3:5 - Figure 3:8). Treatment with F-Cr increased apoptosis after 
48 and 72 h and throughout the washout period in all established glioblastoma cell lines. A 
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small increase in necrosis was seen in U87 cells following washout. Conversely, SMA-Cr only 
caused a statistically significant increase in apoptosis following 72 h in U87, LN-18, and A172 
cells. Following washout of SMA-Cr, no cell lines showed apoptosis excluding U87 cells 
where a small (4.3%) but statistically significant level of apoptosis was observed following 
24 h washout but not in the subsequent time points.  
The F-Co induced apoptosis following treatment and washout in all cell lines (Figure 3:5 - 
Figure 3:8). Furthermore, following 72 h treatment, the apoptosis induced by F-Co treatment 
was in general synergistic relative to the single treatments. The only apparent increase in 
necrosis was seen in U87 cells. SMA-Co treatment only induced a statistically significant 
increase in apoptosis after 72 h incubation in all cell lines. Following washout, the recovery of 
cells from treatment was cell line dependent. In LN-18 and A172 cells, the proportion of cell 
death 72 h following washout remained high in the F-Cr (32.4% and 29.1%, respectively) and 
F-Co treatment groups (50.4% and 39.7%, respectively). In U373 cells, the number of apoptotic 
cells following F-Cr or F-Co treatment progressively decreased over the 72 h washout period 
(33.6% at 24 h to 11.8% at 72 h washout). In U87 cells, the proportion of apoptotic cells 
following washout rapidly reduced to 7.3% and remained at this level throughout the 72 h 
period. SMA-Co treatment only maintained cell death following washout in A172 cells. 
 
Figure 3:6: Mode of cell death following TKI treatment and washout in LN-18 cells. Cells 
were treated and analyzed 48 and 72 h after treatment (-48 h and -72 h, respectively). Following 
this, the treatment was washed off and fresh media was applied. The cells were then analyzed 
24, 48 and 72 h after washout. A) Free formulations, B) micellar formulations. Bars denote 
necrotic; ■ (PI stained) and apoptotic;  (annexin V-stained). Data is mean ± SEM, experiments 
were conducted in triplicate and repeated independently three times. Statistical analysis utilized 
a one-way ANOVA with a Bonferroni post hoc test, p ≤ 0.05 relative to control for annexin V 




Figure 3:7: Mode of cell death following TKI treatment and washout in U373 cells. Cells 
were treated and analyzed 48 and 72 h after treatment (-48 h and -72 h, respectively). Following 
this, the treatment was washed off and fresh media was applied. The cells were then analyzed 
24, 48 and 72 h after washout. A) Free formulations, B) micellar formulations. Bars denote 
necrotic; ■ (PI stained) and apoptotic;  (annexin V-stained). Data is mean ± SEM, experiments 
were conducted in triplicate and repeated independently three times. Statistical analysis utilized 
a one-way ANOVA with a Bonferroni post hoc test, p ≤ 0.05 relative to control for annexin V 
(*) and PI (ƚ). 
 
Figure 3:8: Mode of cell death following TKI treatment and washout in A172 cells. Cells 
were treated and analyzed 48 and 72 h after treatment (-48 h and -72 h, respectively). Following 
this, the treatment was washed off and fresh media was applied. The cells were then analyzed 
24, 48 and 72 h after washout. A) Free formulations, B) micellar formulations. Bars denote 
necrotic; ■ (PI stained) and apoptotic;  (annexin V-stained). Data is mean ± SEM, experiments 
were conducted in triplicate and repeated independently three times. Statistical analysis utilized 
a one-way ANOVA with a Bonferroni post hoc test, p ≤ 0.05 relative to control for annexin V 
(*) and PI (ƚ). 
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3.3.4 The effect of treatment on the activation of apoptotic markers 
Apoptosis is a highly regulated form of cell death which, as well as causing the exposure of 
phosphatidylserine on the plasma membrane, also activates a highly conserved group of 
proteins called the caspases. These caspases mediate various proteolytic events to regulate 
apoptotic cell death when they have been cleaved by the intrinsic or extrinsic apoptotic 
pathways (Taylor et al., 2008). Therefore, in order to further confirm that the mode of cell 
death was apoptotic, the expression of cleaved caspase-3 was assessed. 
 
Figure 3:9: Expression of apoptotic markers in glioblastoma cells. F: free formulation, 
SMA: micellar formulation. Cells were treated with the indicated TKIs for 48 h before being 
lysed, normalized and probed with anti-cleaved caspase-3 antibody. The experiment was 
independently repeated three times and representative blots are shown.  
As can be seen in Figure 3:9, the activation of caspase-3 via cleavage was observed in the four 
established and two primary glioblastoma cell lines following 48 h of treatment in the F-Cr and 
F-Co treatments. This is consistent with the annexin V labeling of the same cells following 
48 h of treatment as shown in (Figure 3:5 - Figure 3:8). U87, LN-18, U373, NZG1003 and 
NZG0906 cells show a small increase in cleaved caspase-3 following SMA-Co treatment. This 
is consistent with annexin V labeling not showing a statistically significant increase in 
glioblastoma cells until 72 h. Experiments to assess cleaved caspase-3 following 72 h of 
treatment was unsuccessful due to the low expression of cleaved caspase-3 and the extremely 
low protein yield due to cytotoxicity. 
69 
  
3.4   Cell cycle progression 
3.4.1  Alteration of DNA synthesis by TKI treatment 
 
Figure 3:10: [H3]thymidine incorporation in glioblastoma cells following TKI treatment.  
Cells were synchronized and treated. The media was supplemented with 0.25 µCuries of 
[H3]thymidine. A) U87, B) LN-18, C) U373, and D) A172 cells. Bars denote mean ± SEM. 
Experiments were conducted in triplicate and independently repeated three times. * denotes p 
≤ 0.05 relative to control as determined by a one-way ANOVA with a Bonferroni post hoc test. 
While the reduction in cell number following crizotinib treatment (Figure 3:3) can be accounted 
for by the induction of apoptotic cell death, as determined by annexin V staining (Figure 3:5 - 
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Figure 3:8) and cleaved caspase-3 expression (Figure 3:9), there was no comparable increase 
in cell death markers to account for the decrease in cell number following dasatinib treatment. 
This leaves the possibility that the reduction in cell number may be a consequence of dasatinib 
acting as a cytostatic agent. In order to assess this possibility, DNA synthesis was determined 
using [H3]thymidine incorporation. The incorporation of [H3]thymidine from the media into 
the DNA strand during replication serves as a highly sensitive method to determine the rate of 
DNA synthesis via the measurement of radioactivity (Thorin-Trescases et al., 2000).  
In U87 cells, thymidine incorporation decreased by 9.9% and 3.4% following 24 h of F-D and 
SMA-D treatment, respectively (Figure 3:10). Following 48 h, thymidine incorporation was 
decreased by 21.3% following F-D treatment but only 2.4% in the SMA-D treated cells. F-Cr 
treatment for 24 and 48 h decreased [H3]thymidine incorporation by 37% and 40.1%, 
respectively. SMA-Cr decreased [H3]thymidine incorporation by 11.3% and 42.8% following 
24 and 48 h treatment, respectively. The large decrease in [H3]thymidine incorporation 
following 48 h of SMA-Cr preceded the increase in the annexin V-labeled cells (Figure 3:5). 
In LN-18 cells, F-D and SMA-D slightly, but non-significantly, increased [H3]thymidine 
incorporation (Figure 3:10), which is inconsistent with the reduction in cell number (Figure 
3:3) and lack of cell death markers (Figure 3:6). F-Cr, F-Co, SMA-Cr and SMA-Co treatment 
significantly reduced [H3]thymidine incorporation following 48 h of treatment to 58.5%, 
36.9%, 74.7% and 60.9% of control, respectively (p ≤ 0.05).  
In U373 cells, there was no statistically significant difference in [H3]thymidine incorporation 
in any treatment group following 24 h of treatment (Figure 3:10). Following 48 h of treatment, 
the incorporation of [H3]thymidine was significantly reduced following F-D and SMA-D 
treatment to 68.5% and 74.0% of control, respectively (p ≤ 0.05). Free and micellar crizotinib 
did not significantly reduce the [H3]thymidine incorporation while F-Co and SMA-Co 
treatment reduced [H3]thymidine incorporation to 91.4% and 82.8% of control, respectively. 
In A172 cells, F-D treatment decreased [H3]thymidine incorporation following 24 and 48 h of 
F-D treatment (79.8% and 87.7% of control, respectively) (Figure 3:10). There was no decrease 
in [H3]thymidine incorporation of the cells treated with SMA-D at the time points examined. 
F-Cr decreased [H3]thymidine incorporation following 24 and 48 h to 60.4% and 77.3% of 
control, respectively. F-Co decreases the incorporation of [H3]thymidine to 43.9% and 32.2% 
of control at 24 and 48 h, respectively. Conversely, SMA-Cr and SMA-Co reduce 
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[H3]thymidine incorporation to 87.4% and 83.5% of control following 24 h treatment but show 
no statistically significant decrease in incorporation following 48 h treatment. 
 
Figure 3:11: Cell cycle analysis following TKI treatment and washout in U87 cells.  DNA 
content was assessed by PI staining. Cells were treated and analyzed 48 and 72 h after treatment 
(-48 h and -72 h, respectively). Following this, the treatment was washed off and fresh media 
was applied. The cells were then analyzed 24, 48 and 72 h after washout. A) Free formulations, 
B) micellar formulations. Bars denote mean ± SEM of the percentage of cells with 1X DNA; 
■, 2X DNA; ■, 4X DNA; ■, 8X DNA; ■ and the transition phases between the respective DNA 
content designations; ■. Experiments were conducted in triplicate and repeated independently 
three times. For statistical analysis, the data was subjected to Logit transformation and analyzed 
by a one-way ANOVA with a Bonferroni post hoc test. The statistical analysis is available in 
supplementary Table 5:1. 
72 
  
3.4.2 Cell cycle analysis 
 
Figure 3:12: Distribution of U87 cells based on DNA content following TKI treatment 
and washout.  DNA content was assessed by PI staining. Cells were treated and analyzed 48 
and 72 h after treatment (-48 h and -72 h, respectively). Following this, the treatment was 
washed off and fresh media was applied. The cells were then analyzed 24, 48 and 72 h after 
washout. A) 1X, B) 2X, C) 4X, and D) 8X. Data points denote mean ± SEM of F-C (●), F-D 
(■), F-Cr (▲), F-Co (▼), SMA-C (♦), SMA-D (●), SMA-Cr (■) and SMA-Co (▲). 
Experiments were conducted in triplicate and repeated independently three times. For statistical 
analysis, the data was subjected to Logit transformation and analyzed by a one-way ANOVA 




Figure 3:13: Cell cycle analysis following TKI treatment and washout in LN-18 cells.  
DNA content was assessed by PI staining. Cells were treated and analyzed 48 and 72 h after 
treatment (-48 h and -72 h, respectively). Following this, the treatment was washed off and 
fresh media was applied. The cells were then analyzed 24, 48 and 72 h after washout. A) Free 
formulations, B) micellar formulations. Bars denote mean ± SEM of the percentage of cells 
with 1X DNA; ■, 2X DNA; ■, 4X DNA; ■, 8X DNA; ■ and the transition phases between the 
respective DNA content designations; ■. Experiments were conducted in triplicate and 
repeated independently three times. For statistical analysis, the data was subjected to Logit 
transformation and analyzed by a one-way ANOVA with a Bonferroni post hoc test. The 




Figure 3:14: Distribution of LN-18 cells based on DNA content following TKI treatment 
and washout.  DNA content was assessed by PI staining. Cells were treated and analyzed 48 
and 72 h after treatment (-48 h and -72 h, respectively). Following this, the treatment was 
washed off and fresh media was applied. The cells were then analyzed 24, 48 and 72 h after 
washout. A) 1X, B) 2X, C) 4X, and D) 8X. Data points denote mean ± SEM of F-C (●), F-D 
(■), F-Cr (▲), F-Co (▼), SMA-C (♦), SMA-D (●), SMA-Cr (■) and SMA-Co (▲). 
Experiments were conducted in triplicate and repeated independently three times. For statistical 
analysis, the data was subjected to Logit transformation and analyzed by a one-way ANOVA 
with a Bonferroni post hoc test. The statistical analysis is available in supplementary Table 5:2. 
The thymidine incorporation indicated significant treatment induced changes in the progression 
of glioblastoma cells through the cell cycle following all treatments. Therefore, the relative 
distribution of the cells through the cell cycle following treatment was investigated. 
Following F-D and SMA-D treatment, the quantity of human glioblastoma cells with 1X DNA 
(equivalent to the G0/1 phase of the cell cycle) appear to be slightly higher in all cell lines 
following 48 and 72 h of treatment (Figure 3:11 - Figure 3:18). This effect was not statistically 
significant (supplementary Table 5:1 – Table 5:4) which is likely a consequence of the small 




Figure 3:15: Cell cycle analysis following TKI treatment and washout in U373 cells.  DNA 
content was assessed by PI staining. Cells were treated and analyzed 48 and 72 h after treatment 
(-48 h and -72 h, respectively). Following this, the treatment was washed off and fresh media 
was applied. The cells were then analyzed 24, 48 and 72 h after washout. A) Free formulations, 
B) micellar formulations. Bars denote mean ± SEM of the percentage of cells with 1X DNA; 
■, 2X DNA; ■, 4X DNA; ■, 8X DNA; ■ and the transition phases between the respective DNA 
content designations; ■. Experiments were conducted in triplicate and repeated independently 
three times. For statistical analysis, the data was subjected to Logit transformation and analyzed 
by a one-way ANOVA with a Bonferroni post hoc test. The statistical analysis is available in 




Figure 3:16: Distribution of U373 cells based on DNA content following TKI treatment 
and washout. DNA content was assessed by PI staining. Cells were treated and analyzed 48 
and 72 h after treatment (-48 h and -72 h, respectively). Following this, the treatment was 
washed off and fresh media was applied. The cells were then analyzed 24, 48 and 72 h after 
washout. A) 1X, B) 2X, C) 4X, and D) 8X. Data points denote mean ± SEM of F-C (●), F-D 
(■), F-Cr (▲), F-Co (▼), SMA-C (♦), SMA-D (●), SMA-Cr (■) and SMA-Co (▲). 
Experiments were conducted in triplicate and repeated independently three times. For statistical 
analysis, the data was subjected to Logit transformation and analyzed by a one-way ANOVA 
with a Bonferroni post hoc test. The statistical analysis is available in supplementary Table 5:3. 
F-Cr treatment consistently increased the percentage of cells in the G2/M phase of the cell 
cycle, defined here as 2X. Following correctly executed mitosis, the duplicated DNA will be 
divided evenly between the daughter cells. However, cells treated with F-Cr do not complete 
mitosis and generate two daughter cells with identical DNA content. Instead, the cells duplicate 
their DNA, fail to divide and then re-enter the cell cycle to develop large, statistically 
significant 4X and 8X populations (equivalent to 4- and 8-fold the DNA content at the G0/1 
phase, respectively). Conversely, the cells treated with SMA-Cr showed no statistically 
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significant increase in the cell populations with ≥ 2X DNA content (supplementary Table 5:1 
– Table 5:4). 
 
Figure 3:17: Cell cycle analysis following TKI treatment and washout in A172 cells.  DNA 
content was assessed by PI staining. Cells were treated and analyzed 48 and 72 h after treatment 
(-48 h and -72 h, respectively). Following this, the treatment was washed off and fresh media 
was applied. The cells were then analyzed 24, 48 and 72 h after washout. A) Free formulations, 
B) micellar formulations. Bars denote mean ± SEM of the percentage of cells with 1X DNA; 
■, 2X DNA; ■, 4X DNA; ■, 8X DNA; ■ and the transition phases between the respective DNA 
content designations; ■. Experiments were conducted in triplicate and repeated independently 
three times. For statistical analysis, the data was subjected to Logit transformation and analyzed 
by a one-way ANOVA with a Bonferroni post hoc test. The statistical analysis is available in 




Figure 3:18: Distribution of A172 cells based on DNA content following TKI treatment 
and washout.  DNA content was assessed by PI staining. Cells were treated and analyzed 48 
and 72 h after treatment (-48 h and -72 h, respectively). Following this, the treatment was 
washed off and fresh media was applied. The cells were then analyzed 24, 48 and 72 h after 
washout. A) 1X, B) 2X, C) 4X, and D) 8X. Data points denote mean ± SEM of F-C (●), F-D 
(■), F-Cr (▲), F-Co (▼), SMA-C (♦), SMA-D (●), SMA-Cr (■) and SMA-Co (▲). 
Experiments were conducted in triplicate and repeated independently three times. For statistical 
analysis, the data was subjected to Logit transformation and analyzed by a one-way ANOVA 
with a Bonferroni post hoc test. The statistical analysis is available in supplementary Table 5:4. 
F-Co treatment increased the 2X populations relative to control, consistent with the effects of 
F-Cr treatment. F-Co treatment, however, showed a reduced quantity of 4X and 8X populations 
relative to F-Cr treatment in all four cell lines examined. This pattern suggests that, while F-D 
co-treatment was able to prevent re-entry into the cell cycle following failed mitosis as a result 
of F-Cr treatment, it was not able to prevent initial entry into the S phase. SMA-Co, like 




In order to determine if the cells were able to rapidly correct the polyploidy induced by F-Cr 
and F-Co treatment and infer if this polyploidy was associated with the resulting cell death, 
washout experiment using the same procedure as in the apoptosis/necrosis assay was pursued. 
The percentage of cells in the G0/1 phase of the cell cycle (1X) following washout of F-D and 
SMA-D was reduced following washout, likely a result of the growth stimulating effect of the 
application of new growth media.  
Following washout of F-Cr, the percentage of cells with 8X DNA rapidly increased in U87, 
U373, and A172 cells (Figure 3:12; Figure 3:16; Figure 3:18) despite the removal of the media 
containing the drug. Conversely, the percentage of polyploid cells reduced rapidly in LN-18 
cells and no progression to a higher DNA content was observed.  
Following the washout of F-Co treatment, the inhibition of cell cycle progression by the F-D 
co-treatment was lost and the cell populations that had previously been restricted to 2X DNA 
progressed to 4X populations in U87, U373, and A172 cells (Figure 3:12; Figure 3:16; Figure 
3:18). LN-18 cells showed the same pattern of increased 4X populations following washout, 
however this increase was not as large as in the other cell lines.  
3.4.3 F-Cr treatment disrupts mitotic spindle formation 
The observation of significant polyploid populations following F-Cr and F-Co treatment 
suggested that the treatment was causing abnormalities in the mitotic machinery, preventing 
the DNA from being correctly separated into two daughter cells. The mitotic spindle, an 
apparatus composed of α/β heterodimers, is responsible for the correct separation of 
chromosomes before the completion of mitosis. If the dynamics of the mitotic spindle is not 
correctly regulated, polyploidy can develop (Castedo et al., 2004) which is potentially the 
mechanism by which the cell cycle disruption was produced. Subsequently, the mitotic spindle 
integrity was assessed in LN-18 cells as it was not possible to find mitotic cells in the other cell 
lines following 48 h of F-Co treatment. 
As can be seen in Figure 3:19, control, F-D and SMA-D treated cells exhibited a well-organized 
mitotic spindle which formed around the condensed chromosomes. After 48 h, treatment with 
F-Cr, but not SMA-Cr, the formation of the α-tubulin labeled mitotic spindle was disrupted 
which was not reversed following co-treatment with F-D. This provides strong evidence that 
the polyploidy observed following cell cycle analysis was a consequence of incorrect mitotic 




Figure 3:19: Formation of mitotic spindle in LN-18 cells following TKI treatment.  Cells 
were treated for 48 h before fixation and staining. Nuclei were visualized by DAPI staining 
while β-tubulin was stained with a fluorescein conjugated mouse anti-human secondary 
antibody. Experiments were repeated three times independently and representative images are 
shown. Magnification 1000 X, the scale bar denotes 10 µm. 
A review of the literature suggests that the observed polyploidy (Figure 3:11; Figure 3:13; 
Figure 3:15; Figure 3:17) and abortive formation of the mitotic apparatus (Figure 3:19) of 
mitosis may be a consequence of the inhibition of aurora kinases (AURK) A and B by 
crizotinib. AURKs are serine/threonine kinases that regulate the polymerization and 
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depolymerization of the mitotic spindle to ensure the correct chromosome separation. 
Subsequently, inhibition of AURKs results in incorrect chromosome separation and polyploidy 
(Ditchfield et al., 2003; Harrington et al., 2004; Lee et al., 2013).  
 
Figure 3:20: IC50 of tozasertib in glioblastoma cell lines.  (▼) U87, (●) LN-18, (▲) U373, 
and (■) A172 cells. Cell number was assessed using an SRB assay following 72 h treatment. 
Data points are mean ± SEM. Experiments were conducted in triplicate and independently 
repeated three times.  
However, polyploidy and multinucleation does not necessarily induce cell death and some cell 
types are known to be resistant to mitotic catastrophe. In order to assess if mitotic catastrophe 
was a factor in the onset of apoptosis, the cytotoxicity of the AURK inhibitor tozasertib 
(Ki against AURK-A, AURK-B and AURK-C of 0.6 nM, 18.0 nM, and 4.6 nM, respectively) 
was assessed in the established glioblastoma cell lines and showed that there was a significant 
drop in cell number in all cell lines in sub-micromolar concentrations with a very small 
decrease in cell number from 1.0 to 10.0 µM (Figure 3:20). 
As can be seen in Table 3:3, the IC50 of tozasertib, which induced polyploidy in the 
glioblastoma cell lines between 0.1 to 0.5 µM (data not shown), was higher than the IC50 of 
crizotinib in all examined cell lines except LN-18, indicating that glioblastoma cells were not 




Table 3:3: The IC50 of crizotinib and tozasertib in glioblastoma cell lines. 
Cell line Crizotinib IC50 Tozasertib IC50 
U87 2.1 µM > 10 µM 
LN-18 1.5 µM 0.1 µM 
U373 3.3 µM > 10 µM 
A172 3.0 µM 5.2 µM 
 
3.4.4 Regulation of cell cycle progression following TKI treatment 
Cell cycle analysis showed that correct progression through the cell cycle was impaired 
following F-Cr and F-Co treatment, manifesting in the presentation of large cell populations 
with 4X and 8X DNA content. While it is likely that the large 2X population was a consequence 
of off-target AURK inhibition, this does not account for the cells continuing to synthesize DNA 
to form 4X and 8X populations. Subsequently, the expression of cell cycle protein CD1 and 
CE2 were assessed to determine if TKI treatment was altering cyclin expression to promote 
cell cycle re-entry. 
Following treatment with F-D the expression of CD1 was either unchanged or decreased 
(Figure 3:21), consistent with the increase in 1X populations (Figure 3:11; Figure 3:13; Figure 
3:15; Figure 3:17) and reduction in thymidine incorporation (Figure 3:10). Following treatment 
with F-Cr the expression of CD1 was increased in most cell lines except U87 cells where the 
expression was similar to control (e.g. 423.8% ± 21.81% for LN-18 cells, 367% ± 25.4% for 
A172 cells and 112.6% ± 7.4% for NZG1003 cells). F-Co treatment reduced the expression of 
CD1 relative to F-Cr treatment in most cell lines (80.54% ± 27.0% for LN-18 cells, 
62% ± 20.4% for A172 cells and 1.6% ± 0.5% for NZG1003 cells). The pattern of CD1 
expression in these cells closely reflected the development of polyploidy which was expected 
as CD1 is involved in the progression through the cell cycle, rising as the cell initiates G1/S 
phase transition and remaining high until the cell has completed mitosis (Crosby, 2007).  
CE2 is specifically raised in the G1/S transition phase and remained low throughout the rest of 
the cell cycle (Crosby, 2007). Curiously, the expression of CE2 was increased following F-D 
treatment in U87 (85.9-fold of control), LN-18 (24.9-fold of control) and U373 cells (6.6-fold 
of control) and SMA-D treatment in U87 (70.1-fold of control) and LN-18 cells (30.3-fold of 
control). CE2 expression was unchanged in U373 cells following 48 h SMA-D treatment 
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(1.07-fold of control). In A172, NZG1003 and NZG0906 cells, CE2 expression was unchanged 
or decreased following F-D and SMA-D treatment. Treatment with F-Co increased the level of 
CE2 expression in U87 (624-fold of control), LN-18 (48.8-fold of control), U373 (36.3-fold of 
control), and NZG0906 cells (9.2-fold of control), which is consistent with the increased 
percentage of cells with a DNA content in excess of 1X (Figure 3:21). In A172 and NZG1003 
cells the CE2 expression was decreased following exposure to F-Co (13.7% ± 8.5% and 
62% ± 19.3%, respectively) despite the increase in polyploid cells.  
 
Figure 3:21: Cell cycle proteins in primary and established glioblastoma cells following 
48 h treatment. F: free formulation, SMA: micellar formulation. Comparison of the basal 
expression of the respective proteins are shown beneath the treatment blots. Experiments were 
repeated three times independently and representative blots are shown. 
CE2 expression was increased relative to the respective crizotinib treatment in NZG0906 cells 
following F-Co (49.6% ± 6.3% higher than F-Cr) and SMA-Co (84.4% ± 23.2% higher than 
SMA-Cr) treatment. CE2 expression was also elevated in U87 cells following SMA-Co 
treatment (614.3-fold of control). The expression of CE2 was unchanged or decreased in LN-
18, U373, A172 and NZG1003 cells following F-Co and SMA-Co cells relative to the 
respective crizotinib treatments (Figure 3:21). 
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3.5  Tyrosine kinase activity 
3.5.1  Targets of dasatinib 
As seen in Figure 3:22, the nRTKs FAK, SRC and LYN, all targets of dasatinib, show basal 
expression in all glioblastoma cells, both established and primary. The expression of FAK was 
heavily reduced in all cell lines following both free and micellar dasatinib and combination 
treatments. FAK expression was unchanged following F-Cr and SMA-Cr treatment in the 
established cell lines but was reduced or unaffected following F-Cr in NZG1003 cells 
(5.4% ± 3.2%) and F-Cr and SMA-Cr in NZG0906 cells (91.3% ± 10.8% and 23% ± 5.2%, 
respectively) (Figure 3:22). Unfortunately, due to low protein yield and the cytotoxicity of the 
treatments, protein levels were not high enough to detect phosphorylated FAK. 
Total SRC expression was not affected by single treatments but was reduced in F-Co treatments 
in U87 (58.8% ± 7.6%) and NZG0906 (18.5% ± 15.6%) cells. SRC phosphorylation was 
heavily reduced or abolished by F-D and SMA-D, alone or in combination (e.g. 4.1% ± 3.3% 
and 21.9% ± 18.0% for F-D and SMA-D, respectively in U87 cells).  
While F-Cr and SMA-Cr had variable effects on the suppression of SRC phosphorylation, 
combination treatment was always more effective at suppression than dasatinib treatment 
alone. For example, in U87 cells the expression of P-SRC was 2.3% ± 0.7% and 9.5% ± 8.4% 
for F-Co and SMA-Co, respectively. This indicates that the concentration of dasatinib inhibited 
the relevant targets and the combination with crizotinib either increased or did not alter 
inhibition of SRC phosphorylation by dasatinib. Curiously, reduction of P-SRC following free 
or micellar crizotinib treatment, as with FAK, was only observed in the primary cells (Figure 
3:22). 
The expression of the SFK LYN was also examined and showed unchanged expression in A172 
and NZG1003 cells and increased expression following crizotinib and combination treatments 
in U373 cells. LN-18 cells showed decreased expression following crizotinib treatments and 
increased expression following combination treatments. In NZG0906 cells, F-Co and SMA-Co 
treatment decreased LYN expression while in U87 cells F-Co treatment decreased LYN 





Figure 3:22: Expression and/or activity of dasatinib targets following 48 h treatment. F: 
free drug formulations, SMA: micellar drug formulations. Comparison of the basal expression 
of the respective proteins are shown beneath the treatment blots. Experiments were repeated 
three times independently and representative blots are shown. 
3.5.2  Target of crizotinib 
Both crizotinib and dasatinib inhibited or abolished the phosphorylation of Met in primary and 
established glioblastoma cell lines (Figure 3:23) but only crizotinib induced cell death (Figure 
3:5 - Figure 3:8). This implies that the inhibition of Met was not likely to be responsible for 





Figure 3:23: Expression and/or activity of crizotinib targets following 48 h treatment.  F: 
free drug formulations, SMA: micellar drug formulations. Comparison of the basal expression 
of the respective proteins are shown beneath the treatment blots. Experiments were repeated 
independently three times independently and representative blots are shown. 
As can be seen in Figure 3:23, Met was basally expressed and this expression was decreased 
following F-D and SMA-D treatment in all cell lines except following SMA-D treatment in 
U87 cells (102.9% ± 3.9%) and U373 cells (105.5% ± 11.73%). Conversely, F-Cr and SMA-Cr 
treatment increased the expression of the Met receptor relative to control in all cell lines (e.g. 
112.9% ± 6.1% and 112.1% ± 28.8% for F-Cr and SMA-Cr respectively in U87 cells). Free 
and micellar combination reduced but did not abolish the expression of Met relative to 
crizotinib treatment in all cell lines (e.g. 20.4% ± 2.2% and 82.3% ± 7.3% for F-Co and 
SMA-Co respectively in U87 cells). The Met receptor was basally phosphorylated and this 
phosphorylation was suppressed by treatment with free or micellar dasatinib (e.g. 2.9% ± 1.3% 
and 6.1% ± 3.2% for F-D and SMA-D respectively in A172 cells) and abolished following 
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treatment with free or micellar or crizotinib or combination treatments (e.g. 0.9% ± 0.2% for 
F-Co and 2.3% ± 0.5% for SMA-Cr in A172 cells). As can be seen in the comparison blots, 
Met expression was approximately equal in all cell lines except U373 where the expression 
was very high. This very high expression did not correspond to unusually high Met 
phosphorylation in U373 cells which was comparable to U87, LN-18 and NZG1003 cells. 
Basal Met phosphorylation was low in A172 and NZG0906 cells relative to the other cell lines. 
ROS1 is another RTK target of crizotinib however, unlike Met, the expression of ROS1 was 
unaffected following dasatinib treatment and was not increased following crizotinib treatment. 
Indeed, ROS1 expression was only consistently decreased relative to control following F-Co 
treatment. SMA-Co treatment only decreased the expression of ROS1 relative to control in 
LN-18 and U373 cells. Unfortunately, P-ROS1 was not able to be detected. 
3.5.2.1 Alternative Met inhibitors  
In order to assess the response of glioblastoma cells to TKIs that target Met, ALK, and ROS1, 
a range of inhibitors were assessed with different potencies towards the TKIs. As can be seen 
in Figure 3:24 the alternative Met inhibitors SU11274 and AMG-208 were significantly less 
potent in all glioblastoma cells despite the IC50 of these TKIs being slightly higher against the 
Met RTK (12.0 nM, 10.0 nM and 9.0 nM for crizotinib, SU11274 and AMG-208, respectively). 
There are no reports of the IC50 of SU11274 or AMG-208 towards ALK or ROS1 but, should 
the inhibition of Met be responsible for the induction of cell death, it would be expected that 
SU11274 and AMG-208 would have similar cytotoxicity. The reduced potency of these 
alternative Met inhibitors, combined with the observation of dasatinib also inhibiting Met 
phosphorylation (Figure 3:23) but not inducing cell death (Figure 3:5 - Figure 3:8) indirectly 
indicates that Met is not likely to be responsible for inducing the observed cell death.  
In order to establish if ALK inhibition by crizotinib was likely to be responsible for induction 
of cell death, the ALK inhibitor ceritinib was pursued. Ceritinib has an IC50 of 3.1 µM against 
Met and 0.2 nM against ALK, relative to 12.0 nM and 24.0 nM for crizotinib, respectively. 
Ceritinib was significantly more potent and efficacious against glioblastoma cell lines than the 
Met inhibitors in all cell lines excluding A172 cells where the efficacy and potency was not 
significantly different (Figure 3:24). Together, these data suggest that the inhibition of ALK 




Figure 3:24: Potency of alternative Met inhibitors against glioblastoma cell lines.  A) U87 
cells, B) LN-18 cells, C) U373 cells and D) A172 cells. Data points denote crizotinib (▼), 
ceritinib (▲), SU11274 (●) and AMG-208 (■). Data is expressed as mean ± SEM. Experiments 
were conducted in triplicate and independently repeated three times. 
3.5.2.2 Met knockdown 
Although the alternative Met inhibitors show reduced potency against the glioblastoma cells 
relative to crizotinib, this could be a consequence of several confounding factors. These 
inhibitors could be more likely to be effluxed by proteins such as P-gp or BCRP. Alternatively, 
they could show reduced plasma membrane permeability, more rapid metabolism or increased 
protein binding. Furthermore, not all of the targets of the alternative inhibitors are known and 
the reduced potency may be a consequence of activity (or lack thereof) against other targets. 
Therefore, as confirmation of the role of the Met receptor specifically in the cytotoxicity of 
crizotinib, the expression of the Met receptor was knocked down using gene editing 
CRISPR/Cas9 system.  
In order to directly determine whether the inhibition of the Met RTK was responsible for the 
crizotinib induced cytotoxicity, the expression of Met was knocked down in the LN-18 cell 
line. This cell line was chosen as the expression of Met in this cell line is approximately average 
when compared to the other cell lines (Figure 3:23) and was suitable for transfection. Following 
Met knockdown, the effect of crizotinib and dasatinib treatment on cell number and the rate of 
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cell proliferation was assessed. As can be seen in Figure 3:25, 10 µg of DNA was sufficient to 
heavily reduce the expression of Met. Further, the phosphorylation of the Met RTK was 
reduced and showed a slightly increased molecular weight. The effect of dasatinib and 
crizotinib treatment on the cell number was similar regardless of the Met expression of the 
cells. The rate of proliferation was not significantly altered regardless of the alteration of Met 
expression and phosphorylation.  
 
Figure 3:25: Transfection of LN-18 cells using the Anti-Met CRISPR/Cas9 system.  Data 
points denote control (●), transfection with 2.0 µg DNA (●), transfection with 5.0 µg DNA 
(▲) and transfection with 10 µg DNA (▼). A) Efficacy of dasatinib against transfected cells, 
B) Efficacy of crizotinib against transfected LN-18 cells, C) Proliferation of transfected LN-18 
cells, D) Met, P-Met and EGFR expression in transfected LN-18 cells. Data is expressed as 




3.5.3   Downstream signaling 
Though EGFR is not a direct target of the TKIs examined here, Met and EGFR are known to 
compensate for the lost activity of the alternate receptor to sustain downstream signaling. 
Therefore, it is important to consider the expression of both RTKs.  
As seen in Figure 3:26, EGFR and AKT were basally expressed and approximately equal across 
all glioblastoma cells, both established and primary. In U87, U373, and NZG0906 cells, the 
expression of EGFR was abolished following F-Co treatment but not SMA-Co treatment. In 
A172 and NZG1003 cells, the expression of EGFR was reduced following F-Co treatments 
(23.8% ± 7.9% and 50.4% ± 12.3%, respectively) relative to single treatments. Following 
SMA-Co treatment, the EGFR expression of A172 cells was comparable to SMA-D treatment 
(74.4% ± 5.4% and 80.2% ± 5.4% for SMA-Co and SMA-D treatment, respectively). In LN-
18 cells the expression of EGFR was reduced following treatment with F-Co (44.2% ± 19.5%) 
and SMA-Co (83.2% ± 6.3 to a similar degree as following F-D (62.5% ± 11.2%) and SMA-
D (79.4% ± 5.5%) treatment. 
All of the RTKs and nRTKs considered here signal through AKT to promote survival, a critical 
factor in the efficacy of radiotherapy and chemotherapy. Therefore, the expression and activity 
of AKT in response to treatment can be informative about the potential efficacy of the 
treatment. The expression of total AKT was not reduced by treatment excluding following 
F-Co treatment in A172 cells (58.0% ± 18.3%) and NZG0906 cells (1.9% ± 1.4%). The 
expression of P-AKT was significantly altered, even in single treatment groups. P-AKT was 
reduced by F-D treatment in LN-18 (72.3% ± 12.1%), A172 (9.9% ± 1.9%), NZG1003, and 
NZG0906 but was only reduced following SMA-D treatment in LN-18 (60.6% ± 20.9%) and 
A172 (25.0% ± 5.6%) cells. P-AKT expression was significantly reduced following F-Cr 
treatment in all cell lines except U373 (105.0% ± 15.1%) while SMA-Cr significantly reduced 
P-AKT expression in all cell lines except U373 (91.1% ± 21.0%) and NZG1003 (1.4% ± 0.6%). 
In U87, LN-18, A172, NZG1003, and NZG0906 cells, the expression of P-AKT was heavily 
reduced following F-Co and SMA-Co treatment relative to control. In U373 cells, the 
expression of P-AKT was heavily reduced following F-Co (6.3% ± 4.7%) treatment and 




Figure 3:26: Expression and/or activity of important cellular signaling proteins following 
48 h treatment. F: free drug formulations, SMA: micellar drug formulations. Comparison of 
the basal expression of the respective proteins are shown beneath the treatment blots. 
Experiments were repeated independently three times and representative blots are shown. 
3.6  Tyrosine kinase localization 
Although the expression and phosphorylation of the relevant tyrosine kinases was reduced, the 
localization of these tyrosine kinases plays a significant role in their functionality. 
Subsequently, whether or not treatment modified the intracellular localization of the target 
tyrosine kinases or altered the cellular morphology was assessed. This was assessed in LN-18 
and U373 cells as LN-18 has approximately average Met expression while U373 has the 
highest expression (Figure 3:23).  
In LN-18 cells, SRC primarily showed perinuclear localization (Figure 3:27). Treatment with 
free and micellar crizotinib and/or dasatinib resulted in the perinuclear localization of SRC 
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becoming less prominent. In U373 cells, control cells showed a significant accumulation of 
SRC in the nucleus. Following free or micellar crizotinib or dasatinib treatment, SRC was 
excluded from the nucleus and diffused throughout the cytoplasm (Figure 3:28).  
 
Figure 3:27: SRC and Met localization in LN-18 cells following TKI treatment.  Nuclei 
were visualized by DAPI staining while SRC was stained with a fluorescein conjugated mouse 
anti-human secondary antibody and Met was stained with a Texas red conjugated rabbit 
anti-human secondary antibody. Experiments were independently repeated three times and 
representative images are shown. Magnification 1000 X, the scale bar denotes 10 µm.  
In both LN-18 and U373 cells (Figure 3:27; Figure 3:28), control cells showed localization of 
Met receptors in the perinuclear space but also a clear definition of the cell margins, indicating 
the presence of the Met receptor on the plasma membrane. Following treatment with F-D, the 
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perinuclear localization of Met was less intense and distinct than observed in control, but still 
showed significant perinuclear localization in both cell lines. It must be noted, however, that 
the effect of dasatinib on kinase localization was difficult to clearly observe in LN-18 cells due 
to the large decrease in cell area. This observation is consistent with the understanding of the 
SFKs in the modulation of sodium and potassium ion transporters to regulate cell volume 
(Cohen, 2005). It is worthwhile to note the F-Cr and F-Co treatment also resulted in the 
presentation of deformed nuclei. For example, in Figure 3:27, the top cell in the F-Co treatment 
has three lobes to the nuclei. 
 
Figure 3:28: SRC and Met localization in U373 cells following TKI treatment.  Nuclei 
were visualized by DAPI staining while SRC was stained with a fluorescein conjugated 
secondary antibody and Met was stained with a Texas red conjugated secondary antibody. 
Experiments were independently repeated three times and representative images are shown. 
Magnification 1000 X the scale bar denotes 10 µm.  
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There was also an observation of multiple nuclei following SMA-Cr treated cells (Figure 3:28), 
but the nuclei were not misshapen and the quantity of cells with this characteristic was much 
lower than for the F-Cr treated cells. This data is consistent with the previous observations 
concerning DNA content following F-Cr and F-Co treatment assessed with cell cycle and the 
absence of large abnormalities following SMA-Cr and SMA-Co treatment (Figure 3:15).  
 
Figure 3:29: Cytoskeleton integrity in LN-18 cells TKI treatment.  Cells were treated for 
48 h before being fixed and stained. Nuclei were visualized by DAPI staining while α-tubulin 
stained with fluorescein conjugated secondary antibody. Experiments were independently 
repeated three times and representative images are shown. Magnification 1000 X, the scale bar 
denotes 10 µm.  
Cells were stained with DAPI to highlight the nucleus (blue), an antibody targeted to SRC 
(green) and an antibody targeted to Met (red). Following treatment with crizotinib, both free 
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and micellar, the cells showed a statistically significant increase in cell area (quantification is 
available in supplementary Figure 5:5). Furthermore, the distribution of Met in the cells was 
altered, no longer showing intense staining in the perinuclear region. The change in cell area is 
unlikely to be a consequence of Met inhibition as dasatinib also inhibited Met phosphorylation 
(Figure 3:23) but did not show an increase in cell area. The altered localization of Met is a 
possible mechanism for the disrupted cytoskeleton (Figure 3:29). Without localization on the 
plasma membrane where it can be activated by extracellular HGF or transactivated by other 
RTKs, Met will be unable to correctly signal downstream to regulate cytoskeleton kinetics and 
subsequent invasion. Furthermore, following F-Cr and F-Co treatment the nucleus of the cells 
appears to be misshapen or there were multiple nuclei in the cells (Figure 3:27 - Figure 3:28).  
In cells treated with combination treatments, the effect of treatment on kinase localization was 
difficult to assess as the combination treatments, both free and micellar, greatly decreased the 
cell area, a characteristic consistent with the previously observed onset of apoptosis (Figure 
3:6). Furthermore, evidence of membrane blebbing can be observed following F-Co treatment, 
another characteristic consistent with apoptosis. Unfortunately, these pictures are 2D and 
therefore unable to give information about cell volume. 
3.7 Cytoskeleton integrity 
Met and SRC are known to be involved in the formation and motility of the cytoskeleton. As 
can be seen in Figure 3:29, the cytoskeleton of non-dividing control cells showed a network of 
filaments that have been labeled with a green fluorescent anti-α-tubulin antibody.  
Treatment with F-D resulted in a shrinkage of cell volume and subsequently, the cytoskeleton 
integrity was difficult to assess. Treatment with F-Cr and F-Co resulted in the presentation of 
short, feathered cytoskeletal filaments. Cells treated with SMA-D showed normal cytoskeleton 
filaments while treatment with SMA-Cr, like F-Cr, also resulted in a disorganized cytoskeletal 
structure. Treatment with SMA-Co resulted in a reduction of cell area such that the integrity of 
cytoskeletal filaments could not be observed. A similar pattern was also observed following 
staining of F-actin (data not shown).  
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3.8 Angiogenesis, migration, and invasion 
3.8.1  Tube like formation 
Glioblastoma lesions show relatively high vascular density relative to other tumor types 
(Taurin et al., 2012). A high vascular density increases the proliferation of the tumor, 
increasing the tumor burden and, subsequently, the edema which compromises quality of life. 
Therefore, it is potentially advantageous to prevent the construction of new vasculature. This 
can be modeled via a tube formation assay using endothelial cells.  
 
Figure 3:30: Tube formation of HUVEC cells.  Cells were seeded and allowed to attach for 
2 h before being treated. Images were taken 20 h after treatment. Experiments were conducted 
in triplicate and independently repeated three times. Representative images are shown. 
Magnification is 20 X, the scale bar denotes 500 µm. 
 
Figure 3:31: Tube-like formation of U87 cells.  Cells were seeded and allowed to attach for 
2 h before being treated. Images were taken 20 h after treatment. Experiments were conducted 
in triplicate and independently repeated three times. Representative images are shown. 
Magnification is 20 X, the scale bar denotes 500 µm. 
As can be seen in Figure 3:30, F-D and F-Cr were equipotent at reducing the tube formation of 
HUVEC cells. Tube formation was reduced following treatment with SMA-Cr, but not as 
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effectively as following SMA-D treatment. Both F-Co and SMA-Co treatment abolished 
HUVEC tube formation. 
Although endothelial cells line blood vessels in the healthy BBB (Figure 1:10), the 
phenomenon of vascular mimicry has also been observed wherein the tumor cells line the blood 
vessels (Chen et al., 2012). This can be modeled in vitro using the same assay as with the 
endothelial cells.  
In U87 cells (Figure 3:31), treatment with F-D but not SMA-D disrupted tube-like formation 
while the effect of F-Cr and SMA-Cr was minimal. F-Co treatment completely abolished 
tube-like formation while the SMA-Co only reduced it. 
 
Figure 3:32: Tube-like formation of U373 cells.  Cells were seeded and allowed to attach for 
2 h before being treated. Images were taken 20 h after treatment. Experiments were conducted 
in triplicate and independently repeated three times. Representative images are shown. 
Magnification is 20 X, the scale bar denotes 500 µm.  
 
Figure 3:33: Tube-like formation of A172 cells.  Cells were seeded and allowed to attach for 
2 h before being treated. Images were taken 20 h after treatment. Experiments were conducted 
in triplicate and independently repeated three times. Representative images are shown. 
Magnification is 20 X, the scale bar denotes 500 µm. 
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In U373 cells (Figure 3:32), treatment with F-D and SMA-D disrupted tube-like formation 
while the effect of F-Cr and SMA-Cr on tube-like formation was minimal. F-Co and SMA-Co 
treatment completely abolished tube-like formation and did not show the reduced potency of 
the micellar combination observed with U87 cells (Figure 3:31).  
As can be seen in Figure 3:33, tube-like formation of A172 cells was reduced following 
dasatinib and crizotinib treatment, both free and micellar. In contrast, in A172 cells, SMA-Co 
treatment was more effective at abolishing tube-like formation than the F-Co treatment.  
3.8.2 Migration 
Inhibiting the ability of the tumors to grow new vasculature limits the growth of the lesion. 
However, glioblastoma cells have shown the ability to escape anti-angiogenic treatments by 
invading into the surrounding brain parenchyma until conditions are more suitable and creating 
new lesions (Keunen et al., 2011).  
Subsequently, glioblastoma patients undergoing anti-angiogenic treatment do not show 
improved OS due to the lack of simultaneous anti-invasive therapy to prevent treatment escape. 
Therefore, scratch assays were undertaken in order to assess the effect of treatment on the 
ability of glioblastoma cells to migrate in vitro. Due to the growth patterns of U87 cells, a 
confluent monolayer was not able to be achieved and subsequently migration assays were not 
pursued in this cell line. 
The concentrations used in the migration assays were 0.2 µM dasatinib and 0.75 µM of 
crizotinib which was not cytotoxic following 24 h treatment. This is important because the 
concentration of drug that penetrates the surrounding brain parenchyma sufficiently to reach 
actively invading cells is often sub-cytotoxic.  
The migration of LN-18 cells was reduced following treatment with F-Cr and was abolished 
by F-D and F-Co treatment (Figure 3:34). SMA-D treatment was less effective than the 
corresponding F-D treatment while SMA-Cr was equipotent relative to the respective free 
formulation. SMA-Co treatment was as potent as F-Co treatment at suppressing LN-18 cell 
migration.  
In U373 cells, F-D, F-Cr and F-Co treatment were all potent inhibitors of U373 cell migration, 
abolishing cell movement across the scratch (Figure 3:35). Following treatment with SMA-D, 
the migration of cells was reduced but this was less potent than the F-D treatment. SMA-Cr 
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abolished cell migration as potently as the free formulation. SMA-Co decreased cell migration 
however, SMA-Co was less effective than single treatment with SMA-Cr at reducing 
migration. This was a pattern not observed in the other cell lines but was consistent across the 
independent experimental repeats.  
 
Figure 3:34: LN-18 scratch assay following treatment with free or micellar TKIs.  
A) Representative images of scratch assays, B) quantitation of the area migrated by cells using 
ImageJ. Cells were seeded and grown to a confluent monolayer. A scratch was made in the 
monolayer, the cells were treated for 24 h. Experiments were conducted in triplicate and 
independently repeated three times. Magnification is 40 X, the scale bar denotes 500 µm. Data 
is mean ± SEM of three independent experiments conducted in triplicate. * denotes p ≤ 0.05 as 




Figure 3:35: U373 scratch assay following treatment with free or micellar TKIs.  
A) Representative images of scratch assays, B) quantitation of the area migrated by cells using 
ImageJ. Cells were seeded and grown to a confluent monolayer. A scratch was made in the 
monolayer, the cells were treated for 24 h. Experiments were conducted in triplicate and 
independently repeated three times. Magnification is 40 X, the scale bar denotes 500 µm. Data 
is mean ± SEM of three independent experiments conducted in triplicate. * denotes p ≤ 0.05 as 




Figure 3:36: A172 scratch assay following treatment with free or micellar TKIs.  
A) Representative images of scratch assays, B) quantitation of the area migrated by cells using 
ImageJ. Cells were seeded and grown to a confluent monolayer. A scratch was made in the 
monolayer, the cells were treated for 24 h. Experiments were conducted in triplicate and 
independently repeated three times. Magnification is 40 X, the scale bar denotes 500 µm. Data 
is mean ± SEM of three independent experiments conducted in triplicate. * denotes p ≤ 0.05 as 
determined by a one way ANOVA with a Bonferroni post hoc test. 
In A172 cells, F-D treatment was able to abolish cell migration. F-Cr treatment did not show 
efficacy at reducing A172 cell migration across the scratch. F-Co treatment was at least as 




Figure 3:37: NZG1003 scratch assay following treatment with free or micellar TKIs.  
A) Representative images of scratch assays, B) quantitation of the area migrated by cells using 
ImageJ. Cells were seeded and grown to a confluent monolayer. A scratch was made in the 
monolayer, the cells were treated for 24 h. Experiments were conducted in triplicate and 
independently repeated three times. Magnification is 40 X, the scale bar denotes 500 µm. Data 
is mean ± SEM of three independent experiments conducted in triplicate. * denotes p ≤ 0.05 as 
determined by a one way ANOVA with a Bonferroni post hoc test. 
Following micellar treatment, A172 cell migration was reduced by SMA-D treatment as 
effectively as with F-D treatment. SMA-Cr treatment suppressed migration more effectively 
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than the corresponding free formulation. SMA-Co treatment was more effective than the single 
treatments and showed comparable potency to the free treatment at reducing the migration of 
A172 cells. 
NZG1003 cells showed minimal reduction in migration following F-D and SMA-D treatment, 
a result inconsistent with the other glioblastoma cell lines examined. Both F-Cr and SMA-Cr 
was effective at suppressing glioblastoma cell migration at non-cytotoxic concentrations. 
Combination treatments, both free and micellar, were more effective than the respective single 
treatments at suppressing the migration of NZG1003 cells. Furthermore, the free and micellar 
combination treatments were equally effective at preventing the migration of NZG1003 cells. 
3.8.3 Invasion 
Although migration assays are able to model the ability of cells to move across a surface, they 
do not model the ability of the cells to break down the ECM in order to move through tissue. 
The invasive capacity of glioblastoma is high and the invasive population can be further 
increased in response to pressures such as insufficient nutrient supply. Subsequently, the ability 
of TKIs to suppress the capacity of glioblastoma cells to invade towards a more nutrient rich 
environment was investigated using the Boyden chamber model. This assay was conducted in 
LN-18 cells as these cells had the highest invasive capacity of the glioblastoma cells examined.  
This investigation showed that crizotinib was more effective at suppressing invasion than 
dasatinib in both the free and micellar formulations (Figure 3:38). This was the reverse of the 
pattern observed in the migration assays. As with migration, the free and micellar combination 
was more effective than the respective single treatments. The F-Co treatment was more 




Figure 3:38: Invasion of LN-18 cells through a Geltrex basement membrane.  Cells were 
seeded in starvation media on top of a basement membrane in the top compartment of a Boyden 
chamber with the bottom compartment filled with growth media to produce a chemoattractant 
gradient. Data is mean ± SEM, experiments were conducted in triplicate and independently 
repeated three times. * denotes p ≤ 0.05 as determined by a one-way ANOVA with a Bonferroni 




4.1   Overview 
Despite decades of research, glioblastoma remains a significant challenge and patients have an 
average survival of just 14 months (Stupp et al., 2009). The lack of efficient therapies is often 
attributed to the difficulty in delivering chemotherapeutics through the BBB to the CNS, the 
high degree of heterogeneity of the tumor cell population and the variety of redundant signaling 
pathways making targeted treatments, such as anti-EGFR therapy, only effective in a small 
percentage of the patient population.  
The current work has sought to develop a strategy to complement the available therapies and 
overcome these problems using a combination of TKIs. By inhibiting multiple pathways, the 
potential for drug resistance is, in theory, reduced. In addition, a micellar encapsulated 
formulation was pursued in order to increase the delivery of TKIs to glioblastoma lesions. The 
combination treatments, both free and micellar, showed significant efficacy in in vitro studies, 
inducing apoptotic cell death, preventing invasion and migration and abolishing angiogenesis 
and vascular mimicry. These characteristics are highly favorable, not only due to the advantage 
of these parameters alone but also in combination with the current standard therapies. This 
therapy shows promise for the treatment of glioblastoma and should be further studied in vivo.  
4.2   Micellar TKIs 
Tyrosine kinases are a class of enzymes that are heavily implicated in the development, 
progression, and treatment resistance of glioblastoma. The evaluation of the cytotoxicity of 
13 TKIs against a panel of glioblastoma cells established that a combination of dasatinib, an 
inhibitor of the nRTKs SRC and FAK, and crizotinib, an inhibitor of the RTKs Met, ALK, and 
ROS1, was the most potent at reducing cell number. On this basis, these TKIs were pursued 
for further study. However, there are a number of issues that could potentially contribute to the 
failure of these TKIs in the clinic including unfavorable half-life and biodistribution. 
Subsequently, a micellar formulation of the TKIs was pursued in order to improve the efficacy 
of these agents in vivo. 
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4.2.1   Encapsulation efficiency 
The efficiency of encapsulating the TKIs into the micellar vehicle was 44.8% and 80.9% for 
dasatinib and crizotinib, respectively (Table 3:2). The reason for this discrepancy is likely 
because the encapsulation is dependent upon the physicochemical characteristics of the TKIs. 
Dasatinib, which is typically hydrophobic (Log p = 1.8), has increased water solubility at low 
pH. The solubility of dasatinib in water at pH 2.6 is 18.4 mg/mL while at pH 6.0 the solubility 
is 0.008 mg/mL (EMEA, 2009). The synthesis of the micelles requires the pH to be lowered to 
5.0, thereby increasing the water solubility of dasatinib. This would reduce the interaction of 
dasatinib with the hydrophobic styrene groups of the SMA and limit the loading efficiency. A 
similar pattern of water solubility is true of crizotinib, however, the water solubility is not as 
high. At pH 1.6 the water solubility is 10 mg/mL while at pH 8.2 the water solubility is 
0.1 mg/mL (Medsafe, 2016). This lower maximal water solubility likely resulted in the 
improved loading efficiency of crizotinib relative to dasatinib. As was shown in Table 3:2, the 
solubility of the TKIs was greatly improved following micellar encapsulation, allowing the 
dissolution of 27.2 mg/mL and 53.7 mg/mL of dasatinib and crizotinib, respectively.  
4.2.2   Half-life 
Although the majority of trials involving Met inhibitors have not yet declared results, many 
studies of dasatinib have been completed. These studies have shown poor efficacy of dasatinib 
(Table 1:4) which is potentially a consequence of the unfavorable plasma half-life of dasatinib. 
The plasma dasatinib concentration following oral administration rises rapidly, likely a 
consequence of facilitated oral absorption by the ATP-binding cassette transporter ABCC4 
(Furmanski et al., 2013). The half-life, however, is just 3.6 h due to extensive metabolism and 
efficient excretion (Christopher et al., 2008), resulting in transient inhibition of the targets. This 
is likely a factor in the failure of dasatinib in clinical trials (Table 1:4 – Table 1:5). Therefore, 
an improved plasma half-life of dasatinib may be able to produce sustained target inhibition.  
The size of the micelle encapsulated TKIs, 198 nm and 128 nm for dasatinib and crizotinib 
micelles, respectively, exceeded the 7.0 nm threshold for renal excretion, a characteristic which 
will facilitate a prolonged plasma half-life (Choi et al., 2007; Sarin, 2010). This size may 
increase further in the plasma as proteins in the blood adsorb to the nanoconstructs surface 
(Tenzer et al., 2011). 
107 
  
The sustained release profile of the micelles (Figure 3:2) demonstrates that the constructs were 
stable in solution, indicating that intravenously administered micelles will not break down 
rapidly in circulation. The charge of the micelles was negative. In addition, this micellar 
encapsulation may prevent the metabolism of the TKIs by shielding the reactive groups from 
the relevant metabolic enzymes, further preventing drug breakdown. The combination of 
increased size, stability and protection from metabolism will result in an extended plasma 
half-life in order to produce sustained inhibition of the target kinases. 
4.2.3   Biodistribution 
The distribution of small molecular weight bioactives, such as shown in Table 4:1, to CNS 
lesions is complex. Previous studies have shown that the size of fenestrations in tumor lesions 
range from 0.3 to 4.7 µm (Hashizume et al., 2000) and large molecular weight agents 
extravasate in glioblastoma lesions (Figure 1:11) (Ambruosi et al., 2006; Reichman et al., 
1986). This breakdown of the BBB is restricted to larger tumors where the vasculature has been 
distorted and improperly constructed. Subsequently, cancers that have metastasized to the CNS 
often show a comparable sensitivity to small molecular weight chemotherapeutics as the 
peripheral lesion (Bernardo et al., 2002; Korfel et al., 2002; Lee et al., 1989; Postmus et al., 
2000; Rosner et al., 1986).  
The healthy BBB of the brain surrounding the tumor, however, remains functional and results 
in the penetration of chemotherapeutics 2.0 cm from the tumor margin (Zone 3) being low 
when compared to the concentration in the tumor lesion (Table 4:1). Subsequently, tumor cells 
that have invaded into the surrounding brain will be exposed to sub-cytotoxic concentrations 
of chemotherapeutics. 
Exploiting the EPR effect is a potentially efficacious strategy to favorably alter the 
biodistribution of TKIs. Both dasatinib and crizotinib undergo a degree of tumor accumulation 
via the EPR effect. This is because the TKIs are both bound to plasma albumin in vivo (91% 
and 96% for crizotinib and dasatinib respectively (van Leeuwen et al., 2014)) and therefore 
undergo the same accumulation as seen with the Evans blue dye-albumin conjugate in Figure 
1:11. However, research has established that nanomedicine is able to provide a substantial 
advantage over relying on albumin binding alone. For example, paclitaxel is 95% albumin 
bound in the plasma (Kumar et al., 1993) and therefore shows accumulation via the EPR effect. 
However, encapsulation of paclitaxel into nanoconstructs improves the biodistribution of 
paclitaxel further by 2.5- to 6.5-fold (Bhattacharyya et al., 2015; van Vlerken et al., 2008; 
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Wang et al., 2015). The reason for the improved delivery with nanomedicine is a consequence 
of multiple factors including protection from renal excretion and metabolism prolonging the 
plasma half-life and an increased load of the biological agent delivered per deposition event. 
Table 4:1: Drug penetration into CNS tumors and the surrounding brain 
Drug Tumor type 
Zone 1 
Conc. 
Zone 2 Conc. 
(% of zone 1) 
Zone 3 Conc. 
(% of zone 1) 
Reference 
Etoposide 
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(Stewart et al., 
1983) 
Zone 1: tumor tissue, zone 2: brain adjacent to the tumor, zone 3: brain 2.0 cm distant from the 
tumor margin. 
The microvascular permeability, and therefore the accumulation of macromolecular constructs, 
varies through the different regions of a tumor and is highest in the well-vascularized tumor, 
which accounts for 30% of the tumor burden (Figure 4:1). This aberrant blood vessel assembly 
is a consequence of the imbalance in pro- and anti-angiogenic molecules such as VEGF and 
SEMA3E, respectively (Adams & Alitalo, 2007; Bao et al., 2006) secreted by the surrounding 
tumor cells. Nanomedicines deposit in the well-vascularized tumor tissue, however, 
penetration of the macromolecule beyond the perivascular region is low due to the high cell 
density and the ECM impeding tumor penetration (Yuan et al., 1994). As a consequence, it is 
primarily the released drug that will diffuse through the tumor tissue to reach the tumor cells 
distant from the blood vessels. Therefore, the micelles deliver drug in a fashion reminiscent of 





Figure 4:1: Relative tumor cell burden and capillary permeability of different tumor 
regions in glioblastoma lesions.  The well vascularized tumor has the highest permeability 
due to a higher density of poorly constructed blood vessels. The necrotic core of the tumor has 
a variable permeability, partially a factor of the loss of blood vessels due to high pressure and 
vascular occlusions. The brain adjacent to the tumor has a large number of tumor cells but a 
low permeability due to the lack of newly constructed vasculature and higher cell density. 
Reproduced with permission from Levin et al. (2015). 
4.3   Cytostatic or cytotoxic? 
Cell fate is determined by a highly complex signaling cascade with multiple signaling 
redundancies, signal amplification mechanisms, and pathway crosstalk. Cancer cells often 
show an accelerated rate of DNA mutation as a consequence of rapid cell cycle progression, 
improper DNA repair mechanisms and resistance to cell death. Mutations that are favorable 
alter the cells proliferative, invasive, pro-survival and/or immunosuppressive traits and may be 
heavily selected for and subsequently over-represented in the tumor population. These 
characteristics extend from the loss of pro-death signaling to escaping reliance on external 
mitogenic signaling. These properties are often a consequence of pharmacologically distinct or 
redundant pathways, resulting in treatment resistance. In the case of cancer treatment, the 
challenge is to alter cellular signaling to suppress proliferation, potentially stabilizing the 
disease, and promote cell death, potentially inducing remission.  
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The experiments presented here suggest that the reduction in cell number following F-D and 
SMA-D treatment was a consequence of reduced proliferation rather than induction of cell 
death. This conclusion is supported by the reduction in cell number but absence of increased 
cell death markers such as cleaved caspase-3, permeability to PI or labeling with annexin V in 
all glioblastoma cell lines examined. Cell cycle analysis showed that the percentage of cells in 
the G0/1 phase (1X) increased following F-D and SMA-D treatment at 48 and 72 h in all cell 
lines examined, although this effect was not statistically significant, likely a factor of the highly 
conservative nature of the statistical test.  
Moreover, if the effect of dasatinib treatment is cytostatic, a corresponding reduction in DNA 
synthesis in the [H3]thymidine incorporation assay should be observed. Decreased 
[H3]thymidine incorporation was observed in following F-D treatment in U87, U373, and A172 
cells and following SMA-D treatment in U87, LN-18, and U373 cells which is consistent with 
the expected cytostatic activity. However, an increase in [H3]thymidine incorporation was 
observed following F-D treatment in LN-18 cells, anomalous to the cell number data.  
This difference may be a consequence of the time points examined or problems with the assay. 
For instance, radioactive [H3]thymidine decomposition products are able to be incorporated 
into non-nucleic acid macromolecules such as proteins (Maurer, 1981). Alternatively, SRC 
inhibitors have been shown to reduce the transcription and translation of thymidylate synthase, 
the enzyme responsible for synthesizing thymidine for incorporation into the DNA (Ceppi et 
al., 2012; Ischenko et al., 2008). Should LN-18 cells be dependent upon SRC to induce 
thymidylate synthase expression, the available pool of endogenous thymidine would decrease 
and the uptake and incorporation of exogenous [H3]thymidine would increase. This could 
increase the radioactivity of the sample, even if the rate of total DNA synthesis was unchanged 
or reduced (Maurer, 1981). 
Though both SMA-D and F-D appear to act as cytostatic agents, the potency of SMA-D was 
consistently reduced relative to F-D in all glioblastoma cell lines. This is a common occurrence 
with nanoconstructs in vitro and could be a consequence of several factors. Uptake of large 
constructs requires energy dependent endocytosis which is slower and has a lower capacity 
than the diffusion of free drug through the plasma membrane as occurs with the free drug 
(Hiwase et al., 2008). However, previous reports have not observed this reduced efficacy using 
the SMA construct. Indeed, several papers have shown that the efficacy of SMA encapsulated 
agents was equipotent or more potent than the free agent in vitro (Archibald et al., 2016; Taurin 
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et al., 2014). This discrepancy is likely to be because SMA micelles appear to be dependent 
upon caveolin-1 for endocytosis into the cell (Nehoff et al., 2014) and the cells of the brain 
express much less caveolin-1 than other cell types (Parat & Riggins, 2012). Though increased 
expression of caveolin-1 has been observed in glioblastoma relative to the surrounding healthy 
brain, it has not been determined if the expression is in the tumor cells themselves or in 
infiltrating cells such as microglia, macrophages and endothelial cells which may be present at 
higher levels than in the healthy brain (Parat & Riggins, 2012). The low expression of 
caveolin-1 in glioblastoma cells would limit the endocytosis of the micelles and therefore 
reduce the amount of drug that was delivered to the cells. 
The cytostatic effects of dasatinib observed in this work are consistent with previous studies 
(Premkumar et al., 2010). Cytostatic treatments are able to prevent an increase in tumor burden 
but confer a higher probability of progression (Millar & Lynch, 2003). This is because the cells 
retain the potential to develop resistance, treatment may be disrupted or the cells can invade to 
an area where drug penetration is insufficient and tumor growth can resume. There is low 
penetration of chemotherapeutic agents into the brain surrounding the tumor (Table 4:1). In 
these regions, the BBB is largely functional, preventing drug penetration and effluxing drugs. 
This results in the concentration of therapeutics falling rapidly with increased distance from 
the tumor (Table 4:1). The combination of the cytostatic activity of dasatinib, the short plasma 
half-life and the low penetration beyond the tumor margins could have contributed to the failure 
of dasatinib to improve outcomes in Phase I and II clinical trials in glioblastoma (Franceschi 
et al., 2012; Lassman et al., 2015; Lu-Emerson et al., 2011; Reardon et al., 2008).  
Inducing tumor cell death is more likely to result in remission of disease than preventing cell 
proliferation. There are five accepted modes of cell death, apoptosis, autophagy, necroptosis, 
pyroptosis, and necrosis.  
Apoptosis is a caspase-dependent form of cell death that does not induce inflammation. This 
mode of cell death is characterized by cell shrinkage, DNA fragmentation, membrane blebbing, 
cleavage of caspases, and the exposure of phosphatidylserine on the plasma membrane as a 
signal to macrophages to engulf a cell that is undergoing apoptotic cell death (Fadok et al., 
1992; Inoue & Tani, 2014; Martin et al., 1995; Reed, 2000; Vermes et al., 1995).  
Necroptosis is a pro-inflammatory form of cell death that is caused when a cell initiates, but 
cannot complete, apoptosis. This commonly occurs when caspases are inhibited by virally 
encoded caspase inhibitors (Inoue & Tani, 2014; Tait et al., 2014). Necroptosis, therefore, does 
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cause exposure of phosphatidylserine and labeling with annexin V but does not cause cleavage 
of caspase-3 (Inoue & Tani, 2014; Vandenabeele et al., 2010).  
Autophagy is a non-inflammatory form of programmed cell death that is commonly induced 
by hypoxia, nutrient deprivation, and pathogenic infections. Autophagy is caspase-independent 
but does cause exposure of phosphatidylserine (Glick et al., 2010; Inoue & Tani, 2014).  
Pyroptosis is an inflammatory form of cell death commonly induced by microbial infections 
and the resulting damage-associated molecular pattern molecules. This form of cell death is 
caspase-1 dependent and involves cell swelling, phosphatidylserine exposure and pore 
formation in the plasma membrane. Therefore, cells undergoing this mode of cell death will be 
stained with both annexin V and PI but will not show cleaved caspase-3 expression (Inoue & 
Tani, 2014).  
Necrosis is often caused by infection, inflammation and trauma and is a pro-inflammatory 
mode of cell death. It is not dependent upon caspase activation but does result in some 
phosphatidylserine exposure in the early phase of the cell death. Cells undergoing necrosis are 
permeable to the PI dye and are often swollen (Inoue & Tani, 2014).  
Glioblastoma cells are known to be highly resistant to apoptosis and preferentially undergo 
necrosis as a consequence of an imbalance in pro- and anti-apoptotic signaling. For example, 
p53 is mutated in a significant number of glioblastoma tumors, particularly in the proneural 
subtype (Figure 1:3). Moreover, many glioblastoma cells overexpress Bcl2L12, a member of 
the BCL-2 family, which blocks the pro-apoptotic activity of p53 (Stegh et al., 2010) and 
inactivates effector caspases-3 and -7 (Chou et al., 2012; Stegh et al., 2008; Stegh et al., 2007). 
Necrosis in the CNS is highly damaging, inducing inflammation which promotes edema, the 
leading cause of morbidity in glioblastoma (Burger et al., 1979; Saad & Wang, 2014; Sheline 
et al., 1980). Therefore, treatment options that induce significant necrosis are not ideal. 
In this work, crizotinib treatment, free and micellar, was able to overcome the apoptosis 
resistance of glioblastoma cells to induce apoptotic cell death. Furthermore, the combination 
of crizotinib with the cytostatic agent dasatinib increased apoptotic cell death relative to the 
single treatments. This was demonstrated by the increase in annexin V labeling (Figure 3:5 - 
Figure 3:8) and corresponding elevation of cleaved caspase-3 following 48 h treatment with 
F-Cr and F-Co (Figure 3:9). The expression of cleaved caspase-3 following 48 h of SMA-Cr 
and SMA-Co treatment was not significantly raised in any of the cell lines, also consistent with 
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the absence of annexin V labeling at this time point. Unfortunately, cleaved caspase-3 was not 
able to be detected following 72 h of treatment as the total protein yield was too low to detect 
a target with such low expression. However, it is expected that the increase in cleaved caspase-3 
following SMA-Cr and SMA-Co treatment would be apparent following 72 h treatment. This 
data allows the determination of the mode of cell death. The absence of PI staining rules out 
pyroptosis and necrosis and cleaved caspase-3 expression excludes necroptosis and autophagy 
as potential modes of cell death. Therefore, the only mode of cell death consistent with annexin 
V labeling, PI exclusion, and cleaved caspase-3 expression is apoptosis. 
As previously mentioned, glioblastoma cells are highly resistant to apoptosis and so the 
observation that F-Co treatment-induced apoptosis in over 60% of glioblastoma cells and was 
able to maintain the apoptotic cell death up to 72 h following washout of the drugs is a 
significant finding. This suggests that at least one target of dasatinib may be involved in 
reducing crizotinib induced cell death. This may be via direct modulation of the activity of cell 
death regulators or by compensatory upregulation of alternative survival signaling pathways. 
Alternatively, this could be a result of an effect that occurs only in combination but not 
following the single treatments.  
SRC inhibition has previously been associated with resistance to ALK and Met inhibition 
(Crystal et al., 2014; Sang et al., 2013). The application of ALK/Met inhibitors with SRC 
inhibitors synergistically increased the in vitro and in vivo efficacy of crizotinib and ceritinib 
in NSCLC models, even in ALK/Met inhibitor resistant cell lines (Crystal et al., 2014). In these 
cell lines, only dual treatment successfully inhibited the downstream signaling pathways, 
consistent with the results shown here where combination treatment was more effective than 
the single treatments at abrogating downstream AKT signaling (Figure 3:26). This provides a 
potential mechanism for the increased cell death observed following combination treatment 
that is consistent with previous reports. 
Alternatively, this could be a consequence of the loss of alternative upstream signaling 
pathways. As shown in Figure 3:26, the combination treatments, free and micellar, reduced the 
expression of the EGFR. Resistance to Met inhibitors in general and crizotinib in particular is 
commonly associated with activation of the EGFR pathway in a wide variety of cancer types 
including gastric (Qi et al., 2011), NSCLC (Bean et al., 2007), colon (Troiani et al., 2013), 
HNSCC (Xu et al., 2011), breast (Mueller et al., 2012; Mueller et al., 2010) and glioblastoma 
(Jun et al., 2012; Jun et al., 2014). Although there have not been reports of the involvement of 
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targets of dasatinib in the induction of EGFR expression, the reduced EGFR expression may 
represent an abolished redundancy pathway, decreasing downstream survival signaling (Figure 
3:26).  
4.4   Mitotic disruption and cell cycle 
While dasatinib acted as a cytostatic agent, the effect of crizotinib on cell cycle was starkly 
different. The apoptosis induced by F-Cr treatment was accompanied by the presentation of 
polyploid populations with 2-, 4- and 8-fold the DNA content of a cell in the G0/1 phase of the 
cell cycle (Figure 3:11; Figure 3:13; Figure 3:15; Figure 3:17). F-Co also showed increased 2X 
populations relative to control, however, the presentation of 4X and 8X populations was 
markedly reduced relative to F-Cr treatment prior to drug washout. The micellar formulations 
showed a weak effect on progression through the cell cycle. SMA-Cr showed a small, but often 
non-significant, increase in ≥ 2X DNA cells relative to control and SMA-Co did not show 
statistically significant changes in >2X populations relative to control. The reason for the 
difference is likely to be due to reduced off-target effects following micellar TKI treatment due 
to reduced total drug exposure. As previously discussed, the endocytosis rate of micelles into 
glioblastoma cells will be low due to the low caveolin-1 expression. This results in drug 
exposure being heavily dependent on release, which was less than 40% of the administered 
dose following 72 h (Figure 3:2).  
Significant changes in cyclin-dependent kinases were observed (Figure 3:21). CD1 increases 
as the cell initiates G1/S phase transition and remains high until the cell has completed mitosis. 
CE2 increases during G1/S transition but is low throughout the remainder of the cell cycle. The 
increased proportion of cells with 4X and 8X DNA as a consequence of F-Cr treatment 
corresponded with increased CD1 expression in all cell lines and increased CE2 expression in 
all cell lines bar A172 and NZG1003. It is interesting to note that A172 cells, where the 
expression of CE2 decreased instead of increased (Figure 3:21), was also the cell line with the 
lowest progression to 4X and 8X DNA content (Figure 3:17). This data indicates that the 
increased expression of CD1 and CE2 likely promoted cell cycle re-entry following F-Cr 
treatment which, coupled with the incomplete mitosis, resulted in polyploid cells. However, it 
must be noted that there is significant basal variation in the expression of cyclin proteins 
between the controls. This variation was consistently observed throughout the experimental 
replicates. The variation is likely to be a consequence of the fact that the plates were not 
synchronized for western blot analysis as for thymidine incorporation. As these proteins vary 
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significantly over the cell cycle, small variations between the plates can result in apparent 
variations in basal expression. Furthermore, these small differences may be amplified by the 
sigmoidal nature of the relationship between protein content and optical density (Ferguson et 
al., 2005). 
The increased DNA content following F-Cr and F-Co was accompanied by mitotic spindle 
disruption in both treatment conditions. However, the polyploidy was more severe in the F-Cr 
treatment group relative to the F-Co treatment. This indicates that the reduction in polyploid 
populations (4X and 8X DNA content) following F-Co treatment relative to F-Cr treatment 
was not a consequence of cells being able to complete mitosis successfully. Instead the 
reduction in 4X and 8X populations was likely a consequence of the cells not synthesizing 
more DNA following failed mitosis. This demonstrates that dasatinib maintained its cytostatic 
action when used as a co-treatment with crizotinib and that the cytostatic effects of dasatinib 
are independent of the activity of crizotinib targets. However, F-Co treated cells showed a 
marked increase in the 4X and 8X populations 24 h following washout indicating that the 
cytostatic effects of dasatinib are rapidly lost when the drug concentration falls. This 
observation leads to the conclusion that the dosing schedule of dasatinib should be frequent in 
order to prevent crizotinib induced polyploidy and the associated genetic instability.  
Additionally to promoting genetic instability, polyploidy can also promote secondary 
apoptosis, a process sometimes known as mitotic catastrophe. The presentation of polyploid 
populations in the established glioblastoma cell lines occurred with the onset of apoptosis as 
measured by annexin V and cleaved caspase-3. This raises the possibility that the apoptosis 
was dependent on the mitotic dysregulation, a mode of cell death termed mitotic catastrophe 
(Castedo et al., 2004). The F-Cr and F-Co treatment caused the development of multiple mitotic 
centers per cell with poorly defined spindles (Figure 3:29). These abnormalities likely 
contribute to the previously observed morphological traits such as the cells with multiple nuclei 
(Figure 3:27) or large and misshapen nuclei (Figure 3:29). These abnormalities are likely to be 
a consequence of off-target inhibition of the AURKs, the serine/threonine kinases that regulate 
the construction and dynamics of the mitotic spindle (Carmena & Earnshaw, 2003; Fu et al., 
2007) which are associated with higher glioma grade, treatment resistance and poorer prognosis 
(Araki et al., 2004; Barton et al., 2010; Lehman et al., 2012; Tsuno et al., 2007; Zeng et al., 
2007). Previous binding assays have shown that 1.0 µM of crizotinib can reduce binding to 
AURK-A and AURK-B by 75 and 96.5%, respectively (Lovly et al., 2011) and so the 
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concentrations used in these experiments, 4.0 µM, was likely to cause significant functional 
inhibition of AURK activity. 
Although the off-target effects on the AURKs and subsequent disorganization of the mitotic 
spindle (Figure 3:29) was likely to cause the polyploidy, it was unlikely to be the cause of 
crizotinib induced cell death. This conclusion is supported by several observations. Firstly, 
F-Cr shows a higher number of polyploid cells than the F-Co treatment but less apoptosis. 
Secondly, following the drug washout, the polyploid population in the F-Co treatment groups 
increases but the degree of apoptosis either remained constant (as in LN-18 cells) or decreased 
(as in U87, U373, and A172 cells). Thirdly, the use of a specific AURK inhibitor, tozasertib, 
showed similar polyploidy and morphological alterations as crizotinib but did not show a 
comparable efficacy at reducing cell number (Table 3:3; Figure 3:20). Instead, tozasertib 
displayed a plateau in cell number, indicating that AURK inhibition alone has cytostatic effects. 
Though the combination shows significantly improved potency when compared to the single 
treatments, the development of polyploidy is also associated with chemotherapeutic resistance 
due to factors such as a higher copy number of efflux proteins and genetic reshuffling, resulting 
in subsequent development of more aggressive tumors (Shah et al., 2010; Weihua et al., 2011). 
Ultimately, the micellar system shows a significant advantage, maintaining efficacy while also 
preventing the polyploidy associated with the free formulations.  
4.5    Tyrosine kinase activity 
A number of RTKs, such as EGFR, Met and ROS1, and nRTKs, such as SRC and FAK, were 
targeted by this treatment combination in order to simultaneously inhibit several signaling 
pathways that potentially contribute to the pathology of glioblastoma. 
4.5.1   Met 
Met is heavily involved in the invasive capacity of glioblastoma cells, contributing significantly 
to the failure of surgery to be curative (Bell & Karnosh, 1949; Eckerich et al., 2007; Lal et al., 
2005; Nakada et al., 2007; Wang et al., 2003) and conferring resistance to radiation therapy, 
the most flexible and commonly employed treatment for glioblastoma patients (Lal et al., 
2005).  
Baseline expression and phosphorylation of Met was not predictive of sensitivity to crizotinib 
treatment. A172 and NZG0906 cells had significantly lower basal Met phosphorylation than 
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U373 and NZG1003 cells (Figure 3:23) but did not show altered sensitivity to Met inhibition 
(Figure 3:1). The lack of correlation between Met expression and response to Met inhibitors 
has been previously observed and indicates that the screening of patients for high and low Met 
expression may not be predictive of the response to treatment (Sen et al., 2011). However, 
screening of patients for autocrine HGF loops has shown potential in preclinical work (Xie et 
al., 2012). Western blot analysis showed that Met was continually phosphorylated (Figure 
3:23) and the localization of Met using immunofluorescent microscopy images showed a 
distribution pattern consistent with previous reports of endocytosis and trafficking of the Met 
receptor following activation by HGF.  
The distinct localization of Met in the perinuclear region has previously been observed in HeLa 
cells 2 h following HGF stimulation (Kermorgant et al., 2003). As these experiments did not 
include HGF stimulation, the receptor localization raises the possibility that an autocrine or 
paracrine HGF loop may be active or that the FBS may contain HGF concentrations sufficient 
to maintain the activity of the receptor. Previous studies have demonstrated the presence of 
autocrine and paracrine loops in LN-18, U87 and U373 cells (Abounader et al., 1999; Dua et 
al., 2011; Kwak et al., 2011; Lal et al., 2005; Moriyama et al., 1995; Xie et al., 2012) and in 
human glioblastoma samples (Kwak et al., 2011). Documentation of the concentration of HGF 
in FBS is not available and establishing this concentration would require enzyme-linked 
immunosorbent assay testing. Moreover, previous research has indicated that the presence of 
FBS in the media is sufficient to promote the secretion of HGF by fibroblasts (Ohshima et al., 
2002) and FBS also contains a serine protease capable of activating pro-HGF (Shimomura et 
al., 1992).  
Alternatively, the Met receptor could be activated by other RTKs or by mutation. There have 
been no reports of LN-18 or U373 cells bearing Met receptor mutations that would result in 
constitutive activity. However, Met activating mutations in glioblastoma patient samples have 
been reported (Navis et al., 2015).  
The CRISPR/Cas9 system was used to knock down Met expression. This system is a highly 
specific genome editing technique utilizing 20 nucleotide guide sequences to target regions of 
interest with high specificity (Ran et al., 2013). The Cas9 nuclease produces targeted double 
strand breaks that frequently result in frameshift mutations, abolishing the functionality of the 
gene (Ran et al., 2013). The knockdown of Met using the CRISPR/Cas9 system significantly 
reduced total Met expression but only slightly reduced Met phosphorylation. This was likely 
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to be a consequence of a splice variant not targeted by the commercially available plasmid, 
evidenced by the slight shift of the molecular weight in this band (Figure 3:25). However, 
following Met knockdown in LN-18 cells, the rate of proliferation and the potency of crizotinib 
and dasatinib was not significantly altered. When considered in concert with the western blot 
data and the alternative Met inhibitors, this suggests Met was not the primary regulator of cell 
death following crizotinib treatment.  
Nevertheless, the basal phosphorylation of the Met receptor was suppressed by the treatment 
of glioblastoma cells with either dasatinib or crizotinib. The inhibition of Met activity by 
dasatinib is an interesting observation that has been previously observed in HNSCC (Sen et al., 
2011) and may be a consequence of the role of SRC in the induction of HGF transcription (Sam 
et al., 2007) or direct activation of the Met receptor by SRC (Organ & Tsao, 2011). There is 
strong evidence to support the conclusion that SRC can independently activate or is necessary 
for the activation of a wide range of RTKs including RON (Danilkovitch-Miagkova et al., 
2000), EGFR (Moro et al., 2002), Met (Organ & Tsao, 2011) and the Trk neurotrophin receptor 
family (Lee & Chao, 2001).  
In order to investigate the role of Met further, the efficacy of alternative Met inhibitors was 
assessed. The alternative Met inhibitors SU11274 and AMG-208 have comparable efficacy 
against the Met receptor but showed lower efficacy in the cell lines examined (Figure 3:24). 
Ceritinib, which has no reported efficacy against the Met RTK, is an inhibitor of ALK/ROS1 
(IC50 0.2 nM and 0.7 nM, respectively) and showed higher efficacy in the cell lines indicating 
that ALK and/or ROS1 may be responsible for the crizotinib induced cell death (Figure 3:24). 
Unfortunately, very little is known about the expression or activity of ALK in glioblastoma as 
only one paper has been published regarding glioblastoma showing that ALK regulates 
pleiotrophin induced growth in U87 cells (Powers et al., 2002). Therefore, the evidence for the 
role of ALK in crizotinib induced cell death is weak. Furthermore, the induction of cell death 
by crizotinib could be a result of the inhibition of ROS1.  
4.5.2  ROS1 
ROS1 fusion and expression has previously been reported in glioblastoma samples (Birchmeier 
et al., 1987; Sharma et al., 1989). However, ROS1 is a relatively poorly understood RTK and 
its role in the pathology of glioblastoma is not clearly defined. The phosphorylated form of this 
receptor was unable to be detected, however the western blot analysis showed that F-Co 
treatment reduced the expression of ROS1 in all of the cell lines examined while SMA-Co 
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treatment only reduced ROS1 expression in U87, LN-18, and U373 cells but not A172 cells or 
the primary glioblastoma cell lines NZG1003 and NZG0906. There were no abnormalities in 
the molecular weight of ROS1 in these cell lines indicating that these cells were not likely to 
harbor fusion mutations (116 kDa vs. 259 kDa). Regrettably, there are no ROS1 inhibitors on 
the market that inhibit ROS1 with a significantly higher potency than ALK and so a comparable 
assessment of alternative ROS1 inhibitors was not able to be undertaken. 
4.5.3   SRC 
The expression of total SRC was variable across the cell lines examined (Figure 3:22). The 
highest SRC expression and lowest SRC phosphorylation was identified in U87 cells. In the 
primary cell lines, despite the total expression of SRC being lower than the established cell 
lines, the phosphorylation was comparable to LN-18, U373, and A172 cells.  
SRC was continually active in glioblastoma cells, both established and primary, and 
phosphorylation was specifically inhibited by dasatinib treatment. F-D was more effective at 
suppressing phosphorylation than SMA-D in U87 and LN-18 but equipotent in U373, A172, 
NZG1003 and NZG0906 cells. SRC phosphorylation was also inhibited by crizotinib treatment 
in U87, LN-18, U373, and NZG0906 cells however this inhibition was not as strong as with 
Met inhibition by dasatinib. This indicates that SRC was activated by targets of crizotinib such 
as Met, ALK, and/or ROS1 in some cell lines. 
Interestingly, the sensitivity of the cells to dasatinib was not altered by the basal expression or 
phosphorylation of SRC. Previous investigation of dasatinib in clinical trials with glioblastoma 
patients based upon their expression of the dasatinib targets expressed in glioblastoma (SRC, 
PDGFR, Kit and EPHA2) showed no difference in the efficacy of dasatinib when considering 
the number of targets expressed in their tumor tissue (Lassman et al., 2015). Though dasatinib 
does show poor BBB permeability, as was previously discussed, the reason for the lack of 
efficacy of dasatinib in clinical trials is more likely to be a consequence of resistance to 
treatment by glioblastoma cells than insufficient drug concentration. This is supported by 
previous investigations utilizing dasatinib for intracranial lesions of other dasatinib target 
positive tumor types, such as BCR-ABL positive leukemia. In these tumor types, dasatinib is 
able to induce remission of intracranial metastasis (Abdelhalim et al., 2007; Porkka et al., 
2008), likely because in this tumor, transient inhibition of the BCR-ABL kinase is sufficient to 
commit these cells to apoptosis (Shah et al., 2008). The current study found that dasatinib was 
not sufficient to kill glioblastoma cells unless applied in combination with crizotinib, therefore, 
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the lack of efficacy of dasatinib in clinical trials is expected based upon these results as the 
inhibition of the targets will be transient, and therefore unable to prevent invasion or induce 
cell death.  
Dasatinib treatment, both free and micellar, reduces the area of the cells significantly, making 
identification of localization changes of the kinase difficult. This was likely a factor of the role 
of SFKs in the regulation of cell volume in response to hypertonic and hypotonic stress (Cohen, 
2005). Dasatinib treatment effectively suppressed migration of glioblastoma cells, consistent 
with previous reports of SRC inhibitors and SRC directed siRNA models (Du et al., 2009; 
Nomura et al., 2007). The presence of lamellipodia in dasatinib treated cells was reduced and 
in combination treated cells there was no apparent lamellipodia. This reduction in lamellipodia 
could potentially account for the efficacy of dasatinib at suppressing migration and invasion as 
the leading edge of the cell will be unable to project in order to anchor the cell and retract the 
trailing edge (Nomura et al., 2007; Ridley, 2011).  
4.5.4  FAK 
FAK regulates the cytoskeletal dynamics of cells which allows invasion of glioblastoma cells 
into the surrounding brain parenchyma. There is evidence to suggest that FAK is overexpressed 
in glioblastoma and contributes to the invasive potential of the cells (Chen & Chen, 2006; 
Gutenberg et al., 2004; Long et al., 2010; Mitra & Schlaepfer, 2006). Phosphorylation of FAK 
was unable to be detected using western blot but free and micellar dasatinib treatment 
suppressed total FAK expression (Figure 3:22). F-Co treatment was equipotent at suppressing 
FAK expression in U87, LN-18, and NZG0906 cells but was more potent in U373, A172 and 
NZG1003 cells. FAK inhibitors are currently being pursued in Phase I clinical trials in multiple 
solid tumors including glioblastoma (NCT01138033). When considering standard treatment, 
the addition of FAK inhibition has a good potential to improve the efficacy due the 
interdependence of SRC and FAK in the formation of lamellipodia and subsequently, invasion 
and treatment resistance. 
4.5.5  EGFR 
The results of the TKI screen showed poor in vitro efficacy of EGFR inhibitors such as gefitinib 
and lapatinib (Table 3:1). This result is perhaps predictable as it has been demonstrated that 
there are several redundancy pathways in glioblastoma that can compensate for the loss of 
EGFR activity. The expression of EGFRvIII in U87 cells reduces the activation of Met but 
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maintains the downstream signaling in an apparent “swapping” of stimulatory receptors 
(Stommel et al., 2007) while the inhibition of EGFRvIII results in a switch to HGF mediated 
Met activation (Pillay et al., 2009). This indicates that inhibition of EGFR may be ineffective 
in the clinic due to the ability of Met to compensate for EGFR activity following treatment 
with EGFR inhibitors (Pillay et al., 2009; Stommel et al., 2007). Subsequently, despite the high 
rate of EGFR amplification or mutation in glioblastoma patients and the acceptable side effect 
profile of anti-EGFR agents, their clinical efficacy is as low as 10-20% (Rich et al., 2004).  
Consistent reduction of total EGFR expression was only seen following free and micellar 
combination TKI treatment (Figure 3:26). This suggests a potential mechanism of the efficacy 
of the combination. By inhibiting the expression of both Met and EGFR, the combination can 
abrogate the redundant signaling pathways, preventing the receptor switch that facilitates 
escape from treatment-induced death. 
4.5.6  Crosstalk 
The crosstalk of the investigated kinases is extensive and by no means completely understood, 
despite its importance. This crosstalk mediates pathological processes such as invasion, 
migration, proliferation, angiogenesis and survival. Furthermore, these kinases contribute to 
redundancies and compensatory mechanisms that result in resistance to targeted treatment. This 
includes resistance towards conventional treatment options such as surgery, radiation and 
temozolomide chemotherapy. For example, as previously discussed, invading cells are resistant 
to chemotherapy and radiotherapy induced cell death due to suppressed proliferation (Bell & 
Karnosh, 1949; Giese et al., 2003). In glioblastoma cells, invasion is regulated by the 
SRC/FAK complex that controls the rearrangement of the cytoskeleton to regulate cell motility 
(Mitra & Schlaepfer, 2006). Furthermore, Met is heavily involved in hypoxia-induced 
invasion, prompting cells to invade to areas with a nutrient supply more suitable for 
proliferation. To accomplish this invasion, Met can activate FAK directly or via SRC to 
promote the cytoskeletal rearrangement necessary for motility (Chen et al., 1998; Chen & 
Chen, 2006) and to induce the expression of MMPs which degrade the extracellular matrix 
(Hamasuna et al., 1999; Kermorgant et al., 2003). 
Alternatively, the crosstalk is also able to compensate for kinase directed treatment as has 
previously been shown in a range of tumor types. SRC inhibitors have been successfully 
applied in head and neck cancers to prevent invasion into the surrounding tissues however 
resistance often develops to the treatment. In these resistant cell lines, Met activity becomes 
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independent of SRC and HGF and subsequent addition of a Met inhibitor, PHA665752, to 
dasatinib treatment showed a synergistic increase in apoptosis and a synergistic decrease in 
tumor size (Sen et al., 2011). 
As previously discussed, the EGFR RTK is overexpressed or amplified in 21% of glioblastoma 
tumors (Verhaak et al., 2010) and the crosstalk between EGFR, Met, SRC and FAK is 
extensive. For example, EGFR may transactivate the Met receptor, Met may compensate for 
loss of EGFR activity and both the Met and EGFR RTKs signal through the SRC/FAK complex 
to promote invasion and tumorigenesis (Feng et al., 2012; Li et al., 2011b; Long et al., 2010; 
Lu et al., 2009). This complexity makes the reduction in total EGFR expression, despite the 
lack of anti-EGFR activity, highly relevant for the depletion of potential crosstalk resistance 
and invasion pathways. 
4.6    Angiogenesis, migration and invasion 
The potential of glioblastoma lesions to induce the growth of neovasculature significantly 
contributes to the tumor burden. Furthermore, should a vessel collapse or be occluded, the cells 
that had been supplied by this vessel will then be subjected to hypoxia, promoting invasion as 
will be discussed further below. Neovasculature can be formed by vascular endothelial cells 
(angiogenesis) or by differentiated tumor cells (vascular mimicry). 
Angiogenesis was modeled here using the endothelial tube formation assay. Construction of 
tubes in this assay requires basement membrane attachment, migration, protease activity and 
formation of tubules, all important functions for the successful construction of blood vessels 
that cannot be sufficiently modeled using other assays such as migration (Arnaoutova & 
Kleinman, 2010). As seen in Figure 3:30, treatment of HUVEC cells with dasatinib, both free 
and micellar, suppressed tube formation and was significantly more effective than crizotinib 
treatment. This may be due to the effect of dasatinib on SRC, FAK and Met inhibiting the 
ability of the HUVEC cells to regulate the cytoskeleton dynamics and form the tubules 
necessary to line the new vasculature. Co-localization of SRC and Met was observed in the 
lamellipodia of glioblastoma cells (Figure 3:27) and so the disruption of this crosstalk may be 
sufficient to inhibit the cytoskeleton dynamics that form the tubules. Combination treatment, 




Glioblastoma cells and GSCs have shown the ability to differentiate into vascular endothelial 
cells (Chen et al., 2012; El Hallani et al., 2010; Ricci-Vitiani et al., 2010), a process that is 
stimulated by hypoxia and is independent of common growth factors that regulate the 
vasculature such as VEGF (Soda et al., 2011). This is problematic for anti-angiogenic 
treatments as the tumor cells may be able to compensate for the loss of angiogenesis to maintain 
blood supply to the tumor. Therefore, preventing vascular mimicry reduces the pathways 
available for glioblastoma to develop tolerance to anti-angiogenic treatments.  
U87, U373, and A172 cells showed the ability to form tube-like structures reminiscent of 
HUVEC cells in vitro. In all of the cell lines, dasatinib, free and micellar, was more effective 
at suppressing tube formation than the respective crizotinib treatment and combination 
treatment was more effective than single treatments, consistent with the observations in 
HUVEC cells. However, the efficacy of the F-Co and SMA-Co treatments did not show 
comparable potency at abolishing tube formation in vascular mimicry as was seen with the 
HUVEC cells. Instead, SMA-Co was more potent than F-Co in A172 cells, SMA-Co and F-Co 
were equipotent in U373 cells and SMA-Co was less potent than F-Co in U87 cells. The reason 
for the difference between the cell lines is unknown. It does not reflect the cytotoxicity, 
indicating that endocytic capacity was unlikely to define this pattern. Furthermore, the anti-
tube-like formation activity does not reflect the relative expression of the kinases, and this 
result is likely to be a complex interplay between several factors that vary depending on the 
cell line including drug uptake and the localization of the TKI and its target kinase.  
As previously mentioned, the growth of glioblastoma cells often outstrips the available blood 
supply due to the complex interaction of the pressure of the growing tumor collapsing blood 
vessels, poorly constructed blood vessels clotting and irregular blood vessel distribution 
(Taurin et al., 2012). This irregular blood supply often results in regions of the tumor lacking 
the appropriate oxygen and nutrient supply promoting the selection of more a migratory and 
invasive phenotype, characterized by the appearance of pseudopalisades, the phenotype used 
to distinguish glioblastoma from lower grade gliomas (Brat et al., 2004).  
Subsequently, previous attempts at treating glioblastoma with anti-angiogenic agents have 
failed to improve OS due to the rebound pro-invasive effect of inducing hypoxia. Hypoxia-
induced invasion is highly regulated by the interplay between the RTKs VEGFR and Met (Lu 
et al., 2012; Takeuchi et al., 2012b; Wojta et al., 1999). Furthermore, the co-localization of 
SRC and Met in the lamellipodia of glioblastoma cells facilitates crosstalk between the tyrosine 
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kinases and subsequently, their regulation of cytoskeletal rearrangement during invasion. 
Therefore, the combination is especially promising in the case of invasion as the crosstalk 
necessary to modulate the cytoskeleton correctly to allow invasion of the cells. 
The effect of treatment on migration and invasion was assessed in order to determine the 
potential for invasion as a treatment escape mechanism. Dasatinib treatment, free and micellar, 
was more efficacious than the respective crizotinib treatment at suppressing glioblastoma cell 
migration however the SMA-D treatment was more effective at suppressing migration in A172 
cells than the F-D formulation. The combination treatments, free and micellar, were 
consistently more efficacious than the single treatments. The superior efficacy of dasatinib to 
crizotinib could be a consequence of several factors. For example, these experiments were not 
conducted under hypoxia which reduces the role of Met in stimulating the invasion. 
Furthermore, dasatinib inhibited the expression and/or phosphorylation of Met, FAK and SRC 
strongly while crizotinib does not suppress the expression and/or phosphorylation of the 
nRTKs SRC or FAK strongly and therefore will not impede the cytoskeleton dynamics to the 
same degree. These results closely reflect the vascular mimicry experiments which showed 
higher efficacy of dasatinib relative to crizotinib in single treatment but superior efficacy of 
both combinations relative to the single treatments.  
The increased migration suppression of SMA-D relative to F-D would not be expected based 
upon the micelle reducing the immediately available drug concentration. The SMA-D 
treatment was not more efficacious than the F-D treatment in the tube formation assay, despite 
migration and tube-like formation requiring similar modulation of the cytoskeleton for cell 
movement. The release rate shows that less than 20% of the loaded drug would have been 
released during the 24 h incubation time (Figure 3:2). Moreover, endocytosis of the micelle 
would not be able to deliver as much drug inside the cells as the free drug, which is diffusion 
limited.  
4.7    Limitations 
4.7.1   Pharmacokinetics 
The primary limitation of this work is the exclusive use of in vitro systems. The application of 
drugs directly to the media eliminates pharmacokinetic parameters. Firstly, the application of 
drugs directly to the media eliminated the need for the absorption that occurs following oral 
drug administration. Direct media application also excludes the differential drug 
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biodistribution of the two formulations. The micellar encapsulated drugs will be subject to the 
EPR effect causing increased accumulation in the liver, spleen and tumor (Taurin et al., 2012). 
Only the free TKIs, administered as free agents or released form the micelle, will be effluxed 
by the BBB which is not modeled in the in vitro setting. Finally, the in vitro setting eliminates 
the extensive phase I and phase II metabolism which alters the efficacy of the free TKIs 
considerably. For example, as previously discussed, three of the five main metabolites of 
dasatinib remain active against the targets of dasatinib, albeit reduced relative to dasatinib 
(Christopher et al., 2008). 
4.7.2   Drug penetration 
In vitro systems also primarily utilize monolayer culture conditions. This system represents a 
population that is close to the vasculature with optimal nutrient supply and therefore a higher 
rate of proliferation and greater delivery of the drugs than would be seen in tumor tissue further 
from the vasculature. In order to model drug penetration, a 3D culture system was used here 
(Figure 3:4). Unfortunately, these 3D spheroids are limited in size and are only able to model 
the tumor tissue that is close to the blood vessel. This is because without angiogenic capacity, 
the spheroids are not able to grow to a sufficient size to form a hypoxic core as is found on the 
core of the tumor. 
4.7.3  Heterogeneity 
4.7.3.1 Heterogeneity of cells 
Though cell lines serve as valuable tools for researchers, they do have several drawbacks. There 
are general limitations to the use of cell lines such as being unable to control the passage 
number and, as such, several cell lines from the American Type Culture Collection exceeded 
100 passages when delivered. This gives a long period for the cells to be exposed to in vitro 
selection pressures and makes them less likely to be representative of the original tumor. 
Indeed, utilizing only cell culture produces a skewed representation of the original tumor.  
Some cell types are unable to be cultured and the possibility that certain gene expression 
patterns make a cell able to be cultured in vitro and therefore represented in the literature 
despite being non-representative of the patient population cannot be discounted.  
4.7.3.2 Heterogeneity of proteins such as EGFR 
The subtypes of glioblastoma found in the clinic are not reflected in the available cell lines 
(Verhaak et al., 2010). In primary glioblastoma, EGFR defines the classical subtype and is 
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frequently amplified and/or mutated to the EGFRvIII (Verhaak et al., 2010). This RTK drives 
pathogenic processes including DNA repair (Golding et al., 2009; Mukherjee et al., 2009), 
proliferation (Ekstrand et al., 1991; Ekstrand et al., 1994), angiogenesis (Goldman et al., 1993), 
invasion (Lal et al., 2002; Penar et al., 1997) and resistance to radiotherapy and chemotherapy 
(Chakravarti et al., 2002; Nagane et al., 1998). However, EGFR abnormalities are not found 
in established cell lines bar the SKMG-3 cell line which retains EGFR amplification (Filmus 
et al., 1985; Thomas et al., 2001) but which is not available through the ATCC and therefore 
not widely used. However, if a cell line is maintained in vivo rather than in vitro, the EGFR 
amplification or EGFRVIII expression can be retained (Goike et al., 1999; Malden et al., 1988; 
Yamazaki et al., 1988), providing evidence that the selection pressure towards in vivo EGFR 
activity is not maintained in vitro. Indeed, even in the primary cell lines utilized here, the 
expression of EGFR was remarkably similar to the established cell lines. Unfortunately, 
subtype analysis for these tumors is not available. The loss of in vivo selection pressures is by 
no means restricted to the expression of EGFR and in vitro culture results in the breakdown of 
identifiable in vivo subtypes (Verhaak et al., 2010). 
Following inhibition of EGFR or Met, signaling will switch to the other RTK in order to 
maintain downstream signaling. This has been shown in breast cancer (Mueller et al., 2008; 
Mueller et al., 2010), NSCLC (Bean et al., 2007; Turke et al., 2010) and colon cancer (Bardelli 
et al., 2013; Troiani et al., 2013). Although this signaling paradigm has not yet been validated 
in glioblastoma, EGFR and Met amplifications and mutations are commonly found to be 
present in different populations of the same tumor making single TKI targeting ineffective as 
it leaves other tumor cell populations uninhibited (Snuderl et al., 2011). Furthermore, inhibition 
of EGFR signaling has been shown to induce Met-driven stem cell populations (Jun et al., 
2014) and the EGFRvIII has been shown to cause transactivation of Met in glioblastoma cells 
(Huang et al., 2007). The loss of the characteristic in vivo EGFR expression and/or mutation 
therefore results in the pathways for resistance of glioblastoma cells to crizotinib treatment 
being incomplete in the in vitro setting limiting the conclusions able to be made from this data.  
4.8    Future experiments 
The studies presented here have shown the potential of the combination of dasatinib and 
crizotinib in glioblastoma. However, further studies should be conducted in order to clarify 
some of the results seen here and to confirm that efficacy is retained in vivo. 
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4.8.1  ALK and ROS1 
Future experiments should further assess the role of the RTKs ALK and ROS1 in the induction 
of cell death following crizotinib treatment. ALK is a poorly understood RTK, especially in 
terms of the role of ALK in the pathogenesis of glioblastoma. ALK has been shown to be 
expressed in glioblastoma cell lines however no systematic examination of ALK expression in 
glioblastoma has been conducted in order to determine if the RTK is expressed at levels and 
frequencies that would justify investigation of ALK inhibitors. Furthermore, the role of ALK 
in the pathology of glioblastoma is yet to be clearly elucidated. 
Recently, pleiotrophin and midkine, closely related members of the neurite growth-promoting 
factor family with approximately 50% protein homology, have been identified as ligands for 
ALK (Kadomatsu & Muramatsu, 2004). There is evidence of increased expression of 
pleiotrophin and midkine in glioblastoma lesions but this information cannot be used to 
extrapolate to the role of ALK as pleiotrophin and midkine also interact with the protein 
tyrosine phosphatase receptor ζ, heparin sulfate and the low density lipoprotein receptor-related 
protein to modulate cell signaling (Kadomatsu & Muramatsu, 2004; Lu et al., 2005; Mishima 
et al., 1997; Powers et al., 2002; Ulbricht et al., 2003). The ALK inhibitor ceritinib, which is 
more BBB permeable than crizotinib (Crescenzo & Inghirami, 2015), is currently in clinical 
trials for glioblastoma and several trials investigating crizotinib for glioblastoma have also been 
initiated (Table 1:6; Table 1:9). Ceritinib, and the more recent addition to the ALK inhibitor 
armory alectinib, has previously shown efficacy against CNS metastasis of ALK-positive 
NSCLC, indicating that these TKIs are able to cross the BBB in pharmacologically relevant 
concentrations (Ajimizu et al., 2015; Gadgeel et al., 2014; Gainor et al., 2015; Vansteenkiste, 
2014).  
The examination of ROS1 in glioblastoma is harder to evaluate as there is no known 
endogenous ligand or pharmacological agonists for the RTK. Furthermore, recent publications 
regarding ROS1 have suggested that the ROS1 protein is not expressed in 109 human 
glioblastoma samples assessed by immunohistochemistry and fluorescent in situ hybridization 
(Lim et al., 2015) but does show ROS1 mRNA synthesis (Gillaspy et al., 1992; Watkins et al., 
1994) and is expressed in established glioblastoma cell lines (Birchmeier et al., 1987; Sharma 




For future experiments, the expression and phosphorylation of SRC, Met, ROS1, ALK, and 
AKT over the time points examined for annexin V/PI labeling and cell cycle should be 
assessed. This will give information about how long the drugs are able to inhibit their target 
and the activity of downstream signaling molecules following drug washout and whether or 
not the phosphorylation status of these proteins correlate with the observed apoptosis. How 
rapidly the effect of dasatinib on target proteins is lost will be important to gain insight into 
possible dosing schedules. The effect of combination treatment on the efflux of the drugs 
should also be assessed in order to determine if the inhibition of P-gp by crizotinib can prevent 
the efflux of dasatinib, both from the cancer cells and by the BBB. 
4.8.2  In vivo experiments 
In vivo experiments are justified in the light of this research. The optimal in vivo model would 
utilize the GL261 model, a glioblastoma-like tumor that was chemically induced by 
implantation of methylcholanthrene pellets in the brain from C57/Bl6 mice which allows the 
use of immunocompetent animals (Renner et al., 2015). This consideration is vital as micellar 
encapsulated drugs accumulate via the EPR effect which is exacerbated by inflammation as a 
consequence of inflammatory factors inducing vascular permeability (Maeda et al., 2000). 
Furthermore, the GL261 model is the only available model which successfully recapitulates 
the invasion observed in the human disease while other tumor models grow a large solid tumor 
with no invasive borders or satellite tumors (Jacobs et al., 2011). In light of the role of invasion 
as the primary reason for treatment failure, an invasive model is absolutely crucial in order to 
be able to assess what is perhaps the most promising aspect of this treatment strategy. As was 
established by the TKI screen (Table 3:1), the GL261 cell line was more sensitive to TKI 
inhibition than the human cell lines and so this sensitivity will have to be taken into 
consideration while determining the applied doses.  
Maximum tolerated dose studies should be conducted in order to determine the highest dose 
that the animals will tolerate. Previous studies involving the combination of crizotinib and 
dasatinib in mouse models have established 20 mg/kg/day of dasatinib and 20 mg/kg/day of 
crizotinib to be a safe oral dose in athymic nude mice bearing HNSSC lesions (Sen et al., 2011). 
In vivo experiments should incorporate three main treatment groups, as is shown in Table 4:2, 
utilizing the maximum tolerated dose. 
This treatment strategy will examine the efficacy of the micellar encapsulated TKIs vs. the free 
TKIs using the optimal treatment strategy for each formulation. The once per week dosing of 
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the micellar encapsulated drug is sufficient to maintain therapeutic plasma concentrations while 
avoiding the priming of the reticuloendothelial system towards the nanoconstruct which 
accelerates plasma clearance (Ishida et al., 2003). As infrequent dosing allows a lower 
clearance rate of the micelle from the circulation, the applied drugs will circulate and 
extravasate through the permeable BBB of tumor lesions, being endocytosed or serving as a 
reservoir for TKI release. Furthermore, IV administration of SMA micelles provides 100% 
bioavailability and has previously been shown to allow the application of higher doses than can 
be tolerated with the free treatments (Daruwalla et al., 2007; Greish et al., 2004).  
Table 4:2: Proposed treatment strategy for orthotopic and subcutaneous in vivo studies 
of efficacy and biodistribution. 
Oral treatment IV treatment 
Treatment Frequency Treatment Frequency Treatment Frequency 
F-C 
1/day x 4 
weeks 
F-C 
1/week x 4 
weeks 
SMA-C 
1/week x 4 
weeks 
F-D 
1/day x 4 
weeks 
F-D 
1/week x 4 
weeks 
SMA-D 
1/week x 4 
weeks 
F-Cr 
1/day x 4 
weeks 
F-Cr 
1/week x 4 
weeks 
SMA-Cr 
1/week x 4 
weeks 
F-Co 
1/day x 4 
weeks 
F-Co 
1/week x 4 
weeks 
SMA-Co 
1/week x 4 
weeks 
 
Ideally, in vivo experiments should involve a subcutaneous model and an orthotopic model. 
The subcutaneous model will give information about the efficacy and safety of the drug 
combination when subjected to important pharmacokinetic parameters. The end points of the 
subcutaneous study will be the growth of the tumor, proliferation, apoptosis and microvascular 
density in order to establish whether the results obtained in vitro are reflected in the in vivo 
setting. The addition of an orthotopic model will allow the elucidation of the role of the CNS 
microenvironment on the efficacy of treatment. The BBB actively effluxes small molecule 
pharmacophores that enter the CNS through the disrupted vasculature of the tumor, resulting 
in drug concentrations falling rapidly within a small distance from the primary lesion (Table 
4:1). The endpoints for the orthotopic model will also include the growth of the tumor, 
proliferation, apoptosis and microvascular density but will also require the identification of 
cells that have invaded away from the primary lesion. This will include the invasive border of 
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the tumor and the quantity of microsatellite tumors which is only able to be replicated using 
this model. Furthermore, the orthotopic model also allows the assessment of the treatment on 
CNS function. Edema associated CNS deficits are able to be identified using tasks such as the 
rotarod. This test can indicate the loss of fine motor function associated with the onset of edema 
(Jallo et al., 2006). 
Further to the studies of efficacy, pharmacokinetic analysis should also be undertaken. The 
primary reason behind the micellar formulation was to increase drug accumulation at the tumor 
site and improve the plasma half-life of the drugs. Ideally, this should include the same design 
as the efficacy studies utilizing the subcutaneous and orthotopic models. The biodistribution 
should be conducted following the full 4 week treatment schedule instead of a single treatment 
as is typically used for assessment of biodistribution. This is because of the pharmacokinetic 
parameters of crizotinib. As previously discussed, crizotinib inhibits its own metabolism and 
also inhibits the activity of the efflux protein P-gp. This means that the use of a single dose is 
not appropriate for accurate biodistribution information. This allows comparison of drug 
accumulation relative to the formulation and treatment regime as well as incorporating the 
involvement of the BBB and microenvironment in drug accumulation.  
Moreover, a third study to assess the plasma half-life of the drugs using the various 
combinations, formulation and treatment routes. As both crizotinib and dasatinib are 
principally metabolized by CYP3A4 and crizotinib is a time dependent inhibitor of CYP3A4. 
Plasma concentrations should be assessed every 24 hours for the first 20 days of treatment. 
This is because previous reports have established that the time to steady state plasma 
concentration for crizotinib is 15 days (Li et al., 2011a) and the addition of dasatinib to the 
treatment regime could potentially extend this.  
Should the treatments show efficacy in the subcutaneous but not the orthotopic model, the 
addition of inhibitors of BCRP and P-gp such as elacridar, has been shown to be able to reduce 
efflux of TKIs such as crizotinib by the BBB in animal models of glioblastoma (Agarwal et 
al., 2013; Chuan Tang et al., 2014). The micellar formulation can be functionalized by adding 
targeting moieties, such as chlorotoxin or transferrin, on the surface of the micelle, facilitating 
delivery of macromolecules across the BBB (Cheng et al., 2014; Kang et al., 2015). 
Finally, the assessment of combination TKIs with radiotherapy and chemotherapy in the 
orthotopic model should be pursued. This will establish if the combination is able to be safely 
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applied in amalgamation with the currently utilized clinical tools and whether the combination 
can accentuate the efficacy of these strategies. 
4.9    Conclusion 
In this thesis, we have shown the advantages of the combination of two TKIs, crizotinib and 
dasatinib, which successfully abrogate multiple signaling pathways for development and 
treatment resistance. The combinations overcome apoptosis escape mechanisms and 
pathological characteristics such as angiogenesis and invasion. In addition, the combination 
retains significant in vitro efficacy following encapsulation into a micellar drug delivery system 
without the genetic instability associated with polyploidy. Furthermore, this micellar 
encapsulation has the potential to increase the accumulation of the TKIs at the tumor site via 
the EPR effect. These results are promising and warrant further investigation in in vivo models 






5   Supplementary information 
 
Figure 5:1: SRB vs. cell number for glioblastoma cells. Validation of the SRB assay as a 
quantification of cell number in glioblastoma cells. A) U87, B) LN-18, C) U373, D) A172, 
E) GL261 and F) NZG1003 cells. Experiments were conducted in triplicate and independently 
repeated three times. Data is mean ± SEM.    
 
Figure 5:2: Acid phosphatase activity vs. cell number for glioblastoma cells. Validation of 
the acid phosphatase activity assay as a quantification of cell number in glioblastoma cells. 
A) U87 and B) NZG1003 cells. Experiments were conducted in triplicate and independently 





Figure 5:3: Representative examples of the quadrant designation for GBM cells. A) U87, 
B) LN-18, C) U373 and D) A172 cells. The top left quadrant is annexin V stained, top right 
quadrant is double stained (not included in subsequent analysis), bottom left quadrant is 
unstained cells and bottom right quadrant is PI stained cells.  
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Figure 5:4: Combination treatment strategies to stablish the effective free and 
encapsulated TKI concentrations in LN-18 cells. A) Free drug, B) micellar encapsulated 
drug. C denotes crizotinib, D denotes dasatinib. Numbers are the concentration of the 
respective drug in µM. Cell number was quantified using an SRB assay. Experiments were 
conducted in triplicate and repeated three times independently. Data is mean ± SEM.  
 
Figure 5:5: Quantification of cell area of TKI treated glioblastoma cells. A) LN-18 cells, 
B) U373 cells. Cell area was quantified using Image J following 48 h of the indicated treatment. 
Experiments were independently repeated three times and 25 cells per experiment were 
quantified. Data is mean ± SEM. * denotes p < 0.05 as determined by an ANOVA with a 
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1X; DNA equivalent to G0/1 phase of the cell cycle, 2X; DNA equivalent to G2/M phase of the 
cell cycle, 4X; DNA equivalent to four times the content in G0/1 phase, 8X; DNA equivalent to 
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Source of variation P value 
Drug ≤0.001 
Time ≤0.001 
Interaction NS (0.124) 
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Source of variation P value 
Drug ≤0.001 
Time NS (0.121) 
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Source of variation P value 
Drug ≤0.001 
Time NS (0.254) 
Interaction NS (0.988) 
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Source of variation P value 
Drug NS (0.118) 
Time NS (0.096) 




48 h 72 h 24 h washout 48 h washout 72 h washout 














































Source of variation P value 
Drug NS (0.159) 
Time NS (0.055) 
Interaction NS (0.961) 
1X; DNA equivalent to G0/1 phase of the cell cycle, 2X; DNA equivalent to G2/M phase of the 
cell cycle, 4X; DNA equivalent to four times the content in G0/1 phase, 8X; DNA equivalent to 
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